2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/Heart Failure

Journal of the American College of Cardiology 70, 776-803

DOI: 10.1016/j.jacc.2017.04.025

Citation Report

#	Article	IF	CITATIONS
1	Mastering Interproximal Stripping: With Innovations in Slenderization. International Journal of Clinical Pediatric Dentistry, 2012, 5, 163-166.	0.8	1
2	Prevalence of Spaced and Closed Dentition and its Relation to Malocclusion in Primary and Permanent Dentition. International Journal of Clinical Pediatric Dentistry, 2012, 5, 98-100.	0.8	8
3	Characteristics of Primary Dentition Occlusion in Preschool Children: An Epidemiological Study. International Journal of Clinical Pediatric Dentistry, 2012, 5, 93-97.	0.8	23
4	Applicability of Bolton's Analysis: A Study on Jaipur Population. International Journal of Clinical Pediatric Dentistry, 2012, 5, 113-117.	0.8	8
5	Prosthetic Rehabilitation of a Child Suffering from Hypohidrotic Ectodermal Dysplasia with Complete Anodontia. International Journal of Clinical Pediatric Dentistry, 2012, 5, 148-150.	0.8	6
6	Comparative Evaluation of Oral <i>Candida albicans</i> Carriage in Children with and without Dental Caries: A Microbiological <i>in vivo</i> Study. International Journal of Clinical Pediatric Dentistry, 2012, 5, 108-112.	0.8	8
7	Evaluation and Comparison of the Antibacterial Activity against <i>Streptococcus mutans</i> Of Grape Seed Extract at Different Concentrations with Chlorhexidine Gluconate: An <i>in vitro</i> Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 181-185.	0.8	12
8	Management and Sequelae of Intruded Anterior Primary Teeth: A Systematic Review. International Journal of Clinical Pediatric Dentistry, 2016, 9, 240-250.	0.8	4
9	Comparative Evaluation of Shear Bond Strength of Various Glass Ionomer Cements to Dentin of Primary Teeth: An <i>in vitro</i> Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 192-196.	0.8	35
10	Comparative Evaluation of Remineralizing Potential of Three Pediatric Dentifrices. International Journal of Clinical Pediatric Dentistry, 2016, 9, 186-191.	0.8	7
11	Prevalence of Dental Fluorosis and associated Risk Factors in Bagalkot District, Karnataka, India. International Journal of Clinical Pediatric Dentistry, 2016, 9, 256-263.	0.8	11
12	Evaluation of Role of Myofibroblasts in Oral Cancer: A Systematic Review. International Journal of Clinical Pediatric Dentistry, 2016, 9, 233-239.	0.8	6
13	Autotransplantation of a Strange Positioned Impacted Central Incisor in a surgically Prepared Socket: A Miracle Esthetic Concept. International Journal of Clinical Pediatric Dentistry, 2016, 9, 269-272.	0.8	2
14	A Comparative Analysis of Different Finishing and Polishing Devices on Nanofilled, Microfilled, and Hybrid Composite: A Scanning Electron Microscopy and Profilometric Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 201-208.	0.8	43
15	Success Rate of MTA Pulpotomy on Vital Pulp of Primary Molars: A 3-Year Observational Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 222-227.	0.8	12
16	<i>In vitro</i> Evaluation of Stainless Steel Crowns cemented with Resin-modified Glass Ionomer and Two New Self-adhesive Resin Cements. International Journal of Clinical Pediatric Dentistry, 2016, 9, 197-200.	0.8	12
17	A Comparative Evaluation of the Efficacy of Different Caries Excavation Techniques in reducing the Cariogenic Flora: An <i>in vivo</i> Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 214-217.	0.8	7
18	Soluble ST2 for Prognosis and MonitoringÂin Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2389-2392.	2.8	43

#	Article	IF	CITATIONS
19	The Clinical Use of Ivabradine. Journal of the American College of Cardiology, 2017, 70, 1777-1784.	2.8	114
20	Increased serum lysyl oxidase-like 2 levels correlate with the degree of left atrial fibrosis in patients with atrial fibrillation. Bioscience Reports, 2017, 37, .	2.4	11
21	Loss of Female Sex Hormones Exacerbates Cerebrovascular and Cognitive Dysfunction in Aortic Banded Miniswine Through a Neuropeptide Y–Ca <sup>2+</sup> â€Activated Potassium Channel–Nitric Oxide Mediated Mechanism. Journal of the American Heart Association, 2017, 6, .	3.7	22
22	Caring for Trauma Patients With Coexisting Heart Failure. Journal of Trauma Nursing: the Official Journal of the Society of Trauma Nurses, 2017, 24, 312-316.	0.5	1
23	Therapeutic Targets for the Multi-system Pathophysiology of Heart Failure: Exercise Training. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 87.	0.9	7
24	Heart Failure With Mid-Range (Borderline) Ejection Fraction. JACC: Heart Failure, 2017, 5, 763-771.	4.1	141
25	Palliative Care in the Management of Patients with Advanced Heart Failure. Advances in Experimental Medicine and Biology, 2017, 1067, 295-311.	1.6	23
26	Heart failure with reduced ejection fraction. Nature Reviews Disease Primers, 2017, 3, 17058.	30.5	136
27	New issues on measurement of B-type natriuretic peptides. Clinical Chemistry and Laboratory Medicine, 2017, 56, 32-39.	2.3	20
28	Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy. Cardiovascular Therapeutics, 2017, 35, e12301.	2.5	12
29	Traumatic Brains and Broken Hearts. Journal of the American College of Cardiology, 2017, 70, 1259-1261.	2.8	4
30	The Initial Evaluation and Management of a Patient with Heart Failure. Current Cardiology Reports, 2017, 19, 103.	2.9	1
31	Looking to the future: Introducing palliative care in the cardiorespiratory population. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 468.	1.6	0
32	Prognostic Significance of Low Systolic Blood Pressure at Discharge in Patients with Heart Failure and Preserved Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 405-412.	2.2	0
33	Usefulness of Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 120, 1584-1588.	1.6	2
34	Inpatient Monitoring of Decompensated Heart Failure: What Is Needed?. Current Heart Failure Reports, 2017, 14, 393-397.	3.3	5
35	Enhancing Response in the Cardiac Resynchronization Therapy Patient. JACC: Clinical Electrophysiology, 2017, 3, 1203-1219.	3.2	18
36	Role of Payers in the Development of Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2017, 70, 2822-2830.	2.8	5

#	Article	IF	CITATIONS
37	Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2017, 65, 2431-2440.	2.6	61
38	Cardiovascular Complications of CancerÂTherapy. Journal of the American College of Cardiology, 2017, 70, 2536-2551.	2.8	298
39	Androgen status in non-diabetic elderly men with heart failure. Aging Male, 2017, 20, 215-224.	1.9	10
40	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Current Heart Failure Reports, 2017, 14, 217-222.	3.3	13
41	Mineralocorticoid Receptor Antagonists in Highâ€Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease. Journal of the American Heart Association, 2017, 6, .	3.7	6
42	Representation of cardiovascular magnetic resonance in the AHA / ACC guidelines. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 70.	3.3	59
43	The Biomarker Armamentarium for Heart Failure. Indian Journal of Cardiovascular Disease in Women WINCARS, 2017, 02, 004-006.	0.1	1
44	Identification of the difference in the pathogenesis in heart failure arising from different etiologies using a microarray dataset. Clinics, 2017, 72, 600-608.	1.5	7
45	Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 369-382.	2.3	18
46	Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial. BMC Cardiovascular Disorders, 2017, 17, 274.	1.7	23
47	A Historical Perspective on Presentations of Hypertensive Acute Heart Failure. Journal of Cardiovascular Diseases & Diagnosis, 2017, 05, .	0.0	2
49	Effect of Elevated C-Reactive Protein Level at Discharge on Long-Term Outcome in Patients Hospitalized for Acute Heart Failure. American Journal of Cardiology, 2018, 121, 961-968.	1.6	11
50	Effects of ivabradine on endothelial function, aortic properties and ventricularâ€arterial coupling in chronic systolic heart failure patients. Cardiovascular Therapeutics, 2018, 36, e12323.	2.5	13
51	Rethinking Chronic Obstructive Pulmonary Disease. Chronic Pulmonary Insufficiency and Combined Cardiopulmonary Insufficiency. Annals of the American Thoracic Society, 2018, 15, S30-S34.	3.2	9
52	Cardiac Resynchronization Therapyâ€"Emerging Therapeutic Approaches. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 20.	0.9	4
53	Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure. Current Heart Failure Reports, 2018, 15, 94-105.	3.3	19
54	The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. Current Heart Failure Reports, 2018, 15, 37-43.	3.3	29
55	Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac) Tj ETQq $1\ 1\ 0.78$ Association, 2018, 7, .	34314 rgB <sup>3</sup> 3.7	T /Overlock 1 25

#	Article	IF	Citations
56	Autonomic Nervous System in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 925-927.	1.6	7
57	A Review of the Role of the Pharmacist in Heart Failure Transition of Care. Advances in Therapy, 2018, 35, 311-323.	2.9	41
58	Cardiopulmonary Exercise Testing in Patients Following Massive and Submassive Pulmonary Embolism. Journal of the American Heart Association, $2018, 7, .$	3.7	48
59	Post-Myocardial Infarction Heart Failure. JACC: Heart Failure, 2018, 6, 179-186.	4.1	237
60	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. Canadian Journal of Cardiology, 2018, 34, 632-643.	1.7	56
61	Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor. Indian Heart Journal, 2018, 70, S102-S110.	0.5	22
62	Cardiovascular Disease Progression: A Target for Therapy?. American Journal of Medicine, 2018, 131, 1170-1173.	1.5	8
63	Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 45.	0.9	5
64	Domain Management Approach to HeartÂFailure in the Geriatric Patient. Journal of the American College of Cardiology, 2018, 71, 1921-1936.	2.8	165
65	A Simple and Efficient Method for <em>In Vivo</em> Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice. Journal of Visualized Experiments, 2018, , .	0.3	0
66	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. Current Cardiology Reports, 2018, 20, 39.	2.9	27
67	Real-world management of heart failure in the Netherlands. Netherlands Heart Journal, 2018, 26, 240-241.	0.8	0
68	Mitral Valve Regurgitation in the Contemporary Era. JACC: Cardiovascular Imaging, 2018, 11, 628-643.	5.3	144
69	Management of Sleep Disordered Breathing in Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 123-130.	3.3	9
70	Recurrent Acute Decompensated Heart Failure Admissions for Patients With Reduced Versus Preserved Ejection Fraction (from the Atherosclerosis Risk in Communities Study). American Journal of Cardiology, 2018, 122, 108-114.	1.6	15
71	The 2017 high blood pressure clinical practice guideline: The old and the new. Clinical Cardiology, 2018, 41, 279-281.	1.8	2
72	Clinical Spectrum and ManagementÂofÂHeart Failure inÂHypertrophicÂCardiomyopathy. JACC: Heart Failure, 2018, 6, 353-363.	4.1	105
73	Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure. European Heart Journal Cardiovascular Imaging, 2018, 19, 749-756.	1.2	22

#	Article	IF	CITATIONS
74	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. European Heart Journal, 2018, 39, 363-370.	2.2	199
75	An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?. Current Heart Failure Reports, 2018, 15, 24-36.	3.3	13
76	Implications of the New National Guidelines for Hypertension. Cardiology in Review, 2018, 26, 55-61.	1.4	4
77	Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Failure, 2018, 5, 257-266.	3.1	50
78	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e30-e66.	1.6	500
79	Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection—Focus on Group II Pulmonary Hypertension. Current Heart Failure Reports, 2018, 15, 81-93.	3.3	5
80	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	5.6	17
81	Self-care in Heart Failure Hospital Discharge Instructions—Differences Between Nurse Practitioner and Physician Providers. Journal for Nurse Practitioners, 2018, 14, 18-25.	0.8	4
82	Heart Failure. Primary Care - Clinics in Office Practice, 2018, 45, 63-79.	1.6	1
83	The Burden of Iron Deficiency in HeartÂFailure. Journal of the American College of Cardiology, 2018, 71, 782-793.	2.8	105
84	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 288.	6.1	93
85	Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681775160.	1.8	23
86	Newâ€onset left bundle branch blockâ€associated idiopathic nonischemic cardiomyopathy and time from diagnosis to cardiac resynchronization therapy: The NEOLITH II study. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 143-154.	1.2	28
87	Clinical impact of oral antidiabetic medications in heart failure patients. Heart Failure Reviews, 2018, 23, 325-335.	3.9	10
88	Left Ventricular Dysfunction in CancerÂTreatment. JACC: Heart Failure, 2018, 6, 87-95.	4.1	37
89	<scp>PARADIGM</scp> â€ <scp>HF</scp> Trial: Secondary Analyses Address Unanswered Questions. Pharmacotherapy, 2018, 38, 284-298.	2.6	9
90	2017 ACC Expert Consensus Decision Pathway for Optimization of HeartÂFailure Treatment: Answers to 10ÂPivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	2.8	235
91	Reversing the Cardiac Effects of Sedentary Aging in Middle Age—A Randomized Controlled Trial. Circulation, 2018, 137, 1549-1560.	1.6	135

#	Article	IF	CITATIONS
92	Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently. Indian Heart Journal, 2018, 70, 201-203.	0.5	4
93	Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 1999-2010.	2.8	195
94	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 181-190.	3.3	7
95	Short-Term Global Cardiovascular Disease RiskÂPrediction in Older Adults. Journal of the American College of Cardiology, 2018, 71, 2527-2536.	2.8	56
96	Duration of hospital admission, need of on-demand analgesia and other peri-procedural and short-term outcomes in sub-cutaneous vs. transvenous implantable cardioverter–defibrillators. International Journal of Cardiology, 2018, 258, 133-137.	1.7	7
97	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 86-92.	3.0	57
98	Indications for CardiacÂResynchronizationÂTherapy. JACC: Heart Failure, 2018, 6, 308-316.	4.1	68
99	Natriuretic peptide B plasma concentration increases in the first 12†h of pulmonary edema recovery. European Journal of Internal Medicine, 2018, 53, 52-56.	2.2	1
100	Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry. European Journal of Internal Medicine, 2018, 53, 45-51.	2.2	11
101	Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock. Journal of Heart and Lung Transplantation, 2018, 37, 1313-1321.	0.6	61
102	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. Journal of Cardiac Failure, 2018, 24, 313-320.	1.7	49
103	A Population-Based Study of Early Postoperative Outcomes in Patients with Heart Failure Undergoing Bariatric Surgery. Obesity Surgery, 2018, 28, 2281-2288.	2.1	8
104	In-Hospital Sepsis Mortality Rates Comparing Tertiary and Non-Tertiary Hospitals in Washington State. Journal of Emergency Medicine, 2018, 54, 785-792.	0.7	5
105	Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs, 2018, 78, 479-493.	10.9	38
106	Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines. Drugs, 2018, 78, 567-576.	10.9	7
107	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.7	448
108	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.7	262
109	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	2.8	382

#	Article	IF	CITATIONS
110	Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure. Acta Pharmacologica Sinica, 2018, 39, 1189-1196.	6.1	18
111	Management protocols for chronic heart failure in India. Indian Heart Journal, 2018, 70, 105-127.	0.5	27
112	Modern iron replacement therapy: clinical and pathophysiological insights. International Journal of Hematology, 2018, 107, 16-30.	1.6	132
113	Cost-effectiveness analysis in cardiac surgery: A review of its concepts and methodologies. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1671-1681.e11.	0.8	20
114	Combined assessment of left ventricular end-diastolic pressure and ejection fraction by left ventriculography predicts long-term outcomes of patients with ST-segment elevation myocardial infarction. Heart and Vessels, 2018, 33, 453-461.	1.2	10
115	Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 2018, 71, 2176-2198.	2.8	138
116	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection,ÂEvaluation, and Management ofÂHigh Blood PressureÂinÂAdults: ExecutiveÂSummary. Journal of the American College of Cardiology, 2018, 71, 2199-2269.	2.8	708
117	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 2018, 71, e127-e248.	2.8	4,042
118	Ablation for Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2018, 4, 1.	3.0	19
119	Protecting the heart in cancer therapy. F1000Research, 2018, 7, 1566.	1.6	17
121	Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. Journal of Clinical Oncology, 2018, 36, 2135-2144.	1.6	139
122	Functional Mitral Regurgitation. Cardiology in Review, 2018, 26, 230-238.	1.4	1
123	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. Journal of Thoracic Disease, 2018, 10, S4282-S4295.	1.4	69
124	Etiologic impact on difference on clinical outcomes of patients with heart failure after cardiac resynchronization therapy. Medicine (United States), 2018, 97, e13725.	1.0	5
125	PRO: Persistent Central Sleep Apnea/Hunter-Cheyne-Stokes Breathing, Despite Best Guideline-Based Therapy of Heart Failure With Reduced Ejection Fraction, Is a Compensatory Mechanism and Should Not Be Suppressed. Journal of Clinical Sleep Medicine, 2018, 14, 909-914.	2.6	13
126	sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction. Mediators of Inflammation, 2018, 2018, 1-9.	3.0	18
127	Effects of Ramadan fasting on the symptoms of chronic heart failure. Journal of King Abdulaziz University, Islamic Economics, 2018, 39, 395-400.	1.1	25
128	Exercise-based cardiac rehabilitation for people with implantable ventricular assist devices. The Cochrane Library, 2018, 9, CD012222.	2.8	6

#	Article	IF	Citations
129	Antihypertensive drug therapy. Annals of Translational Medicine, 2018, 6, 123-123.	1.7	1
130	Malattie croniche da ricercare attivamente e mettere in trattamento nel paziente anziano multimorbido al momento della dimissione da un reparto di Medicina Interna a seguito di un ricovero per insufficienza respiratoria acuta attribuita a riacutizzazione di BPCO. Italian Journal of Medicine, 0, . 1-97.	0.3	0
131	OBSOLETE: Heart Failure With Preserved Ejection Fraction. , 2018, , .		O
132	Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure—A Single Center Experience. Biomolecules, 2018, 8, 133.	4.0	4
133	Sacubitril/Valsartan Averts AdverseÂPost-Infarction Ventricular RemodelingÂand Preserves SystolicÂFunction in Rabbits. Journal of the American College of Cardiology, 2018, 72, 2342-2356.	2.8	63
134	The Effect of Chinese Herbal Medicine on Quality of Life and Exercise Tolerance in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Physiology, 2018, 9, 1420.	2.8	6
135	The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 351-359.	2.1	6
136	Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging. Journal of Nuclear Cardiology, 2018, 25, 2159-2167.	2.1	O
137	Guiding Heart Failure Therapy AfterÂGUIDE-IT. Journal of the American College of Cardiology, 2018, 72, 2563-2566.	2.8	1
138	Psychosocial and clinical outcomes of percutaneous versus surgical pulmonary valve implantation. Open Heart, 2018, 5, e000758.	2.3	4
139	Population health challenges in primary care: What are the unfinished tasks and who should do them?. SAGE Open Medicine, 2018, 6, 205031211880020.	1.8	4
140	Fluid balance concepts in medicine: Principles and practice. World Journal of Nephrology, 2018, 7, 1-28.	2.0	73
141	Moving the Needle Toward a More Personalized Means of Patient Care. JAMA Cardiology, 2018, 3, 1146.	6.1	0
142	Association Between Inflammatory Markers and Myocardial Fibrosis. Hypertension, 2018, 72, 902-908.	2.7	29
143	Is B-type natriuretic peptide (BNP) similarly associated with mortality in patients with and without heart failure?. Annals of Translational Medicine, 2018, 6, S9-S9.	1.7	1
144	The E/e' ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. PLoS ONE, 2018, 13, e0209794.	2.5	10
145	The Vulnerable Phase of Heart Failure. American Journal of Therapeutics, 2018, 25, e456-e464.	0.9	25
146	Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clinical Medicine Insights: Cardiology, 2018, 12, 117954681880935.	1.8	33

#	Article	IF	CITATIONS
147	Does nitric oxide mediate effects of ivabradine in a failing heart?. Anatolian Journal of Cardiology, 2018, 20, 273-274.	0.9	0
148	Construction and analysis of the lncRNA‑miRNA‑mRNA network based on competitive endogenous RNA reveals functional genes in heart failure. Molecular Medicine Reports, 2019, 19, 994-1003.	2.4	21
149	Updates in heart failure: what last year brought to us. ESC Heart Failure, 2018, 5, 989-1007.	3.1	10
150	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. Circulation, 2018, 138, 2787-2797.	1.6	3
151	Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circulation: Heart Failure, 2018, 11, e005266.	3.9	143
152	B-type natriuretic peptide in patients with asymptomatic severe aortic stenosis. Heart, 2019, 105, heartjnl-2018-313746.	2.9	28
153	Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2018, 320, 2231.	7.4	72
154	Prevalence, risk factors, and significance of iron deficiency and anemia in nonischemic heart failure patients with reduced ejection fraction from a Himachal Pradesh heart failure registry. Indian Heart Journal, 2018, 70, S182-S188.	0.5	11
155	Imaging and Management of Heart Failure and Preserved Ejection Fraction. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 90.	0.9	8
156	Gene Therapy for Heart Failure: New Perspectives. Current Heart Failure Reports, 2018, 15, 340-349.	3.3	23
157	Improving Provider Adherence to Guideline Recommendations in Heart Failure. Current Heart Failure Reports, 2018, 15, 350-356.	3.3	3
158	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. New England Journal of Medicine, 2018, 379, 2307-2318.	27.0	2,079
159	Icariside II attenuates cardiac remodeling via AMPKα2/mTORC1 inÂvivo and inÂvitro. Journal of Pharmacological Sciences, 2018, 138, 38-45.	2.5	13
160	In-Hospital Initiation of Guideline-Directed Heart Failure Pharmacotherapy to Improve Long-Term Patient Adherence and Outcomes. Critical Care Nurse, 2018, 38, 16-24.	1.0	2
161	What Is the Ideal BloodÂPressure Goal for Heart Failure Patients?. JACC: Heart Failure, 2018, 6, 889-890.	4.1	0
162	Setting Up a Heart Failure Program in 2018: Moving Towards New Paradigm(s). Current Heart Failure Reports, 2018, 15, 357-367.	3.3	3
163	Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature. Journal of Emergency Medicine, 2018, 55, 635-646.	0.7	21
164	Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian Heart Journal, 2018, 70, S435-S441.	0.5	4

#	Article	IF	Citations
165	Sodium Restriction in Heart Failure: Too Much Uncertaintyâ€"Do the Trials. JAMA Internal Medicine, 2018, 178, 1700.	5.1	11
166	Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovascular Diabetology. 2018. 17. 137.	6.8	45
167	Zhenwu decoction for chronic heart failure. Medicine (United States), 2018, 97, e11559.	1.0	14
168	What's new in heart failure therapy 2018?â€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 921-930.	1.1	8
169	Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF). Journal of Medical Systems, 2018, 42, 209.	3.6	18
170	Correlation between B-Type Natriuretic Peptide and N-Terminal pro-B-Type Natriuretic Peptide in a Large Japanese Population at Risk of Stage A Heart Failure. Pulse, 2018, 6, 1-8.	1.9	4
171	Brain Natriuretic Peptide in Plasma as Predictor of All-Cause Mortality in a Large Danish Primary Health Care Population Suspected of Heart Failure. Clinical Chemistry, 2018, 64, 1723-1731.	3.2	9
172	Troponinâ€l levels as a potential prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction: Who will benefit most?. Clinical Cardiology, 2018, 41, 1548-1554.	1.8	6
173	Living Unhappily on Left Ventricular Assist Device Support. JACC: Heart Failure, 2018, 6, 914-916.	4.1	0
174	Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. JAMA Cardiology, 2018, 3, 1206.	6.1	35
175	Cardio-oncology: protecting the heart from curative breast cancer treatment. Gland Surgery, 2018, 7, 350-365.	1.1	9
176	Revisiting the Diabetes-Heart Failure Connection. Current Diabetes Reports, 2018, 18, 134.	4.2	10
177	Role of blood urea nitrogen in predicting the post-discharge prognosis in elderly patients with acute decompensated heart failure. Scientific Reports, 2018, 8, 13507.	3.3	20
178	Cardiac surgery for Chagas disease. Journal of Cardiac Surgery, 2018, 33, 597-602.	0.7	3
179	Preventing Heart Failure in Diabetes. JACC: Heart Failure, 2018, 6, 831-832.	4.1	0
180	Acute Decompensated Heart Failure: A Pharmacotherapy Approach. AACN Advanced Critical Care, 2018, 29, 233-239.	1.1	0
181	Author's response to: letter to the editor. Heart Failure Reviews, 2018, 23, 819-819.	3.9	0
182	Gender Differences in Ischemic Cardiomyopathy. Current Atherosclerosis Reports, 2018, 20, 50.	4.8	21

#	Article	IF	CITATIONS
183	Will the Early Use of Biomarkers Prevent the Development of Heart Failure?. Journal of Cardiac Failure, 2018, 24, 601-602.	1.7	1
184	How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure. Current Atherosclerosis Reports, 2018, 20, 54.	4.8	4
185	Relation of Serum Potassium to Cardiovascular Events in Patients With Heart Failure and Preserved Ejection Fraction: "Mind the Gap― American Journal of Hypertension, 2018, 31, 1087-1089.	2.0	3
186	Effects of spironolactone in heart failure with preserved ejection fraction. Medicine (United States), 2018, 97, e11942.	1.0	14
187	Ambulatory Intra Aortic Balloon Pump in Advanced Heart Failure. Cardiac Failure Review, 2018, 4, 1.	3.0	13
188	One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial. JAMA Cardiology, 2018, 3, 968.	6.1	121
189	Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. American Heart Journal, 2018, 202, 76-83.	2.7	7
190	Sacubitril-valsartan in the real world: From theory to clinical practice. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 497-498.	0.2	2
191	Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes. Journal of the American Heart Association, 2018, 7, .	3.7	46
192	Hyperkalemia in Heart Failure: Probably Not O"K― Journal of the American Heart Association, 2018, 7, .	3.7	10
193	Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure. American Journal of Cardiology, 2018, 122, 683-688.	1.6	14
194	Left ventricular restoration devices post myocardial infarction. Heart Failure Reviews, 2018, 23, 871-883.	3.9	13
195	Efficacy of renin–angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease. European Journal of Preventive Cardiology, 2018, 25, 1268-1277.	1.8	14
196	Current perspectives on the diagnosis and management of dilated cardiomyopathy Beyond heart failure: a Cardiomyopathy Clinic Doctor's point of view. Hellenic Journal of Cardiology, 2018, 59, 254-261.	1.0	26
197	Uso do Sacubitril/Valsartan no «mundo real»: da teoria à prática clÃnica. Revista Portuguesa De Cardiologia, 2018, 37, 497-498.	0.5	3
198	Misconceptions in acute heart failure diagnosis and Management in the Emergency Department. American Journal of Emergency Medicine, 2018, 36, 1666-1673.	1.6	3
199	Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. American Journal of Cardiovascular Drugs, 2018, 18, 333-345.	2.2	12
200	Chagas Cardiomyopathy: A Comprehensive Perioperative Review. Journal of Cardiothoracic and Vascular Anesthesia, 2018, 32, 2780-2788.	1.3	3

#	Article	IF	CITATIONS
201	Unusual case of late dislodgment of a superior vena cava coil. HeartRhythm Case Reports, 2018, 4, 405-407.	0.4	0
202	Preventable delays to intravenous furosemide administration in the emergency department prolong hospitalization for patients with acute heart failure. International Journal of Cardiology, 2018, 269, 207-212.	1.7	4
203	Prevention of Cardiotoxicities With Traditional and Novel Chemotherapeutic Agents. Current Heart Failure Reports, 2018, 15, 260-269.	3.3	10
204	Treatment of Chagas Disease in the United States. Current Treatment Options in Infectious Diseases, 2018, 10, 373-388.	1.9	74
205	Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors. Current Heart Failure Reports, 2018, 15, 270-279.	<b>3.</b> 3	0
206	Outcomes in Cardiogenic Shock Patients with Extracorporeal Membrane Oxygenation Use: A Matched Cohort Study in Hospitals across the United States. BioMed Research International, 2018, 2018, 1-8.	1.9	21
207	Validation of Exercise Capacity as a Surrogate Endpoint in Exercise-Based Rehabilitation for Heart Failure. JACC: Heart Failure, 2018, 6, 596-604.	4.1	47
208	Association of <i>APOL1</i> With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women. JAMA Cardiology, 2018, 3, 712.	6.1	17
209	Incorporating Guideline Adherence and Practice Implementation Issues into the Design of Decision Support for Beta-Blocker Titration for Heart Failure. Applied Clinical Informatics, 2018, 09, 478-489.	1.7	8
210	The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery. Current Heart Failure Reports, 2018, 15, 250-259.	3.3	13
211	Outcomes of "diabetesâ€friendlyâ€∙vs "diabetesâ€unfriendly―βâ€blockers in older nursing home resider with diabetes after acute myocardial infarction. Diabetes, Obesity and Metabolism, 2018, 20, 2724-2732.	<sup>nts</sup> 4.4	13
212	Bioimpedance and Newâ€Onset Heart Failure: A Longitudinal Study of >500Â000 Individuals From the General Population. Journal of the American Heart Association, 2018, 7, .	3.7	31
213	Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand. American Journal of Cardiovascular Drugs, 2018, 18, 405-413.	2.2	24
214	Beta-Adrenergic Receptor Blockade. , 2018, , 539-542.		0
215	Heart Failure With Preserved Ejection Fraction Expert Panel Report. JACC: Heart Failure, 2018, 6, 619-632.	4.1	103
216	Predictors and Clinical Impact of Late Ventricular Arrhythmias in Patients WithÂContinuous-Flow Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2018, 4, 1166-1175.	3.2	58
217	Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. American Journal of Medicine, 2018, 131, 1473-1481.	1.5	26
218	Foreword: Biomarkers in cardiovascular area: your best friend. European Heart Journal Supplements, 2018, 20, G1-G1.	0.1	0

#	Article	IF	CITATIONS
219	Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker?. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H1256-H1258.	3.2	4
220	Are serial measurements of plasma concentrations of natriuretic peptide useful in real-world practice in patients with heart failure?. International Journal of Cardiology, 2018, 269, 220-221.	1.7	1
221	The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports. BMC Cardiovascular Disorders, 2018, 18, 155.	1.7	5
222	An evaluation of a potential calcium channel blocker–lower-extremity edema–loop diuretic prescribing cascade. Journal of the American Pharmacists Association: JAPhA, 2018, 58, 534-539.e4.	1.5	28
223	Screening, assessment and treatment for depression in patients with chronic heart failure. British Journal of Cardiac Nursing, 2018, 13, 386-393.	0.1	2
224	Is Excessive Polypharmacy a Transient or Persistent Phenomenon? A Nationwide Cohort Study in Taiwan. Frontiers in Pharmacology, 2018, 9, 120.	3.5	15
225	Heart Failure and Frailty in the Community-Living Elderly Population: What the UFO Study Will Tell Us. Frontiers in Physiology, 2018, 9, 347.	2.8	5
226	IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. Frontiers in Psychiatry, 2018, 9, 271.	2.6	27
227	Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. BMC Medicine, 2018, 16, 115.	5.5	19
228	Sex-Specific Physiology and Cardiovascular Disease. Advances in Experimental Medicine and Biology, 2018, 1065, 433-454.	1.6	96
229	Cardiac Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 602-604.	2.8	1
230	Myocardial considerations in type 2 diabetes: 2018. Journal of Diabetes, 2018, 10, 784-788.	1.8	1
231	Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?. Journal of Animal Science and Technology, 2018, 5, R65-R75.	2.5	21
232	Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. American Heart Journal, 2018, 205, 133-141.	2.7	13
233	Using Acellular Bioactive Extracellular Matrix Scaffolds to Enhance Endogenous Cardiac Repair. Frontiers in Cardiovascular Medicine, 2018, 5, 35.	2.4	22
234	Heart Failure with Hyperthyroidism Demonstrating Discrepancy between the Clinical Course and B-type Natriuretic Peptide Levels. Internal Medicine, 2018, 57, 1747-1749.	0.7	4
235	Heart Failure With Preserved Ejection Fraction. , 2018, , 464-468.		1
236	microRNA-21 and hypertension. Hypertension Research, 2018, 41, 649-661.	2.7	63

#	Article	IF	CITATIONS
237	Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction. Expert Review of Cardiovascular Therapy, 2018, 16, 579-589.	1.5	38
238	Sacubitril/Valsartan: potential treatment for paediatric heart failure. Cardiology in the Young, 2018, 28, 1077-1081.	0.8	4
239	Multiple hormone deficiency syndrome: a novel topic in chronic heart failure. Future Science OA, 2018, 4, FSO311.	1.9	9
240	Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. International Journal of Molecular Sciences, 2018, 19, 379.	4.1	252
241	The Past, Present and Future of Heart Transplantation. Korean Circulation Journal, 2018, 48, 565.	1.9	92
242	Medical Therapy for Heart Failure WithÂReduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 351-366.	2.8	775
243	Are Guidelines Merely Suggestions?. Journal of the American College of Cardiology, 2018, 72, 367-369.	2.8	7
244	Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. European Heart Journal, 2018, 39, 2859-2866.	2.2	31
245	Cerebral desaturation in heart failure: Potential prognostic value and physiologic basis. PLoS ONE, 2018, 13, e0196299.	2.5	11
246	CSI position statement on management of heart failure in India. Indian Heart Journal, 2018, 70, S1-S72.	0.5	18
247	New, but still the same old story. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1528-1529.	0.8	0
248	Timing of Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy. American Journal of the Medical Sciences, 2018, 356, 262-267.	1.1	2
249	Development and validation of a heart failure with preserved ejection fraction cohort using electronic medical records. BMC Cardiovascular Disorders, 2018, 18, 128.	1.7	29
250	Iron Deficiency in Heart Failure: to Treat or Not to Treat?. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 65.	0.9	5
251	Acute kidney injury in the UK: a replication cohort study of the variation across three regional populations. BMJ Open, 2018, 8, e019435.	1.9	25
252	Effect of Cigarette Smoking on Risk for Adverse Events in Patients With Heart Failure and Preserved Ejection Fraction. American Journal of Cardiology, 2018, 122, 400-404.	1.6	4
253	High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia. Journal of the American College of Cardiology, 2018, 71, 2270-2271.	2.8	29
254	Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatrics, 2018, 18, 109.	2.7	33

#	Article	IF	CITATIONS
255	A peripheral blood transcriptome biomarker test to diagnose functional recovery potential in advanced heart failure. Biomarkers in Medicine, 2018, 12, 619-635.	1.4	10
256	Similar BNP and Mortality AssociationÂinÂPatients With and Without Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2089-2091.	2.8	6
257	New Insights in Peripartum Cardiomyopathy. Obstetrics and Gynecology Clinics of North America, 2018, 45, 281-298.	1.9	3
258	Future Perspectives for Management of Stage A Heart Failure. Journal of Atherosclerosis and Thrombosis, 2018, 25, 557-565.	2.0	8
259	Seven Years of Experiences of Preclinical Experiments of Xeno-Heart Transplantation of Pig to Non-Human Primate (Cynomolgus Monkey). Transplantation Proceedings, 2018, 50, 1167-1171.	0.6	16
260	The therapeutic role of ivabradine in heart failure. Therapeutic Advances in Chronic Disease, 2018, 9, 199-207.	2.5	17
261	A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. JACC: Heart Failure, 2018, 6, 771-779.	4.1	45
262	Management of Heart Failure in Adult Congenital Heart Disease. Progress in Cardiovascular Diseases, 2018, 61, 308-313.	3.1	10
263	Non-response to Cardiac Resynchronization Therapy. Current Heart Failure Reports, 2018, 15, 315-321.	3.3	17
264	Educate, Nurture, Advise, Before Life EndsÂComprehensive Heartcare for Patients and Caregivers (ENABLE CHF-PC): study protocol for a randomized controlled trial. Trials, 2018, 19, 422.	1.6	28
265	Protocol driven palliative care consultation: Outcomes of the ENABLE CHF-PC pilot study. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 533-538.	1.6	6
266	Validating Left Ventricular Filling Pressure Measurements in Patients with Congestive Heart Failure: CardioMEMSâ,, Pulmonary Arterial Diastolic Pressure versus Left Atrial Pressure Measurement by Transthoracic Echocardiography. Cardiology Research and Practice, 2018, 2018, 1-6.	1.1	9
267	Heart Failure. Journal of the American College of Cardiology, 2018, 72, 1180.	2.8	0
268	Electrical manipulation of the failing heart. Heart Failure Reviews, 2018, 23, 885-896.	3.9	2
269	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	2.8	991
270	Current indications for transplantation: stratification of severe heart failure and shared decision-making. Annals of Cardiothoracic Surgery, 2018, 7, 56-66.	1.7	14
271	Cardiac Resynchronization Therapy inÂlnotrope-Dependent HeartÂFailureÂPatients. JACC: Heart Failure, 2018, 6, 734-742.	4.1	7
272	NT-proBNP–guided and conventional therapies did not differ for readmission or mortality in acute decompensated HF. Annals of Internal Medicine, 2018, 169, JC21.	3.9	1

#	Article	IF	CITATIONS
273	Left bundle branch block and the evolving role of QRS morphology in selection of patients for cardiac resynchronization. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 353-374.	1.3	5
274	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2. Expert Opinion on Drug Safety, 2018, 17, 893-915.	2.4	8
275	Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics, 2018, 8, 4155-4169.	10.0	68
276	The Role of the Clinical Examination inÂPatients With Heart Failure. JACC: Heart Failure, 2018, 6, 543-551.	4.1	108
277	Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. Heart Failure Reviews, 2018, 23, 609-629.	3.9	29
278	Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, .	3.7	23
279	Impact of underlying heart disease per se on the utility of preoperative NT-proBNP in adult cardiac surgery. PLoS ONE, 2018, 13, e0192503.	2.5	8
280	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). American Journal of Cardiology, 2018, 122, 821-827.	1.6	3
281	Anemia in the Elderly. HemaSphere, 2018, 2, e40.	2.7	71
282	Editorial Commentary: Blood pressure and cognition in the elderly. Trends in Cardiovascular Medicine, 2019, 29, 19-21.	4.9	0
283	Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. American Journal of Cardiovascular Drugs, 2019, 19, 21-36.	2.2	3
284	Type 2 diabetes increases the risk of hospital admission for heart failure and reduces the risk of in hospital mortality in Spain (2001–2015). European Journal of Internal Medicine, 2019, 59, 53-59.	2.2	10
285	Benefit–risk review of different drug classes used in chronic heart failure. Expert Opinion on Drug Safety, 2019, 18, 37-49.	2.4	10
286	Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. Laboratory Investigation, 2019, 99, 371-386.	3.7	77
287	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: ExecutiveÂSummary. Journal of the American College of Cardiology, 2019, 73, 1494-1563.	2.8	452
288	Safety, Tolerability and efficacy of Rapid Optimization, helped by NTâ€proBNP and GDFâ€15, of Heart Failure therapies (STRONGâ€HF): rationale and design for a multicentre, randomized, parallelâ€group study. European Journal of Heart Failure, 2019, 21, 1459-1467.	7.1	34
289	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Clinical Chemistry, 2019, 65, 1221-1227.	3.2	21
290	Design of a "Lean―Case Report Form for HeartÂFailure Therapeutic Development. JACC: Heart Failure, 2019, 7, 913-921.	4.1	6

#	Article	IF	CITATIONS
291	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clinical Hypertension, 2019, 25, 19.	2.0	31
292	Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study. BMC Cardiovascular Disorders, 2019, 19, 194.	1.7	6
293	Left Ventricular Assist Device: What the Internist Needs to Know. A Review of the Literature. Cureus, 2019, 11, e4399.	0.5	4
294	From innovation to guideline implementation: a long way. European Journal of Heart Failure, 2019, 21, 1114-1116.	7.1	1
295	Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales. Frontiers in Cardiovascular Medicine, 2019, 6, 110.	2.4	23
296	DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H674-H684.	3.2	51
297	Isoproterenol-Induced Cardiac Diastolic Dysfunction in Mice: A Systems Genetics Analysis. Frontiers in Cardiovascular Medicine, 2019, 6, 100.	2.4	15
298	Use of speckle tracking to assess heart failure with preserved ejection fraction. Journal of Cardiology, 2019, 74, 397-402.	1.9	21
299	Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. Circulation Research, 2019, 125, 265-281.	4.5	54
300	Falls, Subclinical Cardiovascular Disease, and a Nonagenarian's Sage Advice. Journal of the American Geriatrics Society, 2019, 67, 1774-1776.	2.6	0
301	The effect of mobile applications for improving adherence in cardiac rehabilitation: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2019, 19, 166.	1.7	48
302	Development and Validation of Deep-Learning Algorithm for Electrocardiography-Based Heart Failure Identification. Korean Circulation Journal, 2019, 49, 629.	1.9	70
303	Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. American Journal of Cardiology, 2019, 124, 966-971.	1.6	11
304	Procalcitonin and N-Terminal Pro-B-Type Natriuretic Peptide for Prognosis in Septic Acute Kidney Injury Patients Receiving Renal Replacement Therapy. Blood Purification, 2019, 48, 262-271.	1.8	5
305	Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?. European Journal of Heart Failure, 2019, 21, 1398-1401.	7.1	3
306	Association between elevated plasma aldosterone concentration and left atrial conduit function in hypertension. International Journal of Cardiology: Hypertension, 2019, 2, 100015.	2.2	2
307	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and HeartÂFailure (Part 2/5). Journal of the American College of Cardiology, 2019, 74, 683-698.	2.8	22
308	Percutaneous Mitral Valve Interventions (Repair): Current Indications and Future Perspectives. Frontiers in Cardiovascular Medicine, 2019, 6, 88.	2.4	29

#	Article	IF	CITATIONS
309	Serial Changes in Left Ventricular Ejection Fraction and Outcomes in Outpatients With Heart Failure and Preserved Ejection Fraction. American Journal of Cardiology, 2019, 124, 729-735.	1.6	6
310	HeartÂFailure Management UnderÂPressure. Journal of the American College of Cardiology, 2019, 73, 3064-3066.	2.8	0
311	Use of Nitrates and Risk of Cardiovascular Events in Patients With Heart Failure With Preserved Ejection Fraction. Mayo Clinic Proceedings, 2019, 94, 1210-1220.	3.0	10
312	Transcatheter Valve Repair for PatientsÂWith Mitral Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1369-1378.	2.9	128
313	Impact of inpatient cardiac rehabilitation on Barthel Index score and prognosis in patients with acute decompensated heart failure. International Journal of Cardiology, 2019, 293, 125-130.	1.7	21
314	Renin Activity in Heart Failure with Reduced Systolic Function—New Insights. International Journal of Molecular Sciences, 2019, 20, 3182.	4.1	31
315	Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacological Reviews, 2019, 71, 539-570.	16.0	235
316	Left Ventricular Systolic Dysfunction and Cardiovascular Outcomes in Tetralogy of Fallot: Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 1784-1790.	1.7	16
317	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2019, 8, 1684.	2.4	5
318	Deep representation learning for individualized treatment effect estimation using electronic health records. Journal of Biomedical Informatics, 2019, 100, 103303.	4.3	12
319	Danshenol A Alleviates Hypertension-Induced Cardiac Remodeling by Ameliorating Mitochondrial Dysfunction and Suppressing Reactive Oxygen Species Production. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-18.	4.0	4
320	A Contemporary Systematic Approach to Assessing the Patient with Heart Failure with Reduced Ejection Fraction: Multimodal Noninvasive and Invasive Evaluation. Cardiology Research and Practice, 2019, 2019, 1-12.	1.1	1
321	Virtual reality for pain management in patients with heart failure: Study rationale and design. Contemporary Clinical Trials Communications, 2019, 16, 100470.	1.1	9
322	Microstructurally Motivated Constitutive Modeling of Heart Failure Mechanics. Biophysical Journal, 2019, 117, 2273-2286.	0.5	12
323	Fulminant Myocarditis: Epidemiology, Pathogenesis, Diagnosis, and Management. American Journal of Cardiology, 2019, 124, 1954-1960.	1.6	54
324	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLASTâ€AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570.	7.1	9
325	Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist. Diagnostics, 2019, 9, 170.	2.6	36
326	Autocuidado del paciente con insuficiencia cardÃaca. Una asignatura pendiente para el sistema sanitario, el paciente y su cuidador. Revista Clinica Espanola, 2019, 219, 394-395.	0.6	0

#	Article	IF	CITATIONS
327	How do and could clinical guidelines support patient-centred care for women: Content analysis of guidelines. PLoS ONE, 2019, 14, e0224507.	2.5	24
328	Acute Kidney Injury in Patients Undergoing Cardiac Transplantation: A Meta-Analysis. Medicines (Basel,) Tj ETQq1	1 <sub>1.4</sub> 78431	4rgBT/Ov
329	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. American Journal of Medicine, 2019, 132, S3-S12.	1.5	0
330	Doing more to serve our patients. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 475-476.	1.6	1
331	Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register. Scandinavian Journal of Primary Health Care, 2019, 37, 434-443.	1.5	8
332	Sex differences in cardiometabolic disorders. Nature Medicine, 2019, 25, 1657-1666.	30.7	244
333	Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. Disease Markers, 2019, 2019, 1-12.	1.3	9
334	YQWY decoction reverses cardiac hypertrophy induced by TAC through inhibiting GATA4 phosphorylation and MAPKs. Chinese Journal of Natural Medicines, 2019, 17, 746-755.	1.3	4
335	Neurogenic Stunned Myocardium in Severe Neurological Injury. Current Neurology and Neuroscience Reports, 2019, 19, 90.	4.2	26
336	Cardiac Rehabilitation to Optimize Medication Regimens in Heart Failure. Clinics in Geriatric Medicine, 2019, 35, 549-560.	2.6	10
337	An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction. Current Oncology, 2019, 26, 240-246.	2.2	14
338	GDMT for heart failure and the clinician's conundrum. Clinical Cardiology, 2019, 42, 1155-1161.	1.8	7
339	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m ESC Heart Failure, 2019, 6, 1199-1207.	3.1	11
340	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	2.8	110
341	Are degree of urbanisation and travel times to healthcare services associated with the processes of care and outcomes of heart failure? A retrospective cohort study based on administrative data. PLoS ONE, 2019, 14, e0223845.	2.5	3
342	Polypharmacy and Nutraceuticals in Veterans: Pros and Cons. Frontiers in Pharmacology, 2019, 10, 994.	3.5	4
343	Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 139, 152-154.	1.6	18
344	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology, 2019, 296, 91-97.	1.7	60

#	Article	IF	CITATIONS
345	Approaches to improving exercise capacity in patients with left ventricular assist devices: an area requiring further investigation. Expert Review of Medical Devices, 2019, 16, 787-798.	2.8	4
346	Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer. Radiation Oncology, 2019, 14, 155.	2.7	6
347	Approach to Management of Premature Ventricular Contractions. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 53.	0.9	0
348	A Prospective, Multicenter, Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Tolvaptan in Patients with Reduced, Preserved, and Mid-Range Ejection Fraction Heart Failure. International Heart Journal, 2019, 60, 1123-1130.	1.0	8
349	Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986837.	2.5	2
350	Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors. Cardiovascular Therapeutics, 2019, 2019, 1-6.	2.5	5
351	Combined determination of B-type natriuretic peptide and high-sensitivity troponin I in the postmortem diagnosis of cardiac disease. Forensic Science, Medicine, and Pathology, 2019, 15, 528-535.	1.4	10
352	Natriuretic Peptide Response and Outcomes in Chronic HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	2.8	54
353	Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations. Current HIV/AIDS Reports, 2019, 16, 371-380.	3.1	26
354	Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. IJC Heart and Vasculature, 2019, 25, 100418.	1.1	27
355	Diagnostic and Therapeutic Gaps inÂPatients With HeartÂFailure and ChronicÂObstructive PulmonaryÂDisease. JACC: Heart Failure, 2019, 7, 823-833.	4.1	55
356	Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations. Cardiac Failure Review, 2019, 5, 78-82.	3.0	3
357	Tachycardiomyopathy in Patients without Underlying Structural Heart Disease. Journal of Clinical Medicine, 2019, 8, 1411.	2.4	12
358	2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 1966-2011.	2.8	222
359	The optimal treatment strategy for secondary mitral regurgitation: a subject of ongoing debate. European Journal of Cardio-thoracic Surgery, 2019, 56, 631-642.	1.4	8
360	Cardiotoxicity from immune checkpoint inhibitors. IJC Heart and Vasculature, 2019, 25, 100420.	1.1	79
361	Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. PLoS ONE, 2019, 14, e0221519.	2.5	8
362	The Impact of Pharmacist-Based Services Across the Spectrum of Outpatient Heart Failure Therapy. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 59.	0.9	6

#	Article	IF	CITATIONS
363	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. JACC: CardioOncology, 2019, 1, 54-65.	4.0	74
364	The Integral Role of Nurse Practitioners in Community Paramedicine. Journal for Nurse Practitioners, 2019, 15, 725-731.	0.8	4
365	Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients. Journal of Clinical Medicine, 2019, 8, 1582.	2.4	33
366	Are Some Patients With Acute HeartÂFailure ANP-Deficient?. JACC: Heart Failure, 2019, 7, 899-901.	4.1	2
367	The use of ECMO in ICU. Recommendations of the Spanish Society of Critical Care Medicine and Coronary Units. Medicina Intensiva (English Edition), 2019, 43, 108-120.	0.2	1
368	Use of Medication for CardiovascularÂDiseaseÂDuring Pregnancy. Journal of the American College of Cardiology, 2019, 73, 457-476.	2.8	177
369	Anemia and iron deficiency in heart failure: a review of echocardiographic features. Echocardiography, 2019, 36, 585-594.	0.9	12
370	Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. Free Radical Biology and Medicine, 2019, 134, 343-349.	2.9	14
371	The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study. Journal of the National Cancer Institute, 2019, 111, 854-862.	6.3	49
372	Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. Trends in Molecular Medicine, 2019, 25, 328-340.	6.7	51
373	Unanswered Questions Regarding Blood Pressure Management for HF Prevention. Current Hypertension Reports, 2019, 21, 7.	3.5	2
374	Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add?. Current Hypertension Reports, 2019, 21, 9.	3.5	5
375	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. Circulation Research, 2019, 124, 1618-1632.	4.5	39
376	ACC/AHA Versus ESC Guidelines onÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 73, 2756-2768.	2.8	195
377	Patients with high-dose diuretics should get ultrafiltration in the management of decompensated heart failure: a meta-analysis. Heart Failure Reviews, 2019, 24, 927-940.	3.9	10
378	Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review. European Journal of Health Economics, 2019, 20, 1103-1116.	2.8	11
379	A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. Genetics in Medicine, 2019, 21, 2815-2822.	2.4	35
380	Beta Blockers Up-Titration in Patients with Heart Failure Reduced Ejection Fraction and Cardiac Resynchronization Therapy, a Single Center Study. Medical Sciences (Basel, Switzerland), 2019, 7, 71.	2.9	1

#	Article	lF	Citations
381	Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials. Cureus, 2019, 11, e3913.	0.5	5
382	Systolic Blood Pressure and OutcomesÂinÂPatients With HeartÂFailure With ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2019, 73, 3054-3063.	2.8	50
383	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031.	7.1	20
384	Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure. International Journal of Molecular Sciences, 2019, 20, 2610.	4.1	3
385	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.9	42
386	Plasma renin levels are associated with cardiac function in primary adrenal insufficiency. Endocrine, 2019, 65, 399-407.	2.3	7
387	Going Beyond the Guidelines in Individualising the Use of Antihypertensive Drugs in Older Patients. Drugs and Aging, 2019, 36, 675-685.	2.7	33
388	Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998.	3.9	33
389	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation, 2019, 140, 529-537.	1.6	81
390	Biomarkers in heart failure: the past, current and future. Heart Failure Reviews, 2019, 24, 867-903.	3.9	87
391	10-Year Outcomes After Left Ventricular Reconstruction: Rethinking the Impact of Mitral Regurgitation. Annals of Thoracic Surgery, 2019, 108, 81-88.	1.3	8
392	Sex-Based Differences in HeartÂFailure Across the Ejection Fraction Spectrum. JACC: Heart Failure, 2019, 7, 505-515.	4.1	114
393	Catheter-Based Splanchnic Denervation for Treatment of Hypertensive Cardiomyopathy. Hypertension, 2019, 74, 47-55.	2.7	16
394	Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target. Heart Failure Reviews, 2019, 24, 847-866.	3.9	25
395	Hypertension Management in the Very Old. Journal of the American Medical Directors Association, 2019, 20, 1057-1059.	2.5	0
396	Economic evaluation of cardiac magnetic resonance with fast-SENC in the diagnosis and management of early heart failure. Health Economics Review, 2019, 9, 13.	2.0	8
397	Risk of Ischemic Mitral Regurgitation Recurrence After Combined Valvular and Subvalvular Repair. Annals of Thoracic Surgery, 2019, 108, 536-543.	1.3	32
398	ST2 and the ST2/IL-33 signalling pathway–biochemistry and pathophysiology in animal models and humans. Clinica Chimica Acta, 2019, 495, 493-500.	1.1	37

#	Article	IF	Citations
399	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 321, 2101.	7.4	47
400	Clinical determinants of plasma cardiac biomarkers in patients with stable chest pain. Heart, 2019, 105, 1748-1754.	2.9	4
401	Pediatric heart failure therapy: why $\hat{l}^21$ -receptor blocker, tissue ACE-I and mineralocorticoid-receptor-blocker?. Translational Pediatrics, 2019, 8, 127-127.	1.2	8
402	Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia. BioMed Research International, 2019, 2019, 1-8.	1.9	3
403	Understanding communal coping among patients and informal caregivers with heart failure: A mixed methods secondary analysis of patient-caregiver dyads. Heart and Lung: Journal of Acute and Critical Care, 2019, 48, 486-495.	1.6	6
404	Change in indication for cardiac resynchronization therapy?. European Journal of Cardio-thoracic Surgery, 2019, 55, i11-i16.	1.4	8
405	Firstâ€inâ€human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure. Catheterization and Cardiovascular Interventions, 2019, 93, 1205-1210.	1.7	16
406	Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. BMC Nephrology, 2019, 20, 171.	1.8	15
407	Cardio-Oncology Fellowship Training and Education. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 27.	0.9	6
408	Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2019, 32, 499-516.	2.0	63
409	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	4.5	115
410	Heart Failure With Preserved Ejection Fraction In Perspective. Circulation Research, 2019, 124, 1598-1617.	4.5	500
411	Estimated Long-Term Survival With Eplerenone. Journal of the American College of Cardiology, 2019, 73, 2357-2359.	2.8	6
412	A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471984019.	2.1	12
413	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 73, 2365-2383.	2.8	327
414	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. International Journal of Molecular Sciences, 2019, 20, 2092.	4.1	25
415	3D echocardiographic global longitudinal strain can identify patients with mildly-to-moderately reduced ejection fraction at higher cardiovascular risk. International Journal of Cardiovascular Imaging, 2019, 35, 1573-1579.	1.5	5
416	10-Year Risk Equations for Incident HeartÂFailure in the General Population. Journal of the American College of Cardiology, 2019, 73, 2388-2397.	2.8	107

#	Article	IF	CITATIONS
417	Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure. Journal of the American College of Cardiology, 2019, 73, 2384-2387.	2.8	30
418	Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions. European Journal of Internal Medicine, 2019, 65, 17-25.	2.2	8
419	Discrepancy between patient-reported quality of life and the prognostic assessment of Japanese patients hospitalized with acute heart failure. Heart and Vessels, 2019, 34, 1464-1470.	1.2	5
420	Awareness and appropriateness of the management of preclinical heart failure in outpatient clinics in Italy: Insights from the VASTISSIMO study - EValuation of the AppropriateneSs of The preclinical phase (Stage A and Stage B) of Heart Fallure Management in Outpatient Clinics in Italy. Monaldi Archives for Chest Disease, 2019, 89.	0.6	3
421	Long-term and clinical profile of heart failure with recovered ejection fraction in a non-tertiary hospital. Medicina ClÃnica (English Edition), 2019, 152, 50-54.	0.2	0
422	Preoperative Evaluation for Ambulatory Anesthesia. Anesthesiology Clinics, 2019, 37, 195-213.	1.4	17
423	Echocardiography and cancer therapeutics-related cardiac dysfunction. Journal of Medical Ultrasonics (2001), 2019, 46, 309-316.	1.3	5
424	Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES). BMC Cardiovascular Disorders, 2019, 19, 76.	1.7	28
425	Is rhythm control superior to rate control in patients with heart failure and preserved ejection fraction?. Journal of Cardiology, 2019, 74, 233-234.	1.9	0
426	Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction â‰ <b>\$</b> 5%. Current Medical Research and Opinion, 2019, 35, 13-18.	1.9	6
427	Serial sodium values and adverse outcomes in heart failure with preserved ejection fraction. International Journal of Cardiology, 2019, 290, 119-124.	1.7	4
428	Circulating MicroRNAs. Journal of the American College of Cardiology, 2019, 73, 1314-1316.	2.8	7
429	Effect of Neprilysin Inhibition on VariousÂNatriuretic Peptide Assays. Journal of the American College of Cardiology, 2019, 73, 1273-1284.	2.8	98
430	Real-World Prevalence of Adverse Events After Initiating Sacubitril/Valsartan Compared With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Systolic Heart Failure. Journal of Cardiac Failure, 2019, 25, 412-413.	1.7	2
431	News from the American Heart Association: more on sodium–glucose coâ€transporter 2 inhibitors, diabetes and heart failure. European Journal of Heart Failure, 2019, 21, 261-263.	7.1	2
432	Heart failure drug treatment. Lancet, The, 2019, 393, 1034-1044.	13.7	233
433	Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. Heart Failure Reviews, 2019, 24, 499-510.	3.9	9
434	New treatments for hyperkalaemia: clinical use in cardiology. European Heart Journal Supplements, 2019, 21, A41-A47.	0.1	6

#	Article	IF	CITATIONS
435	Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndromeâ€"There is Meat on the Bone. Journal of Clinical Medicine, 2019, 8, 270.	2.4	44
436	RNA sequencing discloses the genome‑wide profile of long noncoding RNAs in dilated cardiomyopathy. Molecular Medicine Reports, 2019, 19, 2569-2580.	2.4	8
437	Safety and Patients' Response to Ambulation With a Pulmonary Artery Catheter in the Cardiac Intensive Care Unit. American Journal of Critical Care, 2019, 28, 101-108.	1.6	2
438	Right Ventricular Size and Function in Chronic Heart Failure. Heart Failure Clinics, 2019, 15, 205-217.	2.1	8
439	The Interleukin-1 Axis and Risk of Death inÂPatients With Acutely DecompensatedÂHeart Failure. Journal of the American College of Cardiology, 2019, 73, 1016-1025.	2.8	52
440	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. Journal of the American College of Cardiology, 2019, 73, 1264-1272.	2.8	139
441	Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. European Heart Journal Quality of Care & Dutcomes, 2019, 5, 361-369.	4.0	11
442	Clinical factors related to morbidity and mortality in highâ€risk heart failure patients: the GUIDEâ€IT predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	7.1	36
443	The relationship between coronary artery disease and cardiovascular events early after liver transplantation. Liver International, 2019, 39, 1363-1371.	3.9	30
444	Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy. Canadian Journal of Cardiology, 2019, 35, 727-735.	1.7	14
445	Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia. European Heart Journal Supplements, 2019, 21, A20-A27.	0.1	13
446	Use of Medicines that May Exacerbate Heart Failure in Older Adults: Therapeutic Complexity of Multimorbidity. Drugs and Aging, 2019, 36, 471-479.	2.7	7
447	Protein biomarkers for cardiorenal syndrome. Expert Review of Proteomics, 2019, 16, 325-336.	3.0	6
448	Intravenous iron therapy in heart failure: a different perspective. European Journal of Heart Failure, 2019, 21, 703-714.	7.1	13
449	Anemia and Iron Deficiency in Heart Failure. Heart Failure Clinics, 2019, 15, 359-369.	2.1	18
450	ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine, 2019, 33, 1127-1140.	1.6	392
451	Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis. Frontiers in Physiology, 2019, 10, 267.	2.8	26
452	Common laboratory parameters as indicators of multiâ€organ dysfunction in acute heart failure. European Journal of Heart Failure, 2019, 21, 751-753.	7.1	0

#	Article	IF	CITATIONS
453	Management of Iron Deficiency in Heart Failure. Acta Haematologica, 2019, 142, 51-56.	1.4	9
454	Evaluation of Pharmacist Impact Within an Interdisciplinary Inpatient Heart Failure Consult Service. Annals of Pharmacotherapy, 2019, 53, 905-915.	1.9	4
455	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology, 2019, 5, 1.	1.7	54
456	Mechanisms of cardiac collagen deposition in experimental models and human disease. Translational Research, 2019, 209, 138-155.	5.0	51
457	Surviving Acute Organ Failure: Cell Polyploidization and Progenitor Proliferation. Trends in Molecular Medicine, 2019, 25, 366-381.	6.7	64
458	Target Dose Versus Maximum Tolerated Dose in Heart Failure. JACC: Heart Failure, 2019, 7, 359-362.	4.1	9
459	Comparison of Echocardiographic and Electrocardiographic Mapping for Cardiac Resynchronisation Therapy Optimisation. Cardiology Research and Practice, 2019, 2019, 1-9.	1.1	7
460	Detection of Congestive Heart Failure Based on LSTM-Based Deep Network via Short-Term RR Intervals. Sensors, 2019, 19, 1502.	3.8	51
461	Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction. Heart and Vessels, 2019, 34, 1650-1656.	1.2	18
462	Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II). Revista Espanola De Cardiologia (English Ed ), 2019, 72, 1020-1030.	0.6	0
463	Subclinical thyroid dysfunction is associated with adverse prognosis in heart failure patients with reduced ejection fraction. BMC Cardiovascular Disorders, 2019, 19, 83.	1.7	32
464	Imaging Challenges in Tricuspid Regurgitation and Right Ventricular Failure. JACC: Cardiovascular Imaging, 2019, 12, 768-770.	5.3	2
465	Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine, 2019, 8, 262.	2.4	43
466	Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities. Irish Journal of Medical Science, 2019, 188, 1169-1174.	1.5	2
467	Trending Towards Safer Breast Cancer Surgeries? Examining Acute Complication Rates from A 13-Year NSQIP Analysis. Cancers, 2019, 11, 253.	3.7	31
468	Preventing Heart Failure at the Population Level. JACC: Heart Failure, 2019, 7, 214-216.	4.1	2
469	Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. JAMA - Journal of the American Medical Association, 2019, 321, 753.	7.4	176
470	Myocardial Dysfunction Associated with Cancer Therapy. Cardiovascular Medicine, 2019, , 71-79.	0.0	0

#	Article	IF	CITATIONS
471	How to Choose Between His Bundle Pacing and Biventricular Pacing for Cardiac Resynchronization Therapy. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	0
472	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. Canadian Journal of Cardiology, 2019, 35, 1097-1105.	1.7	19
473	Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?. Journal of the American Heart Association, 2019, 8, e010887.	3.7	27
474	Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients. Current Heart Failure Reports, 2019, 16, 38-46.	3.3	9
475	Target Doses of Heart Failure MedicalÂTherapy and Blood Pressure. JACC: Heart Failure, 2019, 7, 350-358.	4.1	67
476	Heart Failure Care Dyadic Typology. Journal of Cardiovascular Nursing, 2019, 34, 159-165.	1.1	34
477	ACUTE Heart Failure Risk Stratification. Circulation, 2019, 139, 1157-1161.	1.6	24
478	Medication-Taking Behaviors and Perceptions Among Adults With Heart Failure (from the REasons for) Tj ETQq1 1	0.784314 1.6	1 rgBT /Ove 2
479	Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 1-13.	2.4	68
480	An update on the CardioMEMS pulmonary artery pressure sensor. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471982682.	2.1	22
481	His Bundle Pacing in Heart Failureâ€"Concept and Current Data. Current Heart Failure Reports, 2019, 16, 47-56.	3.3	6
482	Finite state machine implementation for left ventricle modeling and control. BioMedical Engineering OnLine, 2019, 18, 10.	2.7	4
483	How to prescribe loop diuretics in oedema. BMJ: British Medical Journal, 2019, 364, 1359.	2.3	11
484	A post-surgical adjunctive hypoxic therapy for myocardial infarction: Initiate endogenous cardiomyocyte proliferation in adults. Medical Hypotheses, 2019, 125, 16-20.	1.5	8
485	The Role of Troponin for Acute Heart Failure. Current Heart Failure Reports, 2019, 16, 21-31.	3.3	20
486	Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovascular Research, 2019, 115, 922-934.	3.8	77
487	Stable Ischemic Heart Disease. Annals of Internal Medicine, 2019, 171, ITC17.	3.9	18
488	Optimisation of diagnosis and treatment of heart failure in a primary care setting. BMJ Open Quality, 2019, 8, e000660.	1.1	6

#	Article	IF	CITATIONS
489	Hospitalizaci $\tilde{A}^3$ n: el momento m $\tilde{A}_i$ s vulnerable. Revista Espanola De Cardiologia Suplementos, 2019, 18, 17-23.	0.2	0
490	Acute heart failure in Yemen. Journal of Cardiovascular Medicine, 2019, 20, 156-158.	1.5	1
491	Efficacy and Safety of Fuzi Formulae on the Treatment of Heart Failure as Complementary Therapy: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-21.	1.2	8
493	Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology, 2019, 42, 1181-1188.	1.8	4
494	Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X―Really Mark the Spot?. Current Heart Failure Reports, 2019, 16, 250-256.	3.3	1
495	Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy. Biomolecules, 2019, 9, 654.	4.0	6
496	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. The Cochrane Library, 2019, 10, CD013015.	2.8	7
497	Analysis Of Re-Hospitalizations For Patients With Heart Failure Caused By Coronary Heart Disease: Data Of First Event And Recurrent Event. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1333-1341.	2.0	5
498	Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery. Annals of Thoracic Surgery, 2019, 108, 1776-1782.	1.3	9
499	Renin-angiotensin-aldosterone system and kidney interactions in heart failure. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988941.	1.7	6
500	Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure. Current Heart Failure Reports, 2019, 16, 240-249.	3.3	12
501	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. American Journal of Cardiology, 2019, 124, S3-S11.	1.6	26
502	Heart failure with preserved ejection fraction: present status and future directions. Experimental and Molecular Medicine, 2019, 51, 1-9.	7.7	46
503	Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. JACC Basic To Translational Science, 2019, 4, 962-972.	4.1	3
504	Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs. Cells, 2019, 8, 1651.	4.1	39
505	Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure. Journal of Cardiovascular Pharmacology, 2019, 73, 301-306.	1.9	4
506	Cardiac Rehabilitation Increases SIRT1 Activity and $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Hydroxybutyrate Levels and Decreases Oxidative Stress in Patients with HF with Preserved Ejection Fraction. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-10.	4.0	23
507	HeartÂFailure Prevention in Older Patients Using Intensive Blood Pressure Reduction. JACC: Heart Failure, 2019, 7, 1032-1041.	4.1	7

#	Article	IF	Citations
508	Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors. Sensors, 2019, 19, 5003.	3.8	38
509	Role of Palliative Care in the Outpatient Management of the Chronic Heart Failure Patient. Current Heart Failure Reports, 2019, 16, 220-228.	3.3	12
510	Influence of Age on Efficacy and Safety ofÂSpironolactone in HeartÂFailure. JACC: Heart Failure, 2019, 7, 1022-1028.	4.1	6
511	Frailty Is Intertwined With HeartÂFailure. JACC: Heart Failure, 2019, 7, 1001-1011.	4.1	160
512	Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making. Current Heart Failure Reports, 2019, 16, 274-284.	3.3	10
513	Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure. Current Heart Failure Reports, 2019, 16, 304-314.	3.3	8
514	The Therapist's Role in the Medical and Pharmacological Management of Heart Failure. Topics in Geriatric Rehabilitation, 2019, 35, 2-14.	0.4	0
515	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Frontiers in Pharmacology, 2019, 10, 1350.	3.5	75
516	Monitoring for sleep-disordered breathing in heart failure. European Heart Journal Supplements, 2019, 21, M36-M39.	0.1	2
517	Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	1.9	2
518	<p>Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction</p> . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 767-777.	1.9	5
519	Update on pediatric heart failure. Current Opinion in Pediatrics, 2019, 31, 598-603.	2.0	9
520	Cardiotoxicity of HER2-targeted therapies. Current Opinion in Cardiology, 2019, 34, 451-458.	1.8	33
521	Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure. Chinese Medical Journal, 2019, 132, 2278-2285.	2.3	9
522	Biomarker developments in heart failure. Current Opinion in Cardiology, 2019, 34, 218-224.	1.8	4
523	Hemodynamic effects of inotropic drugs in heart failure. Medicine (United States), 2019, 98, e18144.	1.0	1
524	Blended Collaborative Care to Treat Heart Failure and Comorbid Depression: Rationale and Study Design of the Hopeful Heart Trial. Psychosomatic Medicine, 2019, 81, 495-505.	2.0	17
525	Assessment of myocardial viability by PET. Current Opinion in Cardiology, 2019, 34, 466-472.	1.8	12

#	Article	IF	CITATIONS
526	Updates in the management of heart failure for the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension, 2019, 28, 262-266.	2.0	6
527	A Randomized Study Examining the Effects of Mild-to-Moderate Group Exercises on Cardiovascular, Physical, and Psychological Well-being in Patients With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2019, 39, 403-408.	2.1	22
528	Therapeutic Advances in the Management of Cardiogenic Shock. American Journal of Therapeutics, 2019, 26, e234-e247.	0.9	15
529	Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. Current Rheumatology Reports, 2019, 21, 68.	4.7	20
530	Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?. Thrombosis and Haemostasis, 2019, 119, 1891-1893.	3.4	5
531	Improving the accuracy of heart failure diagnosis in low-resource settings through task sharing and decentralization. Global Health Action, 2019, 12, 1684070.	1.9	15
532	<p>Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives</p> . Vascular Health and Risk Management, 2019, Volume 15, 571-579.	2.3	7
533	Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB Journal, 2019, 33, 1209-1225.	0.5	28
534	The Increasing Perioperative Impact of Natriuretic Peptides on Cardiovascular Outcomes. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 2065-2069.	1.3	0
535	Loop diuretics in chronic heart failure: how to manage congestion?. Heart Failure Reviews, 2019, 24, 17-30.	3.9	15
536	Left Ventricular Diastolic Dysfunction is Associated with Renal Dysfunction, Poor Survival and Low Health Related Quality of Life in Cirrhosis. Journal of Clinical and Experimental Hepatology, 2019, 9, 324-333.	0.9	23
537	What factors are associated with patients walking fitness when starting cardiac rehabilitation?. IJC Heart and Vasculature, 2019, 22, 26-30.	1.1	4
538	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0
539	Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease., 2019, , 171-177.		0
540	3D Printing and Heart Failure. JACC: Heart Failure, 2019, 7, 132-142.	4.1	24
541	ldiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Advances in Therapy, 2019, 36, 298-317.	2.9	18
542	Iron Deficiency in Heart Failure. JACC: Heart Failure, 2019, 7, 36-46.	4.1	195
543	Extracorporeal membrane oxygenation for refractory cardiogenic shock: patient survival and health-related quality of life. European Journal of Cardio-thoracic Surgery, 2019, 55, 780-787.	1.4	14

#	Article	IF	Citations
544	Left Ventricular End-Systolic Volume Can Predict 1-Year Hierarchical Clinical Composite End Point in Patients with Cardiac Resynchronization Therapy. Yonsei Medical Journal, 2019, 60, 48.	2.2	8
545	The Many Faces of Heart Failure. Cardiac Electrophysiology Clinics, 2019, 11, 11-20.	1.7	80
546	Contemporary Drug Treatment ofÂChronic Heart Failure With ReducedÂEjection Fraction. JACC: Heart Failure, 2019, 7, 13-21.	4.1	122
547	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic KidneyÂDisease. JACC: Heart Failure, 2019, 7, 25-32.	4.1	51
548	Balancing Benefits and Risks of Spironolactone in HFpEF and ChronicÂKidney Disease Patients. JACC: Heart Failure, 2019, 7, 33-35.	4.1	3
549	CaracterÃsticas y evolución de la insuficiencia cardiaca con función sistólica recuperada en un hospital no terciario. Medicina ClÃnica, 2019, 152, 50-54.	0.6	2
550	Moving galectin-3 closer to the goal line. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H580-H582.	3.2	2
551	MicroRNA-19b-1 reverses ischaemia-induced heart failure by inhibiting cardiomyocyte apoptosis and targeting Bcl2 l11/BIM. Heart and Vessels, 2019, 34, 1221-1229.	1.2	22
552	Dietary metabolism, the gut microbiome, and heart failure. Nature Reviews Cardiology, 2019, 16, 137-154.	13.7	449
553	Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm, 2019, 16, 743-753.	0.7	11
554	Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. IJC Heart and Vasculature, 2019, 22, 1-5.	1.1	19
555	Utility of strain imaging in conjunction with heart failure stage classification for heart failure patient management. Journal of Echocardiography, 2019, 17, 17-24.	0.8	22
556	Contribution of the left atrial remodeling to the elevated pulmonary capillary wedge pressure in patients with WHO Group II pulmonary hypertension. Journal of Echocardiography, 2019, 17, 187-196.	0.8	4
557	Perioperative Cardiovascular Evaluation and Management for Noncardiac Surgery., 2019,, 2-15.		0
558	Perioperative Approach to the High-Risk Cardiac Patient. , 2019, , 16-32.		0
559	Advanced Heart Failure Management and Transplantation. Cardiology Clinics, 2019, 37, 105-111.	2,2	7
560	Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women. Heart Failure Clinics, 2019, 15, 1-8.	2.1	12
561	Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care. European Heart Journal Quality of Care & Dinical Outcomes, 2019, 5, 218-224.	4.0	3

#	Article	IF	CITATIONS
562	Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nature Medicine, 2019, 25, 70-74.	30.7	686
563	Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40.	2.8	168
564	Cardiac contractility modulation improves longâ€term survival and hospitalizations in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2019, 21, 1103-1113.	7.1	69
565	Acute Heart Failure: Pearls for the First Posthospitalization Clinic Visit. Journal for Nurse Practitioners, 2019, 15, 80-86.	0.8	1
566	Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Failure Reviews, 2019, 24, 367-377.	3.9	23
567	Achieving Guideline-Directed Heart Rate ControlEarly Posthospitalization. American Journal of Cardiology, 2019, 123, 1096-1100.	1.6	2
568	Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases. International Journal of Cardiology, 2019, 280, 184-189.	1.7	24
569	A quasi-experimental study examining a nurse-led education program to improve knowledge, self-care, and reduce readmission for individuals with heart failure. Contemporary Nurse, 2019, 55, 15-26.	1.0	38
570	Prognostic value of short-term follow-up B-type natriuretic peptide levels after hospital discharge in patients with acute myocardial infarction. International Journal of Cardiology, 2019, 289, 19-23.	1.7	12
571	Impact of a Pharmacist-Led Intervention on 30-Day Readmission and Assessment of Factors Predictive of Readmission in African American Men With Heart Failure. American Journal of Men's Health, 2019, 13, 155798831881429.	1.6	15
572	Prognostic implications of prealbumin level on admission in patients with acute heart failure referred to a cardiac intensive care unit. Journal of Cardiology, 2019, 73, 114-119.	1.9	9
573	Prognostic value of estimated plasma volume in acute heart failure in three cohort studies. Clinical Research in Cardiology, 2019, 108, 549-561.	3.3	39
574	Medication dosing for heart failure with reduced ejection fraction â€" opportunities and challenges. European Journal of Heart Failure, 2019, 21, 286-296.	7.1	57
575	Contemporary Management of Heart Failure in the Elderly. Drugs and Aging, 2019, 36, 137-146.	2.7	8
576	Transfusionâ€associated circulatory overload—a systematic review of diagnostic biomarkers. Transfusion, 2019, 59, 795-805.	1.6	22
577	Updates in heart failure 30-day readmission prevention. Heart Failure Reviews, 2019, 24, 177-187.	3.9	37
578	Association Between Functional Impairment and Medication Burden in Adults with Heart Failure. Journal of the American Geriatrics Society, 2019, 67, 284-291.	2.6	24
579	Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. Acta Diabetologica, 2019, 56, 273-280.	2.5	19

#	Article	IF	Citations
580	Metabolic syndrome is associated to high-sensitivity cardiac troponin T elevation. Biomarkers, 2019, 24, 153-158.	1.9	8
581	Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta Cardiologica, 2019, 74, 100-107.	0.9	21
582	Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 3-11.	3.0	20
583	Physical Activity and Heart Failure: Taking Steps to Control a Major Public Health Burden. American Journal of Lifestyle Medicine, 2020, 14, 555-570.	1.9	3
584	Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction. Acta Cardiologica, 2020, 75, 20-25.	0.9	10
585	Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends in Cardiovascular Medicine, 2020, 30, 22-28.	4.9	48
586	Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 199-205.	1.4	8
587	Gender Differences in Prognostic Markers of All-Cause Death in Patients with Acute Heart Failure: a Prospective 18-Month Follow-Up Study. Journal of Cardiovascular Translational Research, 2020, 13, 97-109.	2.4	5
588	Impact of chronic kidney disease on in-hospital outcomes following left ventricular assist device placement: A national perspective. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 48-53.	1.6	5
589	Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure. Journal of Pharmacy Practice, 2020, 33, 96-98.	1.0	2
590	Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 152-157.	2.0	19
591	ARNIs: balancing "the good and the bad―of neuroendocrine response to HF. Clinical Research in Cardiology, 2020, 109, 599-610.	3.3	5
592	Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. American Journal of Medicine, 2020, 133, e25-e31.	1.5	29
593	Iron Deficiency Is Associated with Adverse Outcomes in Pediatric Heart Failure. Journal of Pediatrics, 2020, 216, 58-66.e1.	1.8	15
594	Higher risk, high yield: renin-angiotensin system blockade after percutaneous coronary intervention in patients with acute coronary syndrome. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 104-106.	0.6	0
595	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
596	Clinical Evaluation of Heart Failure. , 2020, , 403-417.e3.		0
597	Biomarkers and Precision Medicine in Heart Failure. , 2020, , 449-466.e3.		0

#	Article	IF	CITATIONS
598	Slow Untwisting May Identify Risk ofÂProgression in Elderly With StageÂAÂHeartÂFailure. JACC: Cardiovascular Imaging, 2020, 13, 195-197.	5.3	1
599	Structural and myocardial dysfunction in heart failure beyond ejection fraction. Heart Failure Reviews, 2020, 25, 9-17.	3.9	32
600	A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Failure Reviews, 2020, 25, 207-216.	3.9	12
601	Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. Clinical Research in Cardiology, 2020, 109, 194-204.	3.3	19
602	Associations of Advance Directive Knowledge, Attitudes, and Barriers/Benefits With Preferences for Advance Treatment Directives Among Patients With Heart Failure and Their Caregivers. Journal of Cardiac Failure, 2020, 26, 61-69.	1.7	5
603	The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 782-789.	0.7	16
604	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Failure Reviews, 2020, 25, 31-42.	3.9	52
605	Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy. Heart and Vessels, 2020, 35, 214-222.	1.2	8
606	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. European Journal of Internal Medicine, 2020, 71, 23-31.	2.2	29
607	Reducing Heart Failure Risk in People With Diabetes: The STOP HF Midlands Project. Journal of Cardiac Failure, 2020, 26, 444-445.	1.7	0
608	Comparison of Clinical Characteristics and Outcomes of Patients With Reversible Versus Persistent Methamphetamine-Associated Cardiomyopathy. American Journal of Cardiology, 2020, 125, 127-134.	1.6	14
609	An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?. European Journal of Clinical Pharmacology, 2020, 76, 131-132.	1.9	0
610	The role of iron repletion in adult iron deficiency anemia and other diseases. European Journal of Haematology, 2020, 104, 153-161.	2.2	65
611	Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure. Clinical and Translational Science, 2020, 13, 195-203.	3.1	7
612	Preventive Cardio-Oncology: The Time Has Come. Frontiers in Cardiovascular Medicine, 2019, 6, 187.	2.4	34
613	Mindfulness, Anxiety Symptoms, and Quality of Life in Heart Failure. Journal of Cardiovascular Nursing, 2020, 35, 358-363.	1.1	12
614	Reappraisal of Inflammatory Biomarkers in Heart Failure. Current Heart Failure Reports, 2020, 17, 9-19.	3.3	21
615	Approaches for the Management of Resistant Hypertension in 2020. Current Hypertension Reports, 2020, 22, 3.	3.5	12

#	Article	IF	CITATIONS
616	Heart failure with preserved ejection fraction: Similarities and differences between women and men. International Journal of Cardiology, 2020, 304, 101-108.	1.7	18
617	Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take?. Clinical Cardiology, 2020, 43, 137-144.	1.8	16
618	Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology, 2020, 43, 145-155.	1.8	83
619	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America, 2020, 49, 141-149.	2.2	23
620	Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. Journal of Heart and Lung Transplantation, 2020, 39, 27-36.	0.6	15
621	Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiology, 2020, 5, 318.	6.1	42
622	ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast, 2020, 49, 183-186.	2.2	9
623	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361.	1.6	335
624	Ultrafast Ultrasound Imaging in PediatricÂand Adult Cardiology. JACC: Cardiovascular Imaging, 2020, 13, 1771-1791.	5.3	54
625	Design and Region-Specific Adaptation of the Dietary Intervention Used in the SODIUM-HF Trial: A Multicentre Study. CJC Open, 2020, 2, 8-14.	1.5	5
627	Will the new decade bring home remote monitoring of heart failure patients?. Netherlands Heart Journal, 2020, 28, 1-2.	0.8	0
628	Hiding in Plain Sight: Cardiac Amyloidosis, an Emerging Epidemic. Canadian Journal of Cardiology, 2020, 36, 373-383.	1.7	5
629	Roles of arterial pressure volume index and arterial velocity pulse index trajectories in risk prediction in hypertensive patients with heart failure with preserved ejection fraction. Clinical and Experimental Hypertension, 2020, 42, 469-478.	1.3	5
630	Bioanalytical Assessment of Plasma Concentrations of Angiotensin-Converting Enzyme II Inhibitors and Angiotensin Receptor Blockers: A Pilot Study Among Patients Hospitalized With Acute Heart Failure. American Journal of Therapeutics, 2020, 27, e366-e370.	0.9	0
631	B-type natriuretic peptide and its role in altering Ca2+-regulatory proteins in heart failureâ€"mechanistic insights. Heart Failure Reviews, 2020, 25, 861-871.	3.9	1
632	Pathophysiology of Exercise Intolerance and Its Treatment With Exercise-Based Cardiac Rehabilitation in Heart Failure With Preserved Ejection Fraction. Journal of Cardiopulmonary Rehabilitation and Prevention, 2020, 40, 9-16.	2.1	26
633	Prostate Cancer in Men With Treated Advanced Heart Failure: Should we Keep Screening?. Urology, 2020, 136, 46-50.	1.0	6
634	Therapies for Advanced Heart Failure Patients Ineligible for Heart Transplantation: Beyond Pharmacotherapy. Canadian Journal of Cardiology, 2020, 36, 234-243.	1.7	6

#	Article	IF	CITATIONS
635	Risk Prediction in Transition: MAGGIC Score Performance at Discharge and Incremental Utility of Natriuretic Peptides. Journal of Cardiac Failure, 2020, 26, 52-60.	1.7	10
636	cGMP Signaling and Modulation in Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 385-398.	1.9	27
637	Differences in medical treatment and clinical characteristics between men and women with heart failure – a single-centre multivariable analysis. European Journal of Clinical Pharmacology, 2020, 76, 539-546.	1.9	11
638	Low ALT Levels Associated with Poor Outcomes in 8700 Hospitalized Heart Failure Patients. Journal of Clinical Medicine, 2020, 9, 3185.	2.4	10
639	Utility of Restricted Mean Survival Time Analysis for HeartÂFailure Clinical Trial Evaluation and Interpretation. JACC: Heart Failure, 2020, 8, 973-983.	4.1	28
640	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939.	4.1	88
641	Endogenous CCN5 Participates in Angiotensin II/TGF- $\hat{l}^21$ Networking of Cardiac Fibrosis in High Angiotensin II-Induced Hypertensive Heart Failure. Frontiers in Pharmacology, 2020, $11, 1235$ .	3.5	16
642	Congestive heart failure waveform classification based on short time-step analysis with recurrent network. Informatics in Medicine Unlocked, 2020, 21, 100441.	3.4	15
643	The National Coverage Decision for MitraClip in Functional Mitral Regurgitation. JAMA Cardiology, 2021, 6, 9-10.	6.1	0
644	Super-Responders and Nonresponders inÂthe COAPT Trial. Journal of the American College of Cardiology, 2020, 76, 1015-1017.	2.8	1
645	Contemporary Management of SevereÂAcute Kidney Injury and Refractory Cardiorenal Syndrome. Journal of the American College of Cardiology, 2020, 76, 1084-1101.	2.8	55
646	Angiotensin Receptor-Neprilysin Inhibition Based on History of HeartÂFailure and Use of Renin-Angiotensin System Antagonists. Journal of the American College of Cardiology, 2020, 76, 1034-1048.	2.8	32
648	Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report. European Heart Journal - Case Reports, 2020, 4, 1-4.	0.6	2
649	Angiotensin-Neprilysin Inhibition in Black Americans. JACC: Heart Failure, 2020, 8, 859-866.	4.1	11
650	Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 800-810.	4.1	64
651	Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI). JACC: Cardiovascular Interventions, 2020, 13, 2220-2234.	2.9	17
652	Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1506.	7.4	27
653	A manifesto of collaborative longitudinal cardiovascular care in heart failure. Heart Failure Reviews, 2020, 25, 1089-1097.	3.9	2

#	Article	IF	CITATIONS
654	Automated quantitative analysis of CZT SPECT stratifies cardiovascular risk in the obese population: Analysis of the REFINE SPECT registry. Journal of Nuclear Cardiology, 2022, 29, 727-736.	2.1	11
655	Addressing Comorbidities in Heart Failure. Heart Failure Clinics, 2020, 16, 441-456.	2.1	13
656	Soluble ST2 protein as a new biomarker in patients with precapillary pulmonary hypertension. Archives of Medical Science, 2020, , .	0.9	4
657	Polypharmacy in Older Adults Hospitalized for Heart Failure. Circulation: Heart Failure, 2020, 13, e006977.	3.9	102
658	Large Animal Models of HeartÂFailure. JACC Basic To Translational Science, 2020, 5, 840-856.	4.1	29
659	Percutaneous Valve Interventions in Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	1
660	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	7.1	23
661	Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study. Cardiology and Therapy, 2020, 9, 505-521.	2.6	2
662	Discovery of TITIN Gene Truncating Variant Mutations and 5-Year Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. American Journal of Cardiology, 2020, 137, 97-102.	1.6	8
663	The Dentoalveolar Surgical Patient. Oral and Maxillofacial Surgery Clinics of North America, 2020, 32, 495-510.	1.0	2
664	Implications of obesity across the heart failure continuum. Progress in Cardiovascular Diseases, 2020, 63, 561-569.	3.1	43
665	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Revista Portuguesa De Cardiologia, 2020, 39, 517-541.	0.5	8
666	Treatment optimization of beta-blockers in chronic heart failure therapy. Scientific Reports, 2020, 10, 15903.	3.3	6
667	Characteristics and outcomes of patients with suspected heart failure referred in line with National Institute for Health and Care Excellence guidance. Heart, 2020, 106, 1579-1585.	2.9	12
668	Multimodality Imaging in Evaluation of Cardiovascular Complications in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1345-1357.	2.8	47
669	Heart failure with preserved ejection fraction in Belgium: characteristics and outcome of a real-life cohort. Acta Cardiologica, 2021, 76, 697-706.	0.9	6
670	Heart failure-induced atrial remodelling promotes electrical and conduction alternans. PLoS Computational Biology, 2020, 16, e1008048.	3.2	5
671	Driving Habits and Reaction Times on a Driving Simulation in Older Drivers With Chronic Heart Failure. Journal of Cardiac Failure, 2020, 26, 555-563.	1.7	1

#	Article	IF	Citations
672	Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD. Kidney International Reports, 2020, 5, 1052-1060.	0.8	11
673	Gender Differences in Hispanic Patients of Mexican Origin Hospitalized with Heart Failure. Women's Health Issues, 2020, 30, 384-392.	2.0	1
674	Diagnostic value of circulating microRNAâ€19b in heart failure. European Journal of Clinical Investigation, 2020, 50, e13308.	3.4	3
675	Evaluating the confounding effects of medical therapies on potassium intake assessment in patients with heart failure. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1005-1013.	2.6	0
676	Left Ventricular End-Systolic Volume Is a Reliable Predictor of New-Onset Heart Failure with Preserved Left Ventricular Ejection Fraction. Cardiology Research and Practice, 2020, 2020, 1-7.	1.1	6
677	Management of patients with heart failure treated in cardiology consultations: IC-BERG Study. Revista Clínica Espanõla, 2020, 220, 339-349.	0.5	0
678	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?. Current Cardiology Reports, 2020, 22, 95.	2.9	22
679	Biomarkers for coronary artery disease and heart failure. , 2020, , 519-543.		1
680	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, e159-e240.	2.8	364
681	Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department. Egyptian Heart Journal, 2020, 72, 53.	1.2	5
682	Standardized Definitions for EvaluationÂofÂHeart Failure Therapies: Scientific Expert Panel From the HeartÂFailure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	4.1	15
683	Sex Differences in HFpEF. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	2
684	Diagnosis and treatment of right ventricular dysfunction in congenital heart disease. Cardiovascular Diagnosis and Therapy, 2020, 10, 1625-1645.	1.7	11
685	The efficacy of baroreflex activation therapy for heart failure. Medicine (United States), 2020, 99, e22951.	1.0	4
686	Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension. Journal of the American Heart Association, 2020, 9, e018827.	3.7	23
687	Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators. Cardiovascular Diabetology, 2020, 19, 202.	6.8	9
688	Unconventional Natural Gas Development and HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 2875-2877.	2.8	2
689	Circulating Circular RNAs: Novel Biomarkers for Heart Failure. Frontiers in Pharmacology, 2020, 11, 560537.	3.5	13

#	Article	IF	CITATIONS
690	Crossing the chasm: caution for use of angiotensin receptor-neprilysin inhibition in patients with cardiogenic shock– a case report. European Heart Journal - Case Reports, 2020, 4, 1-4.	0.6	3
691	Oxidative stress and its association with ST resolution and clinical outcome measures in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. BMC Research Notes, 2020, 13, 525.	1.4	9
693	Pharmacogenetic factors affecting $\hat{l}^2$ -blocker metabolism and response. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 953-964.	3.3	20
694	Nitrosamine Impurities in Angiotensin Receptor Blockers. Cardiology in Review, 2020, 28, 262-265.	1.4	8
695	Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China. Frontiers in Pharmacology, 2020, 11, 1101.	3.5	14
696	NT-proBNP Response to Sacubitril/Valsartan in Hospitalized HeartÂFailure Patients With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 822-833.	4.1	21
697	Heart-type fatty acid-binding protein: an overlooked cardiac biomarker. Annals of Medicine, 2020, 52, 444-461.	3.8	29
698	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Therapy, 2020, 11, 1925-1934.	2.5	15
699	The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARMâ€CHF randomized controlled trial. ESC Heart Failure, 2020, 7, 3310-3319.	3.1	10
700	Competitive ELISA for N-terminal pro-brain natriuretic peptide (NT-proBNP) determination in human plasma. Analyst, The, 2020, 145, 6719-6727.	<b>3.</b> 5	6
701	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients With Acute Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 123.	2.4	6
702	<i>Platycodon grandiflorum</i> Protects Against Anthracycline-Induced Cardiotoxicity in Early Breast Cancer Patients. Integrative Cancer Therapies, 2020, 19, 153473542094501.	2.0	8
703	Chronic stable heart failure model in ovine species. Artificial Organs, 2020, 44, 947-954.	1.9	1
704	Artificial Intelligence-Enabled ECG Algorithm to Identify Patients With Left Ventricular Systolic Dysfunction Presenting to the Emergency Department With Dyspnea. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008437.	4.8	81
705	Cardiac biomarkers of heart failure in chronic kidney disease. Clinica Chimica Acta, 2020, 510, 298-310.	1.1	53
706	Rationale and design of a riskâ€guided strategy for reducing readmissions for acute decompensated heart failure: the Riskâ€HF study. ESC Heart Failure, 2020, 7, 3151-3160.	3.1	6
707	Renal safety and efficacy of angiotensin receptorâ€neprilysin inhibitor: A metaâ€analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1235-1243.	1.5	14
708	Perioperative management of patients with undergoing durable mechanical circulatory support. Annals of Translational Medicine, 2020, 8, 830-830.	1.7	4

#	Article	IF	CITATIONS
709	Care Gaps in Adherence to HeartÂFailure Guidelines. JACC: Heart Failure, 2020, 8, 725-738.	4.1	55
710	Sodium–glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Current Opinion in Cardiology, 2020, 35, 589-601.	1.8	3
711	Heart failure assessed based on plasma B-type natriuretic peptide (BNP) levels negatively impacts activity of daily living in patients with hip fracture. PLoS ONE, 2020, 15, e0237387.	2.5	9
712	Regulation of energy metabolism by combination therapy attenuates cardiac metabolic remodeling in heart failure. International Journal of Biological Sciences, 2020, 16, 3133-3148.	6.4	17
713	Exercise Training Effects on the Relationship of Physical Function and Health-Related Quality of Life Among Older Heart Failure Patients With Preserved Ejection Fraction. Journal of Cardiopulmonary Rehabilitation and Prevention, 2020, 40, 427-433.	2.1	19
714	A Stepwise Approach to the Management of Heart Failure and its Comorbidities. Journal of Osteopathic Medicine, 2020, 120, 90-99.	0.8	1
715	Searching for Preclinical Models of Acute Decompensated Heart Failure: a Concise Narrative Overview and a Novel Swine Model. Cardiovascular Drugs and Therapy, 2022, 36, 727-738.	2.6	2
718	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. European Journal of Heart Failure, 2021, 23, 703-712.	7.1	87
719	The cancer patient and cardiology. European Journal of Heart Failure, 2020, 22, 2290-2309.	7.1	62
720	Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2020, 22, 82.	3.5	13
721	Easily Multiplexable Immunoplatform to Assist Heart Failure Diagnosis through Amperometric Determination of Galectinâ€3. Electroanalysis, 2020, 32, 2775-2785.	2.9	4
722	Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. ESC Heart Failure, 2020, 7, 3633-3643.	3.1	19
723	BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era. Current Cardiology Reports, 2020, 22, 150.	2.9	7
724	Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure. Journal of Medical Economics, 2020, 23, 1450-1460.	2.1	0
725	Replacing art with numbers: decongesting congestive heart failure. European Journal of Heart Failure, 2020, 22, 1902-1904.	7.1	1
726	<p>Efficacy and Safety Outcome of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Patients with Heart Failure and Preserved Ejection Fraction (HFpEF): Preliminary Results</p> . Research Reports in Clinical Cardiology, 0, Volume 11, 39-47.	0.2	1
727	A nomogram based on a patient-reported outcomes measure: predicting the risk of readmission for patients with chronic heart failure. Health and Quality of Life Outcomes, 2020, 18, 290.	2.4	11
728	Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients. ESC Heart Failure, 2020, 7, 2711-2724.	3.1	2

#	Article	IF	CITATIONS
729	Efficacy of adding ramipril ( <scp>VAsotop</scp> ) to the combination of furosemide (Lasix) and pimobendan ( <scp>VEtmedin</scp> ) in dogs with mitral valve degeneration: The <scp>VALVE</scp> trial. Journal of Veterinary Internal Medicine, 2020, 34, 2232-2241.	1.6	17
730	Advanced heart failure beckons: where are the cardiologists?. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 294-296.	0.6	1
731	Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection. Frontiers in Cardiovascular Medicine, 2020, 7, 157.	2.4	0
732	Management of Cardiac Toxicity Induced by Chemotherapy. Journal of Clinical Medicine, 2020, 9, 2885.	2.4	24
733	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	329.8	29
734	Rethinking the Meaning of Palliation in Heart Failure. Current Heart Failure Reports, 2020, 17, 309-313.	3.3	0
736	Potential mechanism of left ventricular spherical remodeling: association of mitral valve complex-myocardium longitudinal tissue remodeling mismatch. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H694-H704.	3.2	1
737	Management of the Patient with Heart Failure and an Implantable Pulmonary Artery Hemodynamic Sensor. Current Cardiovascular Risk Reports, 2020, 14, 1.	2.0	6
738	A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction. Cardiology and Therapy, 2020, 9, 561-568.	2.6	0
739	Potential Molecular Mechanism of the <i>NPPB</i> Gene in Postischemic Heart Failure with and without T2DM. BioMed Research International, 2020, 2020, 1-17.	1.9	2
740	Comparison of effectiveness and survival after the MitraClip or Carillon procedure for severe functional mitral regurgitation: a single-center retrospective analysis. Archives of Medical Sciences Atherosclerotic Diseases, 2020, 5, 171-177.	1.0	1
741	Challenges and Potential Improvements to Patient Access to Pharmaceuticals. Circulation, 2020, 142, 790-798.	1.6	7
742	<p>Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study</p> . Patient Preference and Adherence, 2020, Volume 14, 2225-2230.	1.8	4
743	Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data. Scientific Reports, 2020, 10, 21340.	3.3	28
744	The Proportion of Women Authors and the Inclusion of Sex and Gender Content Among the American College of Cardiology Clinical Practice Guidelines, 2008–2018. Journal of Women's Health, 2021, 30, 1616-1625.	3.3	9
745	Cardiac allograft rejection in the current era of continuous flow left ventricular assist devices. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 124-134.e8.	0.8	8
746	Association of Soluble Suppression of Tumorigenesis-2 (ST2) with Endothelial Function in Patients with Ischemic Heart Failure. International Journal of Molecular Sciences, 2020, 21, 9385.	4.1	16
747	<p>MAGGIC Risk Model Predicts Adverse Events and Left Ventricular Remodeling in Non-Ischemic Dilated Cardiomyopathy</p> . International Journal of General Medicine, 2020, Volume 13, 1477-1486.	1.8	2

#	ARTICLE	IF	CITATIONS
748	Potential Role and Prognostic Value of Erythropoietin Levels in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Frontiers in Cardiovascular Medicine, 2020, 7, 605257.	2.4	1
749	Impact of contrast-induced acute kidney injury on the association between renin-angiotensin system inhibitors and long-term mortality in heart failure patients. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032097979.	1.7	1
750	Sex Differences in Left Ventricular Remodeling and Outcomes in Chronic Aortic Regurgitation. Journal of Clinical Medicine, 2020, 9, 4100.	2.4	3
751	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOISTâ€WHF in perspective. ESC Heart Failure, 2020, 7, 3261-3267.	3.1	16
752	Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction. CJC Open, 2020, 2, 447-453.	1.5	11
<b>7</b> 53	Minimizing hardware using physiological conduction system pacing: A case. IHJ Cardiovascular Case Reports (CVCR), 2020, 4, 130-132.	0.1	0
754	Towards Generating Anomaly Prediction based on Health Checkup Results. Procedia Computer Science, 2020, 176, 1773-1782.	2.0	0
755	Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension. Diagnostics, 2020, 10, 857.	2.6	4
756	Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction. JACC: Clinical Electrophysiology, 2020, 6, 1721-1731.	3.2	20
757	Management and Treatment of Myocarditis in Athletes. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 65.	0.9	16
758	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. Journal of the American College of Cardiology, 2020, 76, 2527-2564.	2.8	41
<b>7</b> 59	Coronary anatomy and comorbidities impact on elective PCI outcomes in left main and multivessel coronary artery disease. Catheterization and Cardiovascular Interventions, 2020, 98, 436-444.	1.7	5
760	Clinical Features and Outcomes of Peripartum Cardiomyopathy in Nigeria. Journal of the American College of Cardiology, 2020, 76, 2352-2364.	2.8	27
761	Promoting Full Recovery and Improved Relapse-Free Prognosis in the Diagnosis and Treatment of Peripartum Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, 2365-2367.	2.8	2
762	Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions. BMC Cardiovascular Disorders, 2020, 20, 208.	1.7	18
763	Novel heat shock protein 90 inhibitor improves cardiac recovery in a rodent model of donation after circulatory death. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e187-e197.	0.8	11
764	Mineralocorticoid Receptor Antagonist Use in Heart Failure With Reduced Ejection Fraction and End-Stage Renal Disease Patients on Dialysis. Cardiology in Review, 2020, 28, 107-115.	1.4	4
765	Managing Hypertension in the elderly: What's new?. American Journal of Preventive Cardiology, 2020, 1, 100001.	3.0	5

#	Article	IF	CITATIONS
766	A Modern Integration of Palliative Care Into the Management of Heart Failure. Canadian Journal of Cardiology, 2020, 36, 1050-1060.	1.7	11
767	Cardiacâ€peripheral transvenous gradients of microRNA expression in systolic heart failure patients. ESC Heart Failure, 2020, 7, 835-843.	3.1	14
768	Detection and management of arrhythmias in peripartum cardiomyopathy. Cardiovascular Diagnosis and Therapy, 2020, 10, 325-335.	1.7	18
769	l̂ <sup>2</sup> -Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. Biomedicine Hub, 2020, 5, 1-10.	1.2	4
770	An overview of heart failure in low- and middle-income countries. Cardiovascular Diagnosis and Therapy, 2020, 10, 244-251.	1.7	32
771	Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. Heart and Vessels, 2020, 35, 1446-1453.	1.2	11
772	Noncardiac comorbidity clustering in heart failure: an overlooked aspect with potential therapeutic door. Heart Failure Reviews, 2022, 27, 767-778.	3.9	6
773	Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovascular Diabetology, 2020, 19, 55.	6.8	27
774	Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Failure Reviews, 2021, 26, 1359-1370.	3.9	41
775	<p>Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure</p> . Clinical Interventions in Aging, 2020, Volume 15, 547-556.	2.9	11
776	Potential use of ubiquinol and d-ribose in patients with heart failure with preserved ejection fraction. Annals of Medicine and Surgery, 2020, 55, 77-80.	1.1	5
777	Noninvasive Positive Pressure Ventilation for Acute Decompensated Heart Failure. Heart Failure Clinics, 2020, 16, 271-282.	2.1	2
778	Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation. Heart, 2020, 106, 292-298.	2.9	12
779	Refocusing on the Primary Prevention of Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	7
780	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	3.0	16
781	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nature Reviews Cardiology, 2020, 17, 641-655.	13.7	143
782	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. European Journal of Heart Failure, 2020, 22, 1615-1624.	7.1	24
783	Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications. Heart Failure Reviews, 2022, 27, 295-319.	3.9	40

#	Article	IF	CITATIONS
784	CPAP is associated with decreased risk of AF recurrence in patients with OSA, especially those younger and slimmer: a meta-analysis. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 369-379.	1.3	13
785	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease ( <scp><b>AMBER</b></scp> ): results in the preâ€specified subgroup with heart failure. European Journal of Heart Failure, 2020, 22, 1462-1471.	7.1	27
786	Predicting severe clinical events by learning about life-saving actions and outcomes using distant supervision. Journal of Biomedical Informatics, 2020, 107, 103425.	4.3	5
787	COVIDâ€19 and reninâ€angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ―ls there any scientific evidence for controversy?. Journal of Internal Medicine, 2020, 288, 410-421.	6.0	38
788	Advanced HeartÂFailure. JACC: Heart Failure, 2020, 8, 523-536.	4.1	154
789	Sacubitril/Valsartan in Advanced HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	4.1	39
790	Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart, 2020, 7, e001257.	2.3	35
791	Rationale and design of the AUGUSTâ€AHF Study. ESC Heart Failure, 2020, 7, 3124-3133.	3.1	6
792	Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor. Biomedicine and Pharmacotherapy, 2020, 129, 110410.	5.6	5
793	The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure. BMC Cardiovascular Disorders, 2020, 20, 262.	1.7	5
794	The Latest Clinical Understandings and Theory of the Cardiovascular Systems for Cardiovascular Emergencies and Their Management. Heart Failure Clinics, 2020, 16, ix-x.	2.1	0
795	Advances in the Management of Acute Decompensated Heart Failure. Medical Clinics of North America, 2020, 104, 601-614.	2.5	7
796	CardioMEMS <sup>TM</sup> System in the Daily Management of Heart Failure: Review of Current Data and Technique of Implantation. Expert Review of Medical Devices, 2020, 17, 637-648.	2.8	8
797	Angiotensin– neprilysin inhibitors: should we initiate them in hospital for patients with acute decompensated heart failure?. BMJ Evidence-Based Medicine, 2020, 25, 151-152.	3.5	0
798	A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA. Cardiovascular Endocrinology and Metabolism, 2020, 9, 36-41.	1.1	0
799	Elevated CA-125 as Humoral Biomarker of Congestive Heart Failure: Illustrative Cases and a Short Review of Literature. Case Reports in Cardiology, 2020, 2020, 1-5.	0.2	7
800	SiTe iC: A telemonitoring system for heart failure patients. International Journal of Medical Informatics, 2020, 141, 104204.	3.3	2
801	Survival After Heart Transplantation in Patients Bridged With Mechanical Circulatory Support. Journal of the American College of Cardiology, 2020, 75, 2892-2905.	2.8	40

#	Article	IF	CITATIONS
802	Cardiac Considerations in Chronic Lung Disease. Respiratory Medicine, 2020, , .	0.1	2
803	Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2020, 75, 3033-3043.	2.8	82
804	Improving physical activity and exercise capacity in heart failure. Taking the first step isÂalways the hardest. European Journal of Heart Failure, 2020, 22, 1734-1736.	7.1	0
805	Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study. Internal and Emergency Medicine, 2020, 15, 1219-1229.	2.0	16
806	Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials. American Journal of Medicine, 2020, 133, e280-e289.	1.5	3
807	ProBNP processing is decreased by obesity in patients with heart failure. Annals of Translational Medicine, 2020, 8, 135-135.	1.7	4
808	Systolic Blood Pressure in HeartÂFailure With Preserved Ejection Fraction TreatedÂWith Sacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 75, 1644-1656.	2.8	46
809	Study on the influence of dynamic/static interface processing methods on CFD simulation results of the axial-flow blood pump. Advances in Mechanical Engineering, 2020, 12, 168781402091057.	1.6	3
810	Factors associated with abnormal left ventricular ejection fraction (decreased or increased) in patients with sepsis in the intensive care unit. PLoS ONE, 2020, 15, e0229563.	2.5	6
812	Emerging Techniques for RiskÂStratification in Nonischemic DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2020, 75, 1196-1207.	2.8	25
813	<i>ALOX5</i> , <i>LPA</i> , <i>MMP9</i> and <i>TPO</i> gene polymorphisms increase atherothrombosis susceptibility in middle-aged Mexicans. Royal Society Open Science, 2020, 7, 190775.	2.4	2
814	Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature. ESC Heart Failure, 2020, 7, 1319-1330.	3.1	12
815	Iron and HeartÂFailure. JACC Basic To Translational Science, 2020, 5, 300-313.	4.1	56
816	Hemodynamic assessment of diastolic function for experimental models. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1139-H1158.	3.2	25
818	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews Cardiology, 2020, 17, 474-502.	13.7	332
819	Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults. Pharmacotherapy, 2020, 40, 544-564.	2.6	3
820	The Emulation and Adaptation of a Global Model of Clinical Practice Guidelines on Chronic Heart Failure in BRICS Countries: A Comparative Study. International Journal of Environmental Research and Public Health, 2020, 17, 1735.	2.6	3
821	A roadmap to build a phenotypic metric of ageing: insights from the Baltimore Longitudinal Study of Aging. Journal of Internal Medicine, 2020, 287, 373-394.	6.0	86

#	Article	IF	CITATIONS
822	Acute heart failure. Nature Reviews Disease Primers, 2020, 6, 16.	30.5	237
823	Population-Level Sex Differences and Predictors for Treatment With Catheter Ablation in Patients With Atrial Fibrillation and Heart Failure. CJC Open, 2020, 2, 85-93.	1.5	3
824	Anesthetic management of women with heart failure during pregnancy: a retrospective cohort study. International Journal of Obstetric Anesthesia, 2020, 44, 40-50.	0.4	5
825	Baroreflex Activation Therapy in Patients With HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 1-13.	2.8	121
826	Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Failure, 2020, 7, 2007-2011.	3.1	63
827	Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure. ESC Heart Failure, 2020, 7, 2621-2628.	3.1	34
828	The Multifaced Perspectives of Genetic Testing in Pediatric Cardiomyopathies and Channelopathies. Journal of Clinical Medicine, 2020, 9, 2111.	2.4	2
829	Identification of Patients with Heart Failure in Large Datasets. Heart Failure Clinics, 2020, 16, 379-386.	2.1	3
830	A patient-centred, comprehensive model for the care for heart failure: the $360 \hat{A}^{\circ}$ heart failure centre. Open Heart, 2020, 7, e001221.	2.3	9
831	Cardiac Imaging in Oncology Patients in Europe: a Model for Advancement of CV Safety and Development of Comprehensive CV Care. Journal of Cardiovascular Translational Research, 2020, 13, 490-494.	2.4	5
832	Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction. PLoS ONE, 2020, 15, e0233161.	2.5	0
833	An outlook on biomarkers in cardiogenic shock. Current Opinion in Critical Care, 2020, 26, 392-397.	3.2	14
834	Epigenetic-sensitive liquid biomarkers and personalised therapy in advanced heart failure: a focus on cell-free DNA and microRNAs. Journal of Clinical Pathology, 2020, 73, 535-543.	2.0	22
835	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3075-e3089.	3.6	11
836	The renin angiotensin aldosterone system and COVID-19. Saudi Pharmaceutical Journal, 2020, 28, 977-984.	2.7	5
837	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. ESC Heart Failure, 2020, 7, 727-736.	3.1	7
838	Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. Vascular Health and Risk Management, 2020, Volume 16, 41-51.	2.3	15
839	Introduction and Vision. Cardiovascular Drugs and Therapy, 2020, 34, 1-2.	2.6	1

#	Article	IF	CITATIONS
840	Study protocol for a randomized controlled trial: Qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST). BMC Complementary Medicine and Therapies, 2020, 20, 38.	2.7	8
841	Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Failure, 2020, 7, 559-566.	3.1	15
842	Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital. Journal of Community Hospital Internal Medicine Perspectives, 2020, 10, 38-44.	0.8	4
843	Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466.	2.8	7
844	Dynamic Augmentation of Left Ventricle and Mitral Valve Function With an Implantable Soft Robotic Device. JACC Basic To Translational Science, 2020, 5, 229-242.	4.1	14
845	Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 92.	1.7	14
846	Heart Failure Dashboard Design and Validation to Improve Care of Veterans. Applied Clinical Informatics, 2020, 11, 153-159.	1.7	15
847	Reviewing the clinical utility of ventricular assist device log files. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 247-255.	0.6	1
848	PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. American Heart Journal, 2020, 223, 98-105.	2.7	12
849	ABCs of Heart Failure Management: A Guide for Nurse Practitioners. Journal for Nurse Practitioners, 2020, 16, 243-248.	0.8	0
850	Managing the elderly patient with hypertension: current strategies, challenges, and considerations. Expert Review of Cardiovascular Therapy, 2020, 18, 117-125.	1.5	3
851	Health-related quality of life and extent of self-care practice among heart failure patients in Ethiopia. Health and Quality of Life Outcomes, 2020, 18, 27.	2.4	20
852	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2020, 69, 1000-1010.	0.6	106
853	Heart failure self-care, factors influencing self-care and the relationship with health-related quality of life: A cross-sectional observational study. Heliyon, 2020, 6, e03412.	3.2	32
854	Drug-induced myocardial dysfunction – recommendations for assessment in clinical and pre-clinical studies. Expert Opinion on Drug Safety, 2020, 19, 281-294.	2.4	1
855	Therapeutic efficacy of shenmai injection as an adjuvant treatment in dilated cardiomyopathy. Medicine (United States), 2020, 99, e19158.	1.0	2
856	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. Expert Review of Cardiovascular Therapy, 2020, 18, 85-101.	1.5	2
857	Manejo de los pacientes con insuficiencia cardiaca atendidos en la consulta de cardiologÃa: Estudio IC-BERG. Revista Clinica Espanola, 2020, 220, 339-349.	0.6	5

#	Article	IF	CITATIONS
858	Serum retinolâ€binding protein 4 as a predictor of cardiovascular events in elderly patients with chronic heart failure. ESC Heart Failure, 2020, 7, 542-550.	3.1	12
859	Barriers to Early Utilization of Palliative Care in Heart Failure: A Narrative Review. Healthcare (Switzerland), 2020, 8, 36.	2.0	15
860	Natriuretic Peptides to Predict Short-Term Mortality in Patients With Sepsis: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 50-64.	2.4	30
861	Editorial commentary: Management of heart failure: Are we there yet?. Trends in Cardiovascular Medicine, 2020, 30, 519-520.	4.9	0
862	Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?. Journal of Clinical Medicine, 2020, 9, 164.	2.4	53
863	Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. Journal of Clinical Medicine, 2020, 9, 241.	2.4	11
864	Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments?. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 9-17.	2.2	25
865	Evaluating risk prediction models for adults with heart failure: A systematic literature review. PLoS ONE, 2020, 15, e0224135.	2.5	54
866	Ceruloplasmin, NT-proBNP, and Clinical Data as Risk Factors of Death or Heart Transplantation in a 1-Year Follow-Up of Heart Failure Patients. Journal of Clinical Medicine, 2020, 9, 137.	2.4	1
867	Patient-Reported Barriers and Facilitators to Deprescribing Cardiovascular Medications. Drugs and Aging, 2020, 37, 125-135.	2.7	23
868	Heart failure after myocardial infarction: Is it all in the risk factors?. REC: CardioClinics, 2020, 55, 1-3.	0.1	0
869	The Biomarkers for Acute Myocardial Infarction and Heart Failure. BioMed Research International, 2020, 2020, 1-14.	1.9	53
870	Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis. BMC Cardiovascular Disorders, 2020, 20, 21.	1.7	32
871	Current pharmacotherapeutic strategies for cardiac arrhythmias in heart failure. Expert Opinion on Pharmacotherapy, 2020, 21, 339-352.	1.8	4
872	Treatment outcome and its predictors among patients of acute heart failure at a tertiary care hospital in Ethiopia: a prospective observational study. BMC Cardiovascular Disorders, 2020, 20, 16.	1.7	18
873	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. Journal of the American College of Cardiology, 2020, 75, 539-555.	2.8	58
874	<p>Prognostic Role of NT-proBNP for in-Hospital and 1-Year Mortality in Patients with Acute Exacerbations of COPD</p> . International Journal of COPD, 2020, Volume 15, 57-67.	2.3	19
875	Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction. Open Heart, 2020, 7, e001112.	2.3	16

#	Article	IF	CITATIONS
876	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure, 2020, 22, 1357-1365.	7.1	66
877	Macrophage Activities in Myocardial Infarction and Heart Failure. Cardiology Research and Practice, 2020, 2020, 1-16.	1.1	36
878	Managing heart failure with preserved ejection fraction. Annals of Translational Medicine, 2020, 8, 395-395.	1.7	7
879	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	6.1	74
880	Longitudinal Association Between Markers of Liver Injury and Mortality in COVIDâ€19 in China. Hepatology, 2020, 72, 389-398.	7.3	346
881	Physical vs. multidimensional frailty in older adults with and without heart failure. ESC Heart Failure, 2020, 7, 1371-1380.	3.1	16
882	Surgical ventricular restoration—meta-analysis of observational studies. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 347-355.	0.6	0
883	Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics. American Heart Journal, 2020, 224, 113-128.	2.7	69
884	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). American Journal of Cardiology, 2020, 125, 1655-1660.	1.6	7
885	Relevance of Fitness to Mortality Risk inÂMen Receiving Contemporary MedicalÂCare. Journal of the American College of Cardiology, 2020, 75, 1538-1547.	2.8	13
886	Novel Devices in HeartÂFailure. JACC: Heart Failure, 2020, 8, 251-264.	4.1	11
887	Incident HeartÂFailure in ChronicÂInflammatory Diseases. JACC: Heart Failure, 2020, 8, 499-500.	4.1	4
888	Practical recommendations for the use of beta-blockers in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2020, 14, 671-678.	2.5	1
889	Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart, 2020, 7, e001153.	2.3	16
890	Cross-Talk between Gut Microbiota and the Heart: A New Target for the Herbal Medicine Treatment of Heart Failure?. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	1.2	5
891	Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls. Journal of Clinical Medicine, 2020, 9, 1130.	2.4	17
892	Impact of the Geriatric Nutritional Risk Index on In-Hospital Mortality and Length of Hospitalization in Patients with Acute Decompensated Heart Failure with Preserved or Reduced Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 1169.	2.4	16
893	Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare. Cardiovascular Drugs and Therapy, 2020, 34, 579-584.	2.6	7

#	Article	IF	CITATIONS
894	Enhancing Clinical Pharmacy Specialist Involvement in Transitions of Care Focusing on Ambulatory Care Sensitive Conditions within a Veterans Affairs Healthcare System. Pharmacy (Basel, Switzerland), 2020, 8, 47.	1.6	3
895	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation, 2020, 141, 1903-1914.	1.6	448
896	With great power comes great… reliability. European Journal of Heart Failure, 2020, 22, 1708-1710.	7.1	0
897	Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1032-1042.	7.1	68
898	A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. International Journal of Cardiology, 2020, 309, 95-99.	1.7	13
899	Specialty-Based Variability in Diagnosing and Managing Heart Failure With Preserved Ejection Fraction. Mayo Clinic Proceedings, 2020, 95, 669-675.	3.0	6
900	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. Arthritis Research and Therapy, 2020, 22, 86.	3.5	21
901	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006645.	3.9	18
902	Prognosis of "pre-heart failure―clinical phenotypes. PLoS ONE, 2020, 15, e0231254.	2.5	1
903	Reverse Remodeling and Current Medical Therapy in Heart Failure with Reduced Ejection Fraction. International Heart Journal, 2020, 61, 197-198.	1.0	2
904	Prevalence and Causes of Anemia in Hospitalized Patients: Impact on Diseases Outcome. Journal of Clinical Medicine, 2020, 9, 950.	2.4	23
905	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. Digestive Diseases and Sciences, 2021, 66, 263-272.	2.3	11
906	Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2021, 21, 73-81.	2.2	8
907	Perceived Stress, Subjective, and Objective Symptoms of Disturbed Sleep in Men and Women with Stable Heart Failure. Behavioral Sleep Medicine, 2021, 19, 363-377.	2.1	8
908	Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system. British Journal of Clinical Pharmacology, 2021, 87, 406-413.	2.4	3
909	The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Heart Failure Reviews, 2021, 26, 799-812.	3.9	24
910	Relationship between low skeletal muscle mass, sarcopenic obesity and left ventricular diastolic dysfunction in Korean adults. Diabetes/Metabolism Research and Reviews, 2021, 37, e3363.	4.0	18
911	Rationale for targeted self-management strategies for breathlessness in heart failure. Heart Failure Reviews, 2021, 26, 71-79.	3.9	6

#	Article	IF	CITATIONS
912	Clinical Management of Hyperkalemia. Mayo Clinic Proceedings, 2021, 96, 744-762.	3.0	87
913	The RightSTEPS initiative: Continuing education impact on clinicians' optimal medical therapy practices for chronic heart failure. Medical Teacher, 2021, 43, 208-215.	1.8	1
914	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. European Journal of Internal Medicine, 2021, 85, 41-49.	2.2	11
915	Effect of angiotensin receptor blockers and angiotensinâ€converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease. Journal of Veterinary Internal Medicine, 2021, 35, 33-42.	1.6	18
916	Left ventricular systolic dysfunction identification using artificial intelligence-augmented electrocardiogram in cardiac intensive care unit patients. International Journal of Cardiology, 2021, 326, 114-123.	1.7	25
917	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest, 2021, 159, 791-797.	0.8	19
918	Machine learning versus conventional clinical methods in guiding management of heart failure patientsâ€"a systematic review. Heart Failure Reviews, 2021, 26, 23-34.	3.9	57
919	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 322, 183-190.	1.7	31
920	Imaging Interstitial Fibrosis, LeftÂVentricular Remodeling, and Function in Stage A and B HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 1038-1052.	<b>5.</b> 3	42
921	A review of biosensor technologies for blood biomarkers toward monitoring cardiovascular diseases at the point-of-care. Biosensors and Bioelectronics, 2021, 171, 112621.	10.1	78
922	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	1.5	14
923	Is Digitalis Therapy Still Viable? Foxglove Therapy Makes a Comeback. American Journal of Medicine, 2021, 134, 1-2.	1.5	5
924	Management of systemic fungal infections in the presence of a cardiac implantable electronic device: A systematic review. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 159-166.	1.2	7
925	Biventricular pacemaker and defibrillator implantation in patients with chronic heart failure in China. ESC Heart Failure, 2021, 8, 546-554.	3.1	7
927	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 127-136.	4.1	47
928	A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure. American Journal of Cardiology, 2021, 141, 152-153.	1.6	10
929	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. Journal of Cardiac Failure, 2021, 27, 435-444.	1.7	6
930	Mediating effects of social support between Type D personality and selfâ€care behaviours among heart failure patients. Journal of Advanced Nursing, 2021, 77, 1315-1324.	3.3	15

#	Article	IF	CITATIONS
931	Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2021, 142, 66-73.	1.6	27
932	Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clinical Chemistry, 2021, 67, 216-226.	3.2	13
933	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. JAMA Cardiology, 2021, 6, 267.	6.1	22
934	Î <sup>2</sup> -Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis. American Journal of Kidney Diseases, 2021, 77, 704-712.	1.9	12
935	Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. Journal of Applied Physiology, 2021, 130, 256-268.	2.5	13
936	2021 ACC/AHA Key Data Elements and Definitions for Heart Failure. Journal of the American College of Cardiology, 2021, 77, 2053-2150.	2.8	29
937	Diagnostic value of circulating microRNA-208a in differentiation of preserved from reduced ejection fraction heart failure. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 71-74.	1.6	7
938	Appropriateness rating for the application of optimal medical therapy and multidisciplinary care among heart failure patients. ESC Heart Failure, 2021, 8, 300-308.	3.1	5
939	Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: The Coronary Artery Risk Development in Young Adults Study. Journal of the American Society of Echocardiography, 2021, 34, 388-400.	2.8	10
940	The predictive value of global longitudinal strain in patients with heart failure mid-range ejection fraction. Journal of Cardiology, 2021, 77, 509-516.	1.9	4
941	Implantable Cardioverter Defibrillator Therapy in Patients with Acute Decompensated Heart Failure with Reduced Ejection Fraction: An Observation from the KCHF Registry. Journal of Cardiology, 2021, 77, 292-299.	1.9	6
942	Stress Echocardiography in Pediatric and Adult Congenital Heart Disease: A Complement in Anatomical and Functional Assessment. Current Problems in Cardiology, 2021, 46, 100762.	2.4	0
943	Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. IJC Heart and Vasculature, 2021, 32, 100690.	1.1	15
944	Inclusion of Performance Parameters and Patient Context in the Clinical Practice Guidelines for Heart Failure. Journal of Cardiac Failure, 2021, 27, 190-197.	1.7	2
945	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	4.1	27
946	2020 ACC/AHA Guideline for the Management of Patients With ValvularÂHeart Disease. Journal of the American College of Cardiology, 2021, 77, e25-e197.	2.8	868
947	Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer, 2021, 153, 186-192.	2.0	16
948	Impact of lipophilic <i>vs</i> hydrophilic statins on the clinical outcome and biomarkers of remodelling in heart failure patients: A prospective comparative randomized study. British Journal of Clinical Pharmacology, 2021, 87, 2855-2866.	2.4	7

#	Article	IF	CITATIONS
949	Heart failure after myocardial infarction: incidence and predictors. ESC Heart Failure, 2021, 8, 222-237.	3.1	243
950	The inflammasome in heart failure. Current Opinion in Physiology, 2021, 19, 105-112.	1.8	13
951	A bridge to transplantation: The life experiences of patients with a left ventricular assist device. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 106-112.	1.6	0
952	Impaired cerebral oxygenation in heart failure patients at rest and during headâ€up tilt testing. ESC Heart Failure, 2021, 8, 586-594.	3.1	6
953	Predicting maximal oxygen uptake from the 6Âmin walk test in patients with heart failure. ESC Heart Failure, 2021, 8, 47-54.	3.1	10
954	The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metabolism, 2021, 33, 629-648.e10.	16.2	137
955	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. Journal of Cardiac Failure, 2021, 27, 2-19.	1.7	16
956	Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. Annals of Pharmacotherapy, 2021, 55, 805-813.	1.9	1
957	Traveling for heart transplantation and returning with COVID-19: a logistical, clinical, and pharmacotherapeutic challenge from the Middle East. Drugs and Therapy Perspectives, 2021, 37, 29-34.	0.6	3
958	Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer, 2021, 127, 458-466.	4.1	16
959	Caloric restriction mimetics for the treatment of cardiovascular diseases. Cardiovascular Research, 2021, 117, 1434-1449.	3.8	27
960	Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2021, 134, 374-382.	1.5	14
961	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. Clinical Diabetes, 2021, 39, 105-116.	2.2	0
962	Trends in Recurrent Coronary Heart Disease After Myocardial Infarction Among US Women and Men Between 2008 and 2017. Circulation, 2021, 143, 650-660.	1.6	48
963	Role of <scp>Pointâ€ofâ€Care</scp> Lung and Inferior Vena Cava Ultrasound in Clinical Decisions for Patients Presenting to the Emergency Department With Symptoms of Acute Decompensated Heart Failure. Journal of Ultrasound in Medicine, 2021, 40, 751-761.	1.7	8
964	Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction. Herz, 2021, 46, 69-74.	1.1	5
965	Sarcopenia in Other Settings: Primary Care, Cardiovascular Disease, Surgery. Practical Issues in Geriatrics, 2021, , 111-131.	0.8	0
966	Heart Failure With Reduced Ejection Fraction. , 2021, , 185-200.		0

#	ARTICLE	IF	CITATIONS
967	Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment. International Journal of Heart Failure, 2021, 3, 81.	2.7	18
968	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. Heart Failure Reviews, 2022, 27, 741-753.	3.9	13
969	Reverse Cardiac Remodeling and ARNI Therapy. Current Heart Failure Reports, 2021, 18, 71-83.	3.3	19
970	Severe Acute Respiratory Infection Surveillance during the Initial Phase of the COVID-19 Outbreak in North India: A Comparison of COVID-19 to Other SARI Causes. Indian Journal of Critical Care Medicine, 2021, 25, 761-767.	0.9	11
971	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support., 2021,, 276-289.		0
972	Pathophysiology of Heart Failure With a Preserved Ejection Fraction: Measurements and Mechanisms Causing Abnormal Diastolic Function. , 2021, , 11-30.		0
973	Efficacy and safety of thyroxine therapy on patients with heart failure and subclinical hypothyroidism. Medicine (United States), 2021, 100, e23947.	1.0	1
974	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	2.2	61
975	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2021, 69, 1309-1318.	2.6	4
976	Cardiovascular and Renal Outcomes ofÂMineralocorticoid Receptor AntagonistÂUse in PARAGON-HF. JACC: Heart Failure, 2021, 9, 13-24.	4.1	22
977	Gender-Related Differences in Heart Failure Biomarkers. Frontiers in Cardiovascular Medicine, 2020, 7, 617705.	2.4	31
978	Right Atrial Strain as a Surrogate Marker for Right Ventricular Function in Patients with Heart Failure. Journal of Cardiovascular Imaging, 2021, 29, 144.	0.7	1
979	Ivabradine in Cardiovascular Disease Management Revisited: a Review. Cardiovascular Drugs and Therapy, 2021, 35, 1045-1056.	2.6	16
980	Deletion of P21-activated kinase-1 induces age-dependent increased visceral adiposity and cardiac dysfunction in female mice. Molecular and Cellular Biochemistry, 2021, 476, 1337-1349.	3.1	8
981	Understanding Obesity-Related High Output Heart Failure and Its Implications. International Journal of Heart Failure, 2021, 3, 160.	2.7	8
982	Crosstalk between Iron and Arteriosclerosis. Journal of Atherosclerosis and Thrombosis, 2022, 29, 308-314.	2.0	7
983	Highâ€protein vs. standardâ€protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Proâ€HEART trial. ESC Heart Failure, 2021, 8, 1342-1348.	3.1	18
984	Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation. Journal of Korean Medical Science, 2021, 36, e252.	2.5	1

#	Article	IF	CITATIONS
985	Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease. International Journal of Medical Sciences, 2021, 18, 2570-2580.	2.5	7
986	Implications for Clinical Practice from a Multicenter Survey of Heart Failure Management Centers. Clinics, 2021, 76, e1991.	1.5	0
987	Endothelial Klf2-Foxp1-TGF $\hat{l}^2$ signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Theranostics, 2021, 11, 1609-1625.	10.0	17
988	Part 1: The Wider Considerations in Translating Heart Failure Guidelines. Current Cardiology Reviews, 2021, 17, e160721190003.	1.5	2
989	Heart Failure in African Americans and Hispanic Americans: A Persistent and Disproportionate Burden in Underrepresented Minorities. Contemporary Cardiology, 2021, , 55-74.	0.1	1
990	Remote monitoring in heart failure: current and emerging technologies in the context of the pandemic. Heart, 2021, 107, 366-372.	2.9	36
991	Recent Trends and Potential Drivers of Non-invasive Cardiovascular Imaging Use in the United States of America and England. Frontiers in Cardiovascular Medicine, 2020, 7, 617771.	2.4	15
992	Pinocembrin ameliorates arrhythmias in rats with chronic ischaemic heart failure. Annals of Medicine, 2021, 53, 830-840.	3.8	13
993	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	5
994	Approach to decongestion therapy in patients with acute decompensated heart failure: the echocardiography guided strategy. Kardiologiya, 2021, 61, 76-82.	0.7	0
995	Prevalence of Guideline-Directed Medical Therapy for Cardiovascular Disease Among Baltimore City Adults in the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. Journal of Racial and Ethnic Health Disparities, 2022, 9, 538-545.	3.2	4
996	ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?. Journal of Clinical Medicine, 2021, 10, 839.	2.4	13
997	Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study. Internal and Emergency Medicine, 2021, 16, 1803-1811.	2.0	6
998	The diagnostic and prognostic value of galectinâ€3 in patients at risk for heart failure with preserved ejection fraction: results from the DIASTâ€CHF study. ESC Heart Failure, 2021, 8, 829-841.	3.1	24
999	Chronic vagus nerve stimulation is associated with multi-year improvement in intrinsic heart rate recovery and left ventricular ejection fraction in ANTHEM-HF. Clinical Autonomic Research, 2021, 31, 453-462.	2.5	7
1000	Risk-Based Approach for the Prediction and Prevention of Heart Failure. Circulation: Heart Failure, 2021, 14, e007761.	3.9	19
1001	Implications of the ACC/AHA risk score for prediction of heart failure: the Rotterdam Study. BMC Medicine, 2021, 19, 43.	5.5	8
1002	Hemodynamics and Clinical Implications of Occult Left Ventricular Dysfunction in Adults Undergoing Ebstein Anomaly Repair. Circulation: Cardiovascular Imaging, 2021, 14, e011739.	2.6	8

#	Article	IF	CITATIONS
1003	Evaluation of Risk-Adjusted Home Time After Hospitalization for Heart Failure as a Potential Hospital Performance Metric. JAMA Cardiology, 2021, 6, 169.	6.1	17
1004	Validation of estimating left ventricular ejection fraction by mitral annular displacement derived from <scp>speckleâ€tracking</scp> echocardiography: A neglected method for evaluating left ventricular systolic function. Journal of Clinical Ultrasound, 2021, 49, 563-572.	0.8	1
1005	Clinical, Echocardiographic, and Therapeutic Characteristics of Heart Failure in Patients with Preserved, Mid-Range, and Reduced Ejection Fraction: Future Directions. International Journal of General Medicine, 2021, Volume 14, 459-467.	1.8	4
1006	Advance Directives and Factors Associated with the Completion in Patients with Heart Failure. International Journal of Environmental Research and Public Health, 2021, 18, 1780.	2.6	3
1007	Coenzyme Q10 for heart failure. The Cochrane Library, 2021, 2021, .	2.8	12
1008	Shedding light on the pathophysiology of preeclampsia-syndrome in the era of Cardio-Obstetrics: Role of inflammation and endothelial dysfunction. Current Hypertension Reviews, 2021, 17, .	0.9	1
1009	2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary. Journal of the American College of Cardiology, 2021, 77, 450-500.	2.8	537
1010	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Failure, 2021, 8, 861-871.	3.1	20
1011	Aortic pulsatility index predicts clinical outcomes in heart failure: a subâ€analysis of the ESCAPE trial. ESC Heart Failure, 2021, 8, 1522-1530.	3.1	12
1012	Obesity paradox in pulmonary hypertension due to left ventricular systolic dysfunction. Herz, 2021, 46, 575-580.	1.1	3
1013	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009203.	4.8	14
1014	Therapeutic effects of medicinal plants on isoproterenol-induced heart failure in rats. Biomedicine and Pharmacotherapy, 2021, 134, 111101.	5.6	11
1015	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	2.8	612
1016	A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure. Frontiers in Physiology, 2021, 12, 642117.	2.8	2
1017	Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy. Frontiers in Pediatrics, 2021, 9, 639551.	1.9	2
1018	The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?. Cells, 2021, 10, 650.	4.1	31
1019	Obesity and Serial NTâ€proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDEâ€IT Trial. Journal of the American Heart Association, 2021, 10, e018689.	3.7	18
1020	Management of rhythm disorders in Duchenne muscular dystrophy: Is sudden death a cardiac or pulmonary problem?. Pediatric Pulmonology, 2021, 56, 760-765.	2.0	0

#	Article	IF	CITATIONS
1021	The role of transcatheter mitral valve leaflet approximation for the treatment of secondary mitral regurgitation: current status and future prospects. Expert Review of Medical Devices, 2021, 18, 261-272.	2.8	1
1022	Advancements in biomarkers for cardiovascular disease: diagnosis, prognosis, and therapy. Faculty Reviews, 2021, 10, 34.	3.9	3
1023	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. Circulation: Heart Failure, 2021, 14, e008090.	3.9	5
1024	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	0
1025	Discordance between lactic acidemia and hemodynamics in patients with advanced heart failure. Clinical Cardiology, 2021, 44, 636-645.	1.8	3
1026	Large- and Medium-sized Arteries Remaining in Transmural Scar Distal to Permanent Coronary Ligation Undergo Neointimal Hyperplasia and Inward Remodeling. Journal of Histochemistry and Cytochemistry, 2021, 69, 321-338.	2.5	1
1027	The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies. International Journal of Molecular Sciences, 2021, 22, 2955.	4.1	9
1028	Spironolactone in Patients With HeartÂFailure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221.	2.8	19
1029	Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arquivos Brasileiros De Cardiologia, 2021, 116, 516-658.	0.8	340
1030	Filling a gap in standardized nursing terminology. Development of a new nursing diagnosis proposal on heart failure selfâ€care. International Journal of Nursing Knowledge, 2022, 33, 18-28.	1.0	3
1031	Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2058-2069.	3.1	25
1032	Updates in Cardiac Amyloidosis Diagnosis and Treatment. Current Oncology Reports, 2021, 23, 47.	4.0	17
1033	Pharmacotherapy for heart failure with reduced ejection fraction and <scp>healthâ€related</scp> quality of life: a systematic review and <scp>metaâ€analysis</scp> . European Journal of Heart Failure, 2021, 23, 578-589.	7.1	22
1034	Racial and ethnic disparities in heart failure: current state and future directions. Current Opinion in Cardiology, 2021, 36, 320-328.	1.8	57
1035	Utilization of an Online Education Module and Standardized Patient Simulation Experience to Improve Nursing Student Learning Outcomes With Heart Failure Patients. Nursing Education Perspectives, 2021, Publish Ahead of Print, .	0.7	0
1036	The Evolving Immunotherapy LandscapeÂand the Epidemiology, Diagnosis, and Management ofÂCardiotoxicity. JACC: CardioOncology, 2021, 3, 35-47.	4.0	80
1037	British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Research and Practice, 2021, 8, G1-G18.	2.5	17
1038	Prognostic role of albumin level in heart failure. Medicine (United States), 2021, 100, e24785.	1.0	26

#	Article	IF	CITATIONS
1039	Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients. Cardiovascular Drugs and Therapy, 2021, , 1.	2.6	3
1040	Temporal trends in heart failure medication prescription in a population-based cohort study. BMJ Open, 2021, 11, e043290.	1.9	7
1041	Automated cardiac volume assessment and cardiac long- and short-axis imaging plane prediction from electrocardiogram-gated computed tomography volumes enabled by deep learning. European Heart Journal Digital Health, 2021, 2, 311-322.	1.7	9
1042	SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and metaâ€analysis. ESC Heart Failure, 2021, 8, 2210-2219.	3.1	26
1043	BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab. JACC: CardioOncology, 2021, 3, 1-16.	4.0	37
1044	Updates in pharmacotherapy of heart failure with reduced ejection fraction. Annals of Translational Medicine, 2021, 9, 516-516.	1.7	5
1045	Invasive Devices and Sensors for Remote Care of Heart Failure Patients. Sensors, 2021, 21, 2014.	3.8	19
1046	Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione. American Journal of Cardiovascular Drugs, 2021, 21, 589-593.	2.2	1
1047	Diabetes and Heart Failure. Journal of Korean Diabetes, 2021, 22, 12-20.	0.3	0
1048	Invasive Hemodynamic and Metabolic Evaluation of HFpEF. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	7
1049	Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal?. Current Opinion in Cardiology, 2021, 36, 413-419.	1.8	12
1050	Patient Education and Sacubitril/Valsartan: A Randomized Comparative Trial. Hospital Pharmacy, 2022, 57, 001857872199980.	1.0	0
1051	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart, 2021, 8, e001585.	2.3	30
1052	Myocardial work index: a marker of left ventricular contractility in pressureâ€or volume overloadâ€induced heart failure. ESC Heart Failure, 2021, 8, 2220-2231.	3.1	21
1053	Management of Patients With Giant Cell Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1122-1134.	2.8	59
1054	Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. HRB Open Research, 2020, 3, 5.	0.6	3
1055	Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. Cardiovascular Drugs and Therapy, 2021, , 1.	2.6	3
1056	Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy, 2021, 41, 526-536.	2.6	5

#	Article	IF	Citations
1057	Evolving Cardiac Electrical Therapies for Advanced Heart Failure Patients. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009668.	4.8	4
1058	The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. Expert Opinion on Pharmacotherapy, 2021, 22, 1319-1341.	1.8	O
1059	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°Pâ€₹IMI 50. Journal of the American Heart Association, 2021, 10, e018673.	3.7	7
1060	Smart Wearables for Cardiac Monitoringâ€"Real-World Use beyond Atrial Fibrillation. Sensors, 2021, 21, 2539.	3.8	63
1061	Stage A Heart Failure. Heart Failure Clinics, 2021, 17, 167-177.	2.1	4
1062	An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis. Cardiology Journal, 2023, 30, 117-124.	1.2	2
1063	Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. JACC: Cardiovascular Imaging, 2021, 14, 779-781.	5.3	1
1064	How I manage acquired pure red cell aplasia in adults. Blood, 2021, 137, 2001-2009.	1.4	29
1065	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2022, 27, 625-643.	3.9	135
1066	Implementing Clinical Decision Support Tools and Pharmacovigilance to Reduce the Use of Potentially Harmful Medications and Health Care Costs in Adults With Heart Failure. Frontiers in Pharmacology, 2021, 12, 612941.	3.5	6
1067	Improve self-care in heart failure. International Journal of Nursing Sciences, 2021, 8, 243-244.	1.3	2
1068	Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. CKJ: Clinical Kidney Journal, 2021, 14, 2391-2400.	2.9	7
1069	Effect of left ventricular ejection fraction on the prognostic impact of chronic total occlusion in a non-infarct-related artery in patients with acute myocardial infarction. IJC Heart and Vasculature, 2021, 33, 100738.	1.1	5
1070	Predictors associated with increased troponin in acute decompensated and chronic heart failure patients. Romanian Journal of Laboratory Medicine, 2021, 29, 153-164.	0.2	0
1071	Quantifying Right Ventricular Fibrosis Burden Using 3D Strain. JACC: Cardiovascular Imaging, 2021, 14, 1321-1323.	5.3	1
1072	Myocardial Angiotensin Metabolism in End-Stage HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1731-1743.	2.8	18
1073	Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy. Antibiotics, 2021, 10, 504.	3.7	7
1074	Mediation of Arterial Stiffness for Hyperuricemia-Related Decline of Cardiac Systolic Function in Healthy Men. Circulation Reports, 2021, 3, 227-233.	1.0	1

#	Article	IF	CITATIONS
1075	Heart Failure: One, None, and a Hundred Thousand. Heart Failure Clinics, 2021, 17, xiii-xv.	2.1	0
1076	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in HeartÂFailure. JACC: Heart Failure, 2021, 9, 293-300.	4.1	28
1077	Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway. Canadian Journal of Cardiology, 2021, 37, 655-664.	1.7	7
1078	Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. Journal of Pharmacy Practice, 2021, , 089719002110048.	1.0	6
1080	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. American Heart Journal, 2021, 234, 90-100.	2.7	20
1081	Biomarkers in Heart Failure. Heart Failure Clinics, 2021, 17, 223-243.	2.1	10
1082	Tailoring the management of hypertension to comorbidities. Current Opinion in Cardiology, 2021, 36, 405-412.	1.8	1
1083	A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction. European Journal of Heart Failure, 2021, 23, 995-999.	7.1	20
1084	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	3.9	1
1085	Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007216.	2.2	7
1086	Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circulation Research, 2021, 128, 1468-1486.	4.5	63
1087	Factors associated with post-infarction myocardial remodeling. , 2021, 17, 62-69.	0.1	0
1088	Mechanisms and Models in Heart Failure. Circulation Research, 2021, 128, 1435-1450.	4.5	24
1089	Quality of care and risk of incident atrial fibrillation in patients with newly diagnosed heart failure: a nationwide cohort study. European Heart Journal Quality of Care & Dinical Outcomes, 2022, 8, 539-547.	4.0	1
1090	Clinical impact of red blood cell transfusion on adverse clinical events in acute heart failure patients with anemia. International Journal of Cardiology, 2021, 330, 145.	1.7	0
1091	Data in a Vacuum? The Desperate Need for a Paradigm Shift to Prevent Heart Failure in Black Americans. Journal of the American Heart Association, 2021, 10, e021048.	3.7	1
1092	Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. Frontiers in Cardiovascular Medicine, 2021, 8, 678121.	2.4	6
1093	Distribution and Correlates of Incident Heart Failure Risk in South Asian Americans: The MASALA Study. Journal of Cardiac Failure, 2021, 27, 1214-1221.	1.7	0

#	Article	IF	Citations
1094	Design and rationale of the EMPAâ€VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC Heart Failure, 2021, 8, 2580-2590.	3.1	18
1095	Atrial Fibrillation Burden and Clinical Outcomes in HeartÂFailure. JACC: Clinical Electrophysiology, 2021, 7, 594-603.	3.2	67
1096	N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer. Deutsches Ärzteblatt International, 2021, 118, 357-362.	0.9	9
1097	Primary Prevention Implantable Cardioverter-Defibrillator Therapy in Heart Failure with Recovered Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 585-596.	1.7	1
1098	Rad-GTPase contributes to heart rate via L-type calcium channel regulation. Journal of Molecular and Cellular Cardiology, 2021, 154, 60-69.	1.9	7
1099	Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 5688.	4.1	6
1100	Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Failure Reviews, $2021$ , , $1$ .	3.9	9
1101	Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 2021, 18, 649-665.	13.7	49
1102	Outcomes in patients with anthracyclineâ€induced cardiomyopathy undergoing left ventricular assist devices implantation. ESC Heart Failure, 2021, 8, 2866-2875.	3.1	7
1103	Pregnancy-specific Reference Intervals for BNP and NT-pro BNPâ€"Changes in Natriuretic Peptides Related to Pregnancy. Journal of the Endocrine Society, 2021, 5, bvab091.	0.2	16
1104	Left Ventricular Noncompaction Cardiomyopathy as a Potential Cause of Bilateral Posterior Cerebral Artery Stroke – a Rare and Unique Clinical Occurrence. American Journal of Case Reports, 2021, 22, e931103.	0.8	3
1105	Rutin Modulates MAPK Pathway Differently from Quercetin in Angiotensin II-Induced H9c2 Cardiomyocyte Hypertrophy. International Journal of Molecular Sciences, 2021, 22, 5063.	4.1	18
1106	Quantification and Pharmacokinetics Study of Pedunculoside in Rats by Using UPLC-MS/MS. Current Pharmaceutical Analysis, 2021, 17, 731-737.	0.6	1
1107	Characterization of Responder Profiles for Cardiac Resynchronization Therapy through Unsupervised Clustering of Clinical and Strain Data. Journal of the American Society of Echocardiography, 2021, 34, 483-493.	2.8	14
1108	Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. ESC Heart Failure, 2021, 8, 2741-2754.	3.1	32
1109	Development and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF). American Journal of Health-System Pharmacy, 2021, 78, 1691-1700.	1.0	4
1110	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2021, 2021, CD012721.	2.8	19
1111	Epidemiology of heart failure and long-term follow-up outcomes in a north-African population: Results from the NAtional TUnisian REgistry of Heart Failure (NATURE-HF). PLoS ONE, 2021, 16, e0251658.	2.5	11

#	Article	IF	CITATIONS
1112	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. American Journal of Preventive Cardiology, 2021, 6, 100183.	3.0	4
1113	State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies. Cardiovascular Diagnosis and Therapy, 2021, 11, 881-895.	1.7	3
1114	Clinical characteristic, red blood cell indices, iron profile and prognosis of heart failure in females. Global Cardiology Science & Practice, 2021, 2021, e202113.	0.4	3
1115	Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease. Journal of the American Heart Association, 2021, 10, e020633.	3.7	13
1116	Classification of HeartÂFailure According to Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 3217-3225.	2.8	56
1117	Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018. Heart, 2022, 108, 543-549.	2.9	11
1118	Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 2021, 188, 21-36.	2.5	62
1119	Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. American Journal of Cardiology, 2021, 152, 138-145.	1.6	11
1120	Clinical effectiveness of a dedicated cardiac resynchronization therapy pre-assessment clinic incorporating cardiac magnetic resonance imaging and cardiopulmonary exercise testing on patient selection and outcomes. IJC Heart and Vasculature, 2021, 34, 100800.	1.1	1
1121	Protocolo terapéutico de la insuficiencia cardÃaca crónica. Medicine, 2021, 13, 2054-2057.	0.0	0
1122	Gender differences in the prevalence of frailty in heart failure: A systematic review and meta-analysis. International Journal of Cardiology, 2021, 333, 133-140.	1.7	36
1123	Demonstration of left bundle capture: Timing is everything. Heart Rhythm, 2021, 18, 944-945.	0.7	0
1124	Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 107424842110226.	2.0	1
1125	Multi-modality assessment and role of left atrial function as an imaging biomarker in cardiovascular disease. International Journal of Cardiovascular Imaging, 2021, 37, 3355-3369.	1.5	8
1126	Pharmacotherapy Considerations in Heart Failure with Mildly-Reduced Ejection Fraction. Journal of Pharmacy Practice, 2021, , 089719002110273.	1.0	0
1127	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ, The, 2021, 373, n1421.	6.0	32
1128	Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension. Hypertension, 2021, 77, 1804-1814.	2.7	5
1129	From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin. International Journal of Molecular Sciences, 2021, 22, 6617.	4.1	6

#	Article	IF	Citations
1130	The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. Frontiers in Clinical Diabetes and Healthcare, 2021, 2, .	0.8	6
1131	A History of Heart Failure Is an Independent Risk Factor for Death in Patients Admitted with Coronavirus 19 Disease. Journal of Cardiovascular Development and Disease, 2021, 8, 77.	1.6	7
1132	Relação entre o Realce Tardio pelo GadolÃnio e os Parâmetros de Repolarização Ventricular em Pacientes com Insuficiência CardÃaca com Fração de Ejeção Reduzida. Arquivos Brasileiros De Cardiologia, 2021, 117, 678-687.	0.8	2
1133	Cardiac Biomarkers in Pediatrics: An Undervalued Resource. Clinical Chemistry, 2021, 67, 947-958.	3.2	13
1134	Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. Pharmacoepidemiology and Drug Safety, 2021, 30, 1420-1427.	1.9	3
1135	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 1518-1524.	7.1	20
1136	Classifying and Risk Stratifying HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 1189-1191.	5.3	0
1137	The combination of carboxyâ€terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathyÂâ€'ÂA multilevel assessment of myocardial fibrosis in dilated cardiomyopathy.  European Journal of Heart Failure, 2021, 23, 933-944.	7.1	34
1138	Assessment and management of cardiovascular disease in the intensive care unit. Heart, 2021, , heartjnl-2019-315568.	2.9	6
1139	Therapeutic Properties of Highly Selective $\hat{I}^2$ -blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2022, 36, 959-971.	2.6	8
1140	Mitral Regurgitation in 2020: The 2020 Focused Update of the 2017 American College of Cardiology Expert Consensus Decision Pathway on the Management of Mitral Regurgitation. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1678-1690.	1.3	1
1141	The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial. Journal of Cardiac Failure, 2021, 27, 662-669.	1.7	8
1142	Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction. Frontiers in Pharmacology, 2021, 12, 646240.	3.5	20
1143	Ironing out mechanisms of iron homeostasis and disorders of iron deficiency. Journal of Clinical Investigation, 2021, 131, .	8.2	54
1144	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "heart and vessels failure". Minerva Cardiology and Angiology, 2022, 70, .	0.7	8
1145	Routine use of natriuretic peptides: Lessons from a big data analysis. Annals of Clinical Biochemistry, 2021, 58, 481-486.	1.6	3
1146	Stateâ€ofâ€theâ€art machine learning algorithms for the prediction of outcomes after contemporary heart transplantation: Results from the UNOS database. Clinical Transplantation, 2021, 35, e14388.	1.6	27
1147	Development and Validation of Machine Learning–Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. Circulation, 2021, 143, 2370-2383.	1.6	56

#	Article	IF	Citations
1148	Acquisition, Processing, and Interpretation of PET 18F-FDG Viability and Inflammation Studies. Current Cardiology Reports, 2021, 23, 124.	2.9	6
1149	Routine Use of Contrast on Admission Transthoracic Echocardiography for Heart Failure Reduces the Rate of Repeat Echocardiography during Index Admission. Journal of the American Society of Echocardiography, 2021, 34, 1253-1261.e4.	2.8	4
1150	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. European Journal of Heart Failure, 2021, 23, 1698-1707.	7.1	37
1151	Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 397-413.	2.1	15
1152	Sudden cardiac death after acute decompensation in heart failure patients: implications of discharge haemoglobin levels. ESC Heart Failure, 2021, 8, 3917-3928.	3.1	2
1153	Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. Journal of Cardiovascular Medicine, 2021, 22, 848-856.	1.5	6
1154	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.8	33
1155	Heart failure with preserved ejection fraction based on aging and comorbidities. Journal of Translational Medicine, 2021, 19, 291.	4.4	14
1156	Increased oxidative stress during exercise predicts poor prognosis in patients with acute decompensated heart failure. ESC Heart Failure, 2021, 8, 3885-3893.	3.1	8
1157	Evidence-based management of arrhythmogenic right ventricular cardiomyopathy in pregnancy. Future Cardiology, 2021, 17, 693-703.	1.2	1
1158	A CNN-based novel solution for determining the survival status of heart failure patients with clinical record data: numeric to image. Biomedical Signal Processing and Control, 2021, 68, 102716.	5.7	24
1159	Effects of Cardiac Rehabilitation in Low- and Middle-Income Countries: A systematic Review and Meta-Analysis of Randomised Controlled Trials. Progress in Cardiovascular Diseases, 2022, 70, 119-174.	3.1	26
1160	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With HeartÂFailure. JACC: Heart Failure, 2021, 9, 497-505.	4.1	5
1161	Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis. Heart Failure Reviews, 2022, 27, 645-654.	3.9	19
1162	Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, 495-502.	2.6	3
1163	Prognostic Value of Natriuretic Peptides for All-Cause Mortality, Right Ventricular Failure, Major Adverse Events, and Myocardial Recovery in Advanced Heart Failure Patients Receiving a Left Ventricular Assist Device: A Systematic Review. Frontiers in Cardiovascular Medicine, 2021, 8, 699492.	2.4	5
1164	Impact of New York Heart Association Functional Class on Outcomes After Transcatheter Aortic Valve Implantation. Cardiovascular Revascularization Medicine, 2022, 38, 19-26.	0.8	3
1165	Principal Morphomic and FunctionalÂComponents of Secondary MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2021, 14, 2288-2300.	5.3	26

#	Article	IF	CITATIONS
1166	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. Current Heart Failure Reports, 2021, 18, 284-289.	3.3	10
1167	Outâ€ofâ€Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States. Journal of the American Heart Association, 2021, 10, e022164.	3.7	27
1168	Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice. Hypertension Research, 2021, 44, 1261-1273.	2.7	2
1169	Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. European Journal of Heart Failure, 2021, 23, 1445-1457.	7.1	60
1170	Sodium–glucose coâ€transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. European Journal of Heart Failure, 2021, 23, 1250-1255.	7.1	17
1171	N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. Journal of Clinical Medicine, 2021, 10, 3313.	2.4	5
1172	Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Current Cardiology Reports, 2021, 23, 117.	2.9	12
1173	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 335, 59-65.	1.7	2
1174	Management of Pulmonary Hypertension in Left Heart Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 115.	1.0	7
1175	Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. Cardiovascular Research, 2022, 118, 2085-2102.	3.8	23
1177	Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure. World Journal of Cardiology, 2021, 13, 183-203.	1.5	11
1178	Is oxygen therapy beneficial for normoxemic patients with acute heart failure? A propensity score matched study. Military Medical Research, 2021, 8, 38.	3.4	5
1179	The combination of coronary sinus ostial atresia/abnormalities and a small persistent left superior vena cavaâe"Opportunity for left ventricular lead implantation and unrecognized source of thromboembolic stroke. Heart Rhythm, 2021, 18, 1064-1073.	0.7	4
1180	Iron Deficiency as a Potential Modulator of Subclinical Deficiencies in Cardiac Performance and Exercise Capacity. Journal of Cardiac Failure, 2021, 27, 822-824.	1.7	2
1181	Predictive Value of the Serum Cystatin C/Prealbumin Ratio in Combination With NT-proBNP Levels for Long-Term Prognosis in Chronic Heart Failure Patients: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 684919.	2.4	5
1182	Calcium and Heart Failure: How Did We Get Here and Where Are We Going?. International Journal of Molecular Sciences, 2021, 22, 7392.	4.1	8
1183	Optimal Heart Rate Modulation Using Ivabradine. International Heart Journal, 2021, 62, 717-721.	1.0	6
1184	Exercise Training Enhances Angiogenesis-Related Gene Responses in Skeletal Muscle of Patients with Chronic Heart Failure. Cells, 2021, 10, 1915.	4.1	12

#	Article	IF	CITATIONS
1185	Which drug is best for a patient with type 2 diabetes and heart failure?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2021, 34, 49-52.	0.3	0
1186	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Network Open, 2021, 4, e2114501.	5.9	49
1187	Vericiguatâ€"A New Addition for Heart Failure With Reduced Ejection Fraction. Journal for Nurse Practitioners, 2021, , .	0.8	0
1188	Usefulness of velocity ratio in patients with moderate aortic stenosis and reduced left ventricular ejection fraction. Scandinavian Cardiovascular Journal, 2021, 55, 1-9.	1.2	0
1189	Inflammation-based assessment for the risk stratification of mortality in patients with heart failure. Scientific Reports, 2021, 11, 14989.	3.3	4
1190	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 530-545.	6.1	9
1191	Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. Journal of the American Society of Nephrology: JASN, 2021, 32, 2020-2030.	6.1	37
1192	Development of hybrid spectrofluorimetric method for simultaneous determination of Valsartan and Sacubitril in LCZ696 tablets. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 256, 119748.	3.9	5
1193	Prevalence and temporal trends of anemia in patients with heart failure. QJM - Monthly Journal of the Association of Physicians, $2021$ , , .	0.5	3
1194	Ventricular non-compaction review. Heart Failure Reviews, 2022, 27, 1063-1076.	3.9	22
1195	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, $2021$ , , $1$ .	3.9	9
1196	Changes over Time in Patient Stated Values and Treatment Preferences Regarding Aggressive Therapies: Insights from the DECIDE-LVAD Trial. Medical Decision Making, 2022, 42, 404-414.	2.4	5
1197	Feasibility of home-based cardiac rehabilitation using an integrated telerehabilitation platform in elderly patients with heart failure: A pilot study. Journal of Cardiology, 2021, 78, 66-71.	1.9	33
1198	Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption. Medicine (United States), 2021, 100, e26809.	1.0	2
1199	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. International Journal of Clinical Practice, 2021, 75, e14681.	1.7	5
1200	Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007476.	2.2	1
1201	Binding Potassium to Improve Treatment With Renin-Angiotensin-Aldosterone System Inhibitors: Results From Multiple One-Stage Pairwise and Network Meta-Analyses of Clinical Trials. Frontiers in Medicine, 2021, 8, 686729.	2.6	1
1202	The association of galectin-3 level with ventricular arrhythmias and left ventricular strain in heart failure patients with implantable cardioverter defibrillator. Acta Cardiologica, 2022, 77, 609-615.	0.9	3

#	ARTICLE	IF	CITATIONS
1203	Contemporary Left Ventricular Assist Device Outcomes in an Aging Population. Journal of the American College of Cardiology, 2021, 78, 883-894.	2.8	27
1204	Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. Cancer, 2021, 127, 4646-4655.	4.1	10
1205	Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis. BJGP Open, 2021, 5, BJGPO.2021.0094.	1.8	7
1206	National Trends in the Use of Sacubitril/Valsartan. Journal of Cardiac Failure, 2021, 27, 839-847.	1.7	9
1207	Influenza vaccination and mortality among adults with heart failure in an integrated healthcare delivery system, 2009–2018. Journal of General Internal Medicine, 2022, 37, 2405-2412.	2.6	3
1208	An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study. Clinics and Practice, 2021, 11, 484-493.	1.4	2
1209	FEV1 Predicts Cardiac Status and Outcome in Chronic Heart Failure. Chest, 2022, 161, 179-189.	0.8	4
1210	Mechanical Circulatory Support in Advanced Heart Failure. Indian Journal of Clinical Cardiology, 2021, 2, 158-170.	0.1	1
1211	Anemia in heart failure: still an unsolved enigma. Egyptian Heart Journal, 2021, 73, 75.	1.2	9
1212	Ability of soluble ST2 to predict left ventricular remodeling in patients with acute coronary syndrome. Heart and Vessels, 2022, 37, 173-183.	1.2	6
1213	Providers' assignment of NYHA functional class in patients with heart failure: A vignette study. Heart and Lung: Journal of Acute and Critical Care, 2021, , .	1.6	2
1214	Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction. Journal of Taibah University Medical Sciences, 2021, 16, 582-590.	0.9	0
1215	Physical Activity in the Treatment and Prevention of Heart Failure: An Update. Current Sports Medicine Reports, 2021, 20, 410-417.	1.2	3
1216	Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. Physiological Reports, 2021, 9, e14974.	1.7	3
1217	Outcome of patients with nonâ€ischaemic cardiogenic shock supported by percutaneous left ventricular assist device. ESC Heart Failure, 2021, 8, 3594-3602.	3.1	9
1218	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 191-201.	1.7	6
1219	Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial. Critical Care, 2021, 25, 289.	5.8	15
1220	A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 3495-3503.	3.1	3

#	Article	IF	CITATIONS
1221	Experiences of Patients Using a Fitness Tracker to Promote Ambulation Before a Heart Transplant. Critical Care Nurse, 2021, 41, e19-e27.	1.0	1
1222	Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure. Circulation: Heart Failure, 2021, 14, e008076.	3.9	34
1223	Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review. Current Cardiology Reviews, 2022, 18,	1.5	1
1224	New Drugs for Heart Failure: What is the Evidence in Older Patients?. Journal of Cardiac Failure, 2022, 28, 316-329.	1.7	1
1225	Implantable vagus nerve stimulation system performance is not affected by internal or external defibrillation shocks. Journal of Interventional Cardiac Electrophysiology, 2021, , 1.	1.3	1
1226	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. Mayo Clinic Proceedings, 2021, 96, 2114-2122.	3.0	15
1227	2020 ACC/AHA guideline for the management of patients with valvular heart disease. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e183-e353.	0.8	100
1228	Caracterização sociodemográfica, perfil clÃnico e cognitivo de pacientes com Insuficiência CardÃaca. Research, Society and Development, 2021, 10, e538101019275.	0.1	0
1229	Use of sodium zirconium cyclosilicate for up-titration of renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure: a case series. European Heart Journal - Case Reports, 2021, 5, ytab281.	0.6	3
1230	Comparison of mortality prediction scores in elderly patients with ICD for heart failure with reduced ejection fraction. Aging Clinical and Experimental Research, 2021, , 1.	2.9	3
1231	Beyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy. Current Cardiology Reviews, 2022, 18, .	1.5	4
1232	Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annual Review of Medicine, 2022, 73, 321-337.	12.2	52
1234	Mineralocorticoid Receptor Antagonist Improves Cardiac Structure inÂType 2ÂDiabetes. JACC: Heart Failure, 2021, 9, 550-558.	4.1	14
1235	Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 30-45.	0.7	11
1236	Relationship of ejection fraction and natriuretic peptide trajectories in heart failure with baseline reduced and mid-range ejection fraction. American Heart Journal, 2022, 243, 1-10.	2.7	5
1237	Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. Clinical Gastroenterology and Hepatology, 2022, 20, e1149-e1156.	4.4	2
1239	The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2021, 77, 1485-1494.	1.9	0
1240	Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction. Experimental Biology and Medicine, 2021, 246, 2511-2521.	2.4	9

#	Article	IF	CITATIONS
1241	A scoping review of palliative care outcome measures in interstitial lung disease. European Respiratory Review, 2021, 30, 210080.	7.1	2
1242	Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2021, 2021, 1-11.	1.7	2
1243	Effect of heart failure and malnutrition, alone and in combination, on rehabilitation effectiveness in patients with hip fracture. Clinical Nutrition ESPEN, 2021, 44, 356-366.	1.2	6
1244	Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Scientific Reports, $2021, 11, 16335$ .	3.3	12
1245	Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. Molecules, 2021, 26, 5006.	3.8	11
1246	A machine-learning-based method to predict adverse events in patients with dilated cardiomyopathy and severely reduced ejection fractions. British Journal of Radiology, 2021, 94, 20210259.	2.2	5
1247	Detecting cardiomyopathies in pregnancy and the postpartum period with an electrocardiogram-based deep learning model. European Heart Journal Digital Health, 2021, 2, 586-596.	1.7	20
1248	Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A metaâ€analysis. Clinical Cardiology, 2021, 44, 1354-1359.	1.8	13
1249	Experience of cardiac implantable electronic device lead removal from a South African tertiary referral centre. Cardiovascular Journal of Africa, 2021, 32, 21-25.	0.4	1
1250	Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 698088.	2.4	1
1251	FGF23 predicts outcomes in heart failure but questions remain unanswered. International Journal of Cardiology, 2021, 338, 145-146.	1.7	3
1252	Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure. ESC Heart Failure, 2021, 8, 5045-5056.	3.1	15
1253	The Intersection of Type 2 Myocardial Infarction and Heart Failure. Journal of the American Heart Association, 2021, 10, e020849.	3.7	2
1254	Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007665.	2.2	9
1255	Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: AÂMeta-analysis. CJC Open, 2021, 3, S202-S208.	1.5	8
1256	Association between number of medications and mortality among older adult patients in a specialized cardiology hospital. Geriatrics and Gerontology International, 2021, 21, 985-995.	1.5	0
1257	Feasibility of late gadolinium enhancement (LGE) in ischemic cardiomyopathy using 2D-multisegment LGE combined with artificial intelligence reconstruction deep learning noise reduction algorithm. International Journal of Cardiology, 2021, 343, 164-170.	1.7	17
1258	Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care. Circulation: Heart Failure, 2021, 14, e008573.	3.9	21

#	Article	IF	CITATIONS
1259	Relationship between highâ€sensitivity cardiac troponin T, Bâ€type natriuretic peptide, and physical function in patients with heart failure. ESC Heart Failure, 2021, 8, 5092-5101.	3.1	5
1260	Biomarkers in Acute Heart Failure Syndromes: An Update. Current Cardiology Reviews, 2021, 17, .	1.5	1
1261	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association ( <scp>HFA</scp> ), European Society of Cardiology ( <scp>ESC</scp> ). European Journal of Heart Failure, 2021, 23, 1610-1632.	7.1	69
1262	Iron replacement therapy in heart failure: a literature review. Egyptian Heart Journal, 2021, 73, 85.	1.2	4
1263	Remote monitoring for heart failure using implantable devices: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Heart Failure Reviews, 2022, 27, 1281-1300.	3.9	15
1264	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Failure, 2021, 8, 4572-4583.	3.1	21
1265	The Role of Patiromer in Delaying the Onset of Renal Replacement Therapy in Patients with Advanced Renal Failure. Case Reports in Nephrology, 2021, 2021, 1-7.	0.4	2
1266	Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial. ESC Heart Failure, 2021, 8, 4997-5009.	3.1	11
1267	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care, 2021, 44, 2573-2581.	8.6	13
1268	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	7.1	23
1269	Machine Learning-Derived Echocardiographic Phenotypes PredictÂHeartÂFailure Incidence in Asymptomatic Individuals. JACC: Cardiovascular Imaging, 2022, 15, 193-208.	5.3	39
1270	Identification of the distinctive role of DPT in dilated cardiomyopathy: a study based on bulk and single-cell transcriptomic analysis. Annals of Translational Medicine, 2021, 9, 1401-1401.	1.7	6
1271	Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. Journal of Heart and Lung Transplantation, 2021, 40, 1605-1613.	0.6	5
1272	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 829-850.e1.	0.8	34
1273	<i>·î²</i> -Arrestin–Biased Allosteric Modulator Potentiates Carvedilol-Stimulated <i>·î²</i> Adrenergic Receptor Cardioprotection. Molecular Pharmacology, 2021, 100, 568-579.	2.3	24
1274	Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. ESC Heart Failure, $2021$ , , .	3.1	9
1275	The HEART Camp Exercise Intervention Improves Exercise Adherence, Physical Function, and Patient-Reported Outcomes in Adults With Preserved Ejection Fraction Heart Failure. Journal of Cardiac Failure, 2021, , .	1.7	6
1276	Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand. Clinical Drug Investigation, 2021, 41, 907-915.	2.2	13

#	Article	IF	CITATIONS
1277	Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction. Children, 2021, 8, 872.	1.5	1
1278	Intestinal congestion and reperfusion injury: damage caused to the intestinal tract and distal organs. Bioscience Reports, 2021, 41, .	2.4	6
1279	Predictors of Cardiac Implantable Electronic Device Artifact on Cardiac MRI: The Utility of a Device Related Score. Heart Lung and Circulation, 2021, 30, 1348-1355.	0.4	3
1280	Rhythm Control in Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4038.	2.4	4
1281	Cardiovascular Manifestations From Therapeutic Radiation. JACC: CardioOncology, 2021, 3, 360-380.	4.0	81
1282	The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure. Current Cardiology Reviews, 2021, 17, e160721193557.	1.5	1
1283	Troponin T in COVID-19 hospitalized patients: Kinetics matter. Cardiology Journal, 2021, , .	1.2	6
1284	Lung Ultrasound–Guided Emergency Department Management of Acute HeartÂFailure (BLUSHED-AHF). JACC: Heart Failure, 2021, 9, 638-648.	4.1	28
1285	Impact of a <scp>pharmacistâ€inclusive postâ€discharge</scp> clinic on outcomes in heart failure patients with reduced ejection fraction: Rates of hospital readmission, emergency department visits, or death. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1516-1523.	1.0	3
1286	Phenotyping heart failure using modelâ€based analysis and physiologyâ€informed machine learning. Journal of Physiology, 2021, 599, 4991-5013.	2.9	16
1287	RBM20-Related Cardiomyopathy: Current Understanding and Future Options. Journal of Clinical Medicine, 2021, 10, 4101.	2.4	20
1288	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the <scp>S</scp> wedish <scp>H</scp> eart <scp>F</scp> ailure <scp>R</scp> egistry. European Journal of Heart Failure, 2021, 23, 1844-1854.	7.1	42
1289	NTâ€proBNP/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme. ESC Heart Failure, 2021, 8, 5081-5091.	3.1	6
1290	Characteristics and outcome of ambulatory heart failure patients receiving a left ventricular assist device. ESC Heart Failure, 2021, , .	3.1	3
1291	Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. Journal of the American Heart Association, 2021, 10, e021276.	3.7	6
1292	Study of the Correlation Between the Ratio of Diastolic to Systolic Durations and Echocardiography Measurements and Its Application to the Classification of Heart Failure Phenotypes. International Journal of General Medicine, 2021, Volume 14, 5493-5503.	1.8	1
1293	Importance of Optimized Guideline-Based Therapy for Preventing Rehospitalization of Chronic Heart Failure Patients ― From the KUNIUMI Acute Cohort ―. Circulation Reports, 2021, 3, 511-519.	1.0	0
1294	Clinical Characteristics and Outcomes of Adults With a History of Heart Failure Hospitalized for COVID-19. Circulation: Heart Failure, 2021, 14, e008354.	3.9	25

#	Article	IF	CITATIONS
1295	Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. American Journal of Medicine, 2021, 134, 1068-1070.	1.5	14
1296	Heart failure with mid-range or mildly reduced ejection fraction. Nature Reviews Cardiology, 2022, 19, 100-116.	13.7	156
1297	Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients. European Journal of Clinical Pharmacology, 2022, 78, 19-25.	1.9	10
1298	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. Journal of the American Heart Association, 2021, 10, e021584.	3.7	12
1299	The effect of cardiac rhythm on artificial intelligence-enabled ECG evaluation of left ventricular ejection fraction prediction in cardiac intensive care unit patients. International Journal of Cardiology, 2021, 339, 54-55.	1.7	4
1300	State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure. Current Cardiology Reviews, 2021, 17, e230421189012.	1.5	1
1301	Cost-utility analysis of medication review with follow-up for cardiovascular outcomes: A microsimulation model. Health Policy, 2021, 125, 1406-1414.	3.0	2
1302	The Use of Machine Learning for the Care of Hypertension and HeartÂFailure. JACC Asia, 2021, 1, 162-172.	1.5	9
1303	In-hospital mortality, length of stay and hospital costs for hospitalized breast cancer patients with comorbid heart failure in the USA. Current Medical Research and Opinion, 2021, 37, 1-5.	1.9	1
1304	Polypharmacy in Heart Failure: Progress But Also Problem. American Journal of Medicine, 2021, 134, 1071-1073.	1.5	11
1305	Cardiac Magnetic Resonance Tissue Characterization in Ischemic Cardiomyopathy. Journal of Thoracic Imaging, 2021, Publish Ahead of Print, 2-16.	1.5	11
1306	Medical and Surgical Management of Left Ventricular Assist Device-Associated Intracranial Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106053.	1.6	7
1307	Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. IJC Heart and Vasculature, 2021, 36, 100860.	1.1	3
1308	Acute-phase initiation of cardiac rehabilitation and clinical outcomes in hospitalized patients for acute heart failure. International Journal of Cardiology, 2021, 340, 36-41.	1.7	16
1309	Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. Value in Health, 2021, 24, 1435-1445.	0.3	3
1310	Effect of iron supplementation in patients with heart failure and iron deficiency: A systematic review and meta-analysis. IJC Heart and Vasculature, 2021, 36, 100871.	1.1	4
1311	Association of Oral Anticoagulation With Stroke in Atrial Fibrillation or Heart Failure. Stroke, 2021, 52, 3151-3162.	2.0	2
1312	Inotropes in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 587-598.	2.1	14

#	Article	IF	CITATIONS
1313	The determinants of plasma brain natriuretic peptide level in severe aortic valve stenosis patients undergoing transcatheter aortic valve implantation. Journal of Cardiology, 2021, 78, 413-422.	1.9	0
1314	Caregiver subjective and physiological markers of stress and patient heart failure severity in family care dyads. Psychoneuroendocrinology, 2021, 133, 105399.	2.7	6
1315	Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102834.	2.8	7
1316	The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. , 2021, 227, 107863.		59
1317	Evaluation of the impact of enhanced virtual forms and gamification on intervention identification in a pharmacist-led ambulatory care clinic. Exploratory Research in Clinical and Social Pharmacy, 2021, 4, 100068.	1.0	1
1318	Implantable Cardiac Devices. , 2022, , 161-166.		0
1319	Detection and characterization of diastolic dysfunction., 2022,, 122-143.		0
1320	Cardiac Complications of Neuromuscular Disorders. , 2022, , 52-78.		O
1321	Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients. Cardiology Research, 2021, 12, 2-9.	1.1	1
1322	Prevalence and association of iron deficiency with anemia among patients with heart failure in the USA: NHANES 2017-2018. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 124-127.	0.8	6
1323	Normal Range of Global Longitudinal Strain in the Elderly. JACC: Cardiovascular Imaging, 2021, 14, 300-302.	5.3	5
1324	Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELDâ€AF. ESC Heart Failure, 2021, 8, 1139-1149.	3.1	18
1325	 <b>Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over <math>400</math></b> $6$ $6$ $6$ $6$ $6$ CPRD) $6$ CKJ: Clinical Kidney Journal, 2021, 14, 2203-2212.	2.9	15
1326	Impact of the state of emergency enacted due to the COVID-19 pandemic on the physical activity of the elderly in Japan. Journal of Physical Therapy Science, 2021, 33, 345-350.	0.6	9
1327	Electrocardiographic assessment and management of arrhythmias in peripartum cardiomyopathy., 2021,, 117-144.		0
1328	Impact of national valsartan recalls on Veterans' outcomes. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110161.	2.4	4
1329	Domain management as the best way of manage patient with heart failure and geriatrics syndromes. Russian Journal of Geriatric Medicine, 2021, , 313-326.	0.6	1
1330	Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review. Breast Cancer Research and Treatment, 2021, 186, 295-303.	2.5	3

#	Article	IF	CITATIONS
1331	Hypertension and Its Relation to Heart Failure With a Preserved Ejection Fraction., 2021,, 258-267.		0
1332	Serum Galectin-3 and Subsequent Risk of Coronary Heart Disease in Subjects With Childhood-Onset Type 1 Diabetes: A Cohort Study. Diabetes Care, 2021, 44, 810-816.	8.6	9
1333	Cardiac Rehabilitation in Heart Failure. International Journal of Heart Failure, 2021, 3, 1.	2.7	17
1334	Mitochondrial bioenergetics and D-ribose in HFpEF: a brief narrative review. Annals of Translational Medicine, 2021, 9, 1504-1504.	1.7	3
1335	Model-based comorbidity clusters in patients with heart failure: association with clinical outcomes and healthcare utilization. BMC Medicine, 2021, 19, 9.	5.5	16
1336	HeartÂFailure Hospitalization and Guideline-Directed Prescribing Patterns Among HeartÂFailure With Reduced Ejection Fraction Patients. JACC: Heart Failure, 2021, 9, 28-38.	4.1	43
1337	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	2.2	213
1338	Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	4.0	19
1339	Costâ€effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration. ESC Heart Failure, 2019, 6, 1178-1187.	3.1	14
1340	Acute Exacerbations of Chronic Lung Disease: Cardiac Considerations. Respiratory Medicine, 2020, , 229-245.	0.1	1
1341	Pathophysiology and Causes of Heart Failure in Adult Congenital Heart Disease. Congenital Heart Disease in Adolescents and Adults, 2018, , 11-30.	0.2	2
1342	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	3.9	3
1343	Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review. Diabetes Therapy, 2020, 11, 1271-1291.	2.5	15
1344	High intensity interval training improves diabetic cardiomyopathy via miR-1 dependent suppression of cardiomyocyte apoptosis in diabetic rats. Journal of Diabetes and Metabolic Disorders, 2020, 19, 145-152.	1.9	6
1345	Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. European Journal of Internal Medicine, 2020, 80, 91-98.	2.2	10
1346	Unraveling the Mystery of TroponinÂElevation in Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2917-2918.	2.8	9
1347	A Machine Learning Approach to Management of HeartÂFailure Populations. JACC: Heart Failure, 2020, 8, 578-587.	4.1	44
1349	Assessing the lifetime benefit of heart failure therapies. Lancet, The, 2020, 396, 75-77.	13.7	2

#	ARTICLE	IF	CITATIONS
1350	Cardiac natriuretic peptides. Nature Reviews Cardiology, 2020, 17, 698-717.	13.7	262
1351	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	2.2	117
1352	Diastolic Heart Failure. Cardiology in Review, 2021, 29, 82-88.	1.4	5
1353	Intraventricular Flow Patterns in Patients Treated with Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 74-83.	1.6	14
1354	Artificial Intelligence Algorithm for Screening Heart Failure with Reduced Ejection Fraction Using Electrocardiography. ASAIO Journal, 2021, 67, 314-321.	1.6	34
1355	New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF). Medicine (United States), 2020, 99, e18341.	1.0	9
1356	Efficacy and safety of Qishen granules for chronic heart failure. Medicine (United States), 2020, 99, e23901.	1.0	2
1357	The Impact of Hemodynamic Reflex Compensation Following Myocardial Infarction on Subsequent Ventricular Remodeling. Journal of Biomechanical Engineering, 2019, 141, .	1.3	14
1358	Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Medical Journal, 2020, 61, 320-326.	0.6	5
1359	Prediction of sudden death in elderly patients with heart failure. Journal of Geriatric Cardiology, 2018, 15, 185-192.	0.2	11
1360	Heart failure mortality compared between elderly and non-elderly Thai patients. Journal of Geriatric Cardiology, 2018, 15, 718-724.	0.2	7
1361	Effect of $\hat{I}^2$ -blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. Journal of Geriatric Cardiology, 2019, 16, 291-297.	0.2	5
1362	Recent advances in the treatment of chronic heart failure. F1000Research, 2019, 8, 2134.	1.6	7
1363	Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports. HRB Open Research, 2020, 3, 5.	0.6	3
1364	Diagnostic accuracy and clinical impact of natriuretic peptide screening for the detection of heart failure in the community: a protocol for systematic review and meta-analysis. Wellcome Open Research, 0, 4, 169.	1.8	2
1365	Diabetes mellitus type 1 in adults. Diabetes Mellitus, 2020, 23, 42-114.	1.9	7
1366	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	1.9	16
1367	Comparing NGS and NanoString platforms in peripheral blood mononuclear cell transcriptome profiling for advanced heart failure biomarker development. Journal of Biological Methods, 2020, 7, e123.	0.6	16

#	Article	IF	CITATIONS
1368	In-Hospital and Long-Term Outcomes of Beta-Blocker Treatment in Cocaine Users: A Systematic Review and Meta-analysis. Cardiology Research, 2019, 10, 40-47.	1.1	2
1369	Indications of Cardiac Resynchronization in Non-Left Bundle Branch Block: Clinical Review of Available Evidence. Cardiology Research, 2020, 11, 1-8.	1.1	5
1370	Phenotyping to Facilitate Accrual for a Cardiovascular Intervention. Journal of Clinical Medicine Research, 2019, 11, 458-463.	1.2	5
1371	Utilization of Ultrasound to Assess Volume Status in Heart Failure. Journal of Clinical Medicine Research, 2020, 12, 230-232.	1.2	2
1372	Fluorodeoxyglucose Applications in Cardiac PET: Viability, Inflammation, Infection, and Beyond. Methodist DeBakey Cardiovascular Journal, 2021, 16, 122.	1.0	12
1373	Impact of Social Media and Virtual Learning on Cardiology During the COVID-19 Pandemic Era and Beyond. Methodist DeBakey Cardiovascular Journal, 2021, 16, 1.	1.0	12
1374	Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers. Clinical Chemistry and Laboratory Medicine, 2021, 59, 79-90.	2.3	42
1375	Clinical relevance of biological variation of cardiac troponins. Clinical Chemistry and Laboratory Medicine, 2021, 59, 641-652.	2.3	36
1376	Sex Differences in Clinical Characteristics and 2-Year Prognosis of Patients with Heart Failure Grouped by Left Ventricular Ejection Fraction Status. International Heart Journal, 2020, 61, 1236-1244.	1.0	2
1377	Haemodynamic Monitoring Devices in Heart Failure: Maximising Benefit with Digitally Enabled Patient Centric Care. Arrhythmia and Electrophysiology Review, 2018, 7, 1.	2.4	6
1378	Ivabradine and AF: Coincidence, Correlation or a New Treatment?. Arrhythmia and Electrophysiology Review, 2020, 8, 300-303.	2.4	6
1379	Applying Heart Failure Management to Improve Health Outcomes: But WHICH One?. Cardiac Failure Review, 2017, 3, 113.	3.0	4
1380	Natriuretic Peptide-based Screening and Prevention of Heart Failure. Cardiac Failure Review, 2017, 3, 83.	3.0	14
1381	Iron Therapy in Heart Failure: Ready for Primetime?. Cardiac Failure Review, 2018, 4, 1.	3.0	31
1382	Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. Cardiac Failure Review, 2020, 6, 1-7.	3.0	8
1383	Hospice Use Among Patients with Heart Failure. Cardiac Failure Review, 2019, 5, 93-98.	3.0	23
1384	The Limitations of Symptom-based Heart Failure Management. Cardiac Failure Review, 2019, 5, 74-77.	3.0	10
1385	Contemporary Management of Secondary Mitral Regurgitation. European Cardiology Review, 2020, 15, e22.	2.2	5

#	Article	IF	Citations
1386	Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review, 2020, 15, e13.	2.2	20
1387	Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?. Sultan Qaboos University Medical Journal, 2018, 18, 13.	1.0	7
1388	Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap. Aging, 2019, 11, 3650-3667.	3.1	27
1389	Metabolic remodeling induced by mitokines in heart failure. Aging, 2019, 11, 7307-7327.	3.1	9
1390	Silent myocardial infarction and risk of heart failure. Annals of Translational Medicine, 2018, 6, S35-S35.	1.7	4
1391	Glycosylation of natriuretic peptides in obese heart failure: mechanistic insights. Annals of Translational Medicine, 2019, 7, 611-611.	1.7	8
1392	<p>Drug Therapy Problems and the Role of Clinical Pharmacist in Surgery Ward: Prospective Observational and Interventional Study</p> . Drug, Healthcare and Patient Safety, 2020, Volume 12, 71-83.	2.5	22
1393	Mobile Phone Apps to Support Heart Failure Self-Care Management: Integrative Review. JMIR Cardio, 2018, 2, e10057.	1.7	86
1394	Structured Telephone Support Intervention: Improved Heart Failure Outcomes. JMIR Aging, 2020, 3, e13513.	3.0	3
1395	Automating Quality Measures for Heart Failure Using Natural Language Processing: A Descriptive Study in the Department of Veterans Affairs. JMIR Medical Informatics, 2018, 6, e5.	2.6	29
1396	Association of Cyr61-cysteine-rich protein 61 and short-term mortality in patients with acute heart failure and coronary heart disease. Biomarkers in Medicine, 2019, 13, 1589-1597.	1.4	5
1397	Implications of the New 2017 American College of Cardiology/American Heart Association Guidelines for Hypertension. Minerva Cardioangiologica, 2019, 67, 399-410.	1.2	9
1398	Le malattie croniche e la medicina di laboratorio. Rivista Italiana Della Medicina Di Laboratorio, 2019, 15, .	0.4	2
1399	Using Physical Function to Predict Hospital Readmission within 1 Year in Patients with Heart Failure. Progress in Rehabilitation Medicine, 2019, 4, n/a.	0.9	7
1400	Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure. Journal of Korean Medical Science, 2019, 34, e133.	2.5	11
1401	Prevalence, Characteristics, and Clinical Significance of Concomitant Cardiomyopathies in Subjects with Bicuspid Aortic Valves. Yonsei Medical Journal, 2019, 60, 816.	2.2	10
1402	Effect of Angiotensin-Converting Enzyme Blockade, Alone or Combined With Blockade of Soluble Epoxide Hydrolase, on the Course of Congestive Heart Failure and Occurrence of Renal Dysfunction in Ren-2 Transgenic Hypertensive Rats With Aorto-Caval Fistula. Physiological Research, 2017, 67, 401-415.	0.9	14
1403	New approaches to assessing the contractile function of the left ventricular in patients with heart failure on the background of modulation of cardiac contractility Kardiologicheskii Vestnik, 2020, , 4-13.	0.4	1

#	Article	IF	CITATIONS
1404	Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. International Journal of Heart Failure, 2019, 1, 4.	2.7	45
1405	Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea. International Journal of Heart Failure, 2019, 1, 25.	2.7	22
1406	Palliative and end-of-life care for heart failure patients in an aging society. Korean Journal of Internal Medicine, 2018, 33, 1039-1049.	1.7	19
1407	Heart failure guidelines: What you need to know about the 2017 focused update. Cleveland Clinic Journal of Medicine, 2019, 86, 123-139.	1.3	5
1408	Meditation for Improved Clinical Outcomes in Patients with Implantable Defibrillators for Heart Failure- Pilot Study. Journal of Atrial Fibrillation, 2020, 12, 2314.	0.5	4
1409	Rationale and Design of the High Platelet Inhibition with Ticagrelor to Improve Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction (HEALING-AMI) Trial. Korean Circulation Journal, 2019, 49, 586.	1.9	5
1410	Temporal Trends of Cardiac Implantable Electronic Device Implantations: a Nationwide Population-based Study. Korean Circulation Journal, 2019, 49, 841.	1.9	32
1411	Matricellular proteins as possible biomarkers for early brain injury after aneurysmal subarachnoid hemorrhage. Neural Regeneration Research, 2018, 13, 1175.	3.0	33
1412	Utilization of guideline-directed medical therapy in patients with de novo heart failure with reduced ejection fraction: A Veterans Affairs study. Journal of Family Medicine and Primary Care, 2020, 9, 3065.	0.9	7
1413	Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World Journal of Cardiology, 2020, 12, 7-25.	1.5	28
1414	A Comparative Evaluation of Marginal Leakage of Different Restorative Materials in Deciduous Molars: An <i>in vitro</i> Study. International Journal of Clinical Pediatric Dentistry, 2012, 5, 101-107.	0.8	16
1415	A Study of Bite Force and Various Variables in Children Segregated by Angle's Classification. International Journal of Clinical Pediatric Dentistry, 2012, 5, 118-123.	0.8	9
1416	Is there an Association between Oral Health Status and School Performance? A Preliminary Study. International Journal of Clinical Pediatric Dentistry, 2012, 5, 132-135.	0.8	22
1417	Dens Invaginatus in Primary Maxillary Molar: A Rare Case Report and Review of Literature. International Journal of Clinical Pediatric Dentistry, 2012, 5, 139-141.	0.8	6
1418	Management of Talons Cusp associated with Primary Central Incisor: A Rare Case Report. International Journal of Clinical Pediatric Dentistry, 2012, 5, 142-144.	0.8	2
1419	Building-up a Smile in a 5-Year-Old Child: A Case Report. International Journal of Clinical Pediatric Dentistry, 2012, 5, 151-154.	0.8	5
1420	Customization of Stock Eye Prosthesis for a Pediatric Patient by a Simplified Technique. International Journal of Clinical Pediatric Dentistry, 2012, 5, 155-158.	0.8	2
1421	Glassfiber Post: An Alternative for Restoring Grossly Decayed Primary Incisors. International Journal of Clinical Pediatric Dentistry, 2012, 5, 159-162.	0.8	4

#	Article	IF	CITATIONS
1422	Acidogenic Potential of Plain Milk, Milk with Sugar, Milk with Cornflakes and Milk Cornflakes with Sugar: A Comparative Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 218-221.	0.8	2
1423	Primary Oral Health Care in India: Vision or Dream?. International Journal of Clinical Pediatric Dentistry, 2016, 9, 228-232.	0.8	5
1424	Prevalence of Early Childhood Caries in Children of West Godavari District, Andhra Pradesh, South India: An Epidemiological Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 251-255.	0.8	17
1425	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. Global Heart, 2020, 15, 44.	2.3	11
1426	Predictors of Hospitalization for Heart Failure Decompensation in 18-months Follow-up After Index Hospitalization for Acute Heart Failure. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2018, 72, 257.	0.9	2
1427	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.2	50
1428	Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes. Hypertension Research, 2022, 45, 97-105.	2.7	20
1429	Cardiomyopathy Management and In-Hospital Outcomes in a Tertiary Care Center: Clinical Components and Venues of Advanced Care. Cureus, 2021, 13, e19054.	0.5	0
1430	Biomarkers Utility: At the Borderline between Cardiology and Neurology. Journal of Cardiovascular Development and Disease, 2021, 8, 139.	1.6	7
1431	Central sleep apnea treatment in patients with heart failure with reduced ejection fraction: a network meta-analysis. Sleep and Breathing, 2022, 26, 1227-1235.	1.7	3
1432	A clinical score to predict mortality in patients after acute heart failure from Japanese registry. ESC Heart Failure, $2021,  ,  .$	3.1	3
1433	Diabetes With Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1599-1602.	2.8	6
1434	Prognostic impact of systolic blood pressure in acute heart failure with preserved ejection fraction in older patients. ESC Heart Failure, 2021, 8, 5493-5500.	3.1	3
1435	The role of hyperglycaemia in the development of diabetic cardiomyopathy. Archives of Cardiovascular Diseases, 2021, 114, 748-760.	1.6	24
1436	Differential impact of antihypertensive drugs on cardiovascular remodeling: a review of findings and perspectives for HFpEF prevention. Hypertension Research, 2022, 45, 53-60.	2.7	7
1437	Quality of Heart Failure Care in the Intensive Care Unit. Journal of Cardiac Failure, 2021, 27, 1111-1125.	1.7	8
1438	Universal Definition and Classification of Heart Failure: Pharmacists' Perspective: Optimizing Guideline-Directed Medical Therapy and Educating Stakeholders. Journal of Cardiac Failure, 2021, 27, 1310-1312.	1.7	1
1439	Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 1682-1699.	2.8	55

#	Article	IF	Citations
1440	The influence of boundary conditions and protein availability on the remodeling of cardiomyocytes. Biomechanics and Modeling in Mechanobiology, 2021, , .	2.8	1
1441	ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction. ESC Heart Failure, 2021, 8, 4607-4616.	3.1	14
1442	Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. European Heart Journal Quality of Care & Dutcomes, 2022, 8, 750-760.	4.0	7
1443	The Impact of Glucocorticoid Therapy on Guideline-Directed Medical Treatment Titration in Patients Hospitalized for Heart Failure with Low Blood Pressure: A Retrospective Study. International Journal of General Medicine, 2021, Volume 14, 6693-6701.	1.8	4
1444	Sacubitril/Valsartan Initiation Among Veterans Who Are Reninâ€Angiotensinâ€Aldosterone System Inhibitor NaÃ⁻ve With Heart Failure and Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e020474.	3.7	1
1445	Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. American Journal of Cardiovascular Drugs, 2021, 21, 701-710.	2.2	9
1446	Predictors of mortality among patients with type 2 diabetes in Jordan. BMC Endocrine Disorders, 2021, 21, 200.	2.2	9
1447	Safety and efficacy of iron supplementation after myocardial infarction in mice with moderate blood loss anaemia. ESC Heart Failure, 2021, 8, 5445-5455.	3.1	8
1448	Measuring lung water adds prognostic value in heart failure patients undergoing cardiac magnetic resonance. Scientific Reports, 2021, 11, 20162.	3.3	4
1449	Temporal Trends in Post Myocardial Infarction Heart Failure and Outcomes Among Older Adults. Journal of Cardiac Failure, 2022, 28, 531-539.	1.7	11
1450	Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart, 2021, 8, e001704.	2.3	3
1451	Biomarkers in the management of acute heart failure: state of the art and role in COVIDâ€19 era. ESC Heart Failure, 2021, 8, 4465-4483.	3.1	10
1452	Using Deep-Learning Algorithms to Simultaneously Identify Right and Left Ventricular Dysfunction From the Electrocardiogram. JACC: Cardiovascular Imaging, 2022, 15, 395-410.	5.3	35
1453	Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 863-872.	1.9	6
1454	Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. American Heart Journal, 2022, 243, 177-186.	2.7	19
1455	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	4.1	32
1456	Rehabilitation of a One-day-Old Neonate with Cleft Lip and Palate using Palatal Obturator: A Case Report. International Journal of Clinical Pediatric Dentistry, 2012, 5, 145-147.	0.8	3
1457	Mutans Streptococci Colonization in Relation to Feeding Practices, Age and the Number of Teeth in 6 to 30-Month-Old Children: An <i>in vivo</i> Study. International Journal of Clinical Pediatric Dentistry, 2012, 5, 124-131.	0.8	3

#	ARTICLE	IF	CITATIONS
1458	A Rare Occurrence of Geminated-Taloned Maxillary Lateral Incisor. International Journal of Clinical Pediatric Dentistry, 2012, 5, 136-138.	0.8	1
1459	Gorlin-Goltz Syndrome: A Rare Case Report of a 11-Year-Old Child. International Journal of Clinical Pediatric Dentistry, 2016, 9, 264-268.	0.8	5
1460	Sealing Ability of Nano-ionomer in Primary Teeth: An ex vivo Study. International Journal of Clinical Pediatric Dentistry, 2016, 9, 209-213.	0.8	3
1461	Hemmstoffe des Renin-Angiotensin-Systems. , 2017, , 211-236.		O
1462	Role of Magnetic Resonance Imaging in the Evaluation of Compressive Myelopathy in Rohilkhand Region, India. International Journal of Advanced and Integrated Medical Sciences, 2017, 2, 130-136.	0.0	0
1464	Clinical Outcomes Study of Echocardiography Imaging to Define Relationship between Significant Pulmonary Hypertension and Right Ventricular Dysfunction: Indian Scenario. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2018, 2, 45-48.	0.1	O
1465	Hemmstoffe des Renin-Angiotensin-Systems. , 2018, , 263-288.		0
1466	Do We Need an Implantable Cardioverter-defibrillator for Primary Prevention in Cardiac Resynchronisation Therapy Patients?. Arrhythmia and Electrophysiology Review, 2018, 7, 157.	2.4	2
1467	Cardiovascular and Cancer Risk: The Role of Cardio-oncology. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.4	9
1468	Role of biomarkers in diagnostics, stratification of risk and prognosis of heart failure Medicni Perspektivi, 2018, 23, 56-63.	0.4	1
1469	Changes of the level of galectin-3, $\hat{l}^2$ -2-microglobulin, albuminuria and end glycation products in patients with chronic heart failure and atrial fibrillation under the influence of treatment Medicni Perspektivi, 2018, 23, 26-34.	0.4	0
1471	Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure. Contemporary Cardiology, 2019, , 105-115.	0.1	0
1472	Herzinsuffizienz und HypoxĀ <b>m</b> ie bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-9.	0.0	0
1473	Treatment of Hypertension: A Review. Yangtze Medicine, 2019, 03, 101-123.	0.1	5
1474	Hemmstoffe des Renin-Angiotensin-Systems. , 2019, , 359-388.		0
1476	Fisiopatologia e Tratamento da Insuficiência CardÃaca com Fração de Ejeção Preservada: Estado da Arte e Perspectivas para o Futuro. Arquivos Brasileiros De Cardiologia, 2019, 114, 120-129.	0.8	2
1477	Can Early Management of Hypertension by General Practitioners Improve Outcome?. US Cardiology Review, 2019, 13, 58-60.	0.5	1
1478	Selección de lo mejor del año 2018 en insuficiencia cardiaca. REC: CardioClinics, 2019, 54, 63-69.	0.1	0

#	Article	IF	CITATIONS
1480	Reading Level and Suitability of Congestive Heart Failure (CHF) Education in a Mobile App (CHF Info) Tj ETQq0 0 C	) rgBT /Ove	rlock 10 Tf
1481	Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF. Global Cardiology Science & Practice, 2019, 2019, 3.	0.4	O
1482	ДиаÑÑ,Đ¾Đ»Đ¸Ñ‡ĐμÑĐºĐ°Ñ•ĐиÑÑ"ÑƒĐ½ĐºÑ†Đ¸Ñ• Đ¾Ñ, Đ¾Ñ,ĐºŇ€Ñ‹Ñ,Đ¸Ñ•ĐѢ¾ Đ¿Đ¾ÑĐ»ĐμĐѢ½Đ¸I	Ñ. <b>oÐ</b> ¾Ð±	Ð1½Ð¾Ð2Ð
1483	Role of novel cardiac biomarkers for the diagnosis, risk stratification, and prognostication among patients with heart failure. Journal of Cardiology and Cardiovascular Medicine, 2019, 4, 103-109.	0.2	O
1484	Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity. Methodist DeBakey Cardiovascular Journal, 2021, 15, 267.	1.0	27
1485	Educational intervention to improve appropriate digoxin therapeutic drug monitoring: a quasi-experimental study. European Journal of Hospital Pharmacy, 2021, 28, 320-324.	1.1	1
1486	Diagnostic accuracy and clinical impact of natriuretic peptide screening for the detection of heart failure in the community: a protocol for systematic review and meta-analysis. Wellcome Open Research, 0, 4, 169.	1.8	0
1487	Myocardial remodeling and arterial stiffness depending on aldosterone level in patients with chronic kidney disease and arterial hypertension. Patolog $\tilde{A}_{f e}$ , 2019, .	0.1	O
1488	Hemmstoffe des Renin-Angiotensin-Systems. , 2020, , 231-259.		0
1489	The analysis of unplanned readmissions after left ventricular assist device implantation as bridge-to-transplant. Turkish Journal of Thoracic and Cardiovascular Surgery, 2020, 28, 55-62.	0.4	O
1490	Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure. US Cardiology Review, 2020, 13, 83-87.	0.5	2
1491	Evaluation of galectin-3 in patients with heart failure and its relationship with NT-proBNP levels: A case-control study. Journal of Surgery and Medicine, 0, , .	0.1	O
1492	Major Cardiac–Psychiatric Drug–Drug Interactions: a Systematic Review of the Consistency of Drug Databases. Cardiovascular Drugs and Therapy, 2021, 35, 441-454.	2.6	6
1493	Heart Failure Drug Class Effects on 30-Day Readmission Rates in Patients with Heart Failure with Preserved Ejection Fraction: A Retrospective Single Center Study. Medicines (Basel, Switzerland), 2020, 7, 30.	1.4	6
1494	Current status and future of development of ventricular assist devices in Japan. Journal of the Japanese Society of Intensive Care Medicine, 2020, 27, 177-183.	0.0	0
1495	Identification of Target Genes and Transcription Factors in Mice with LMNA-Related Dilated Cardiomyopathy by Integrated Bioinformatic Analyses. Medical Science Monitor, 2020, 26, e924576.	1.1	1
1496	Pharmacist- or Nurse Practitioner–Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	2
1498	Drug-Induced Heart Failure (Part 2: Mechanisms of Development, Clinical Signs, Differential Diagnosis,) Tj ETQq1	1 8.78431	1 4 <sub>0</sub> gBT /Ove

#	ARTICLE	IF	CITATIONS
1499	Two-Dimensional and Three-Dimensional Transthoracic Echocardiography as Predictive and Prognostic Indicators of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction in Patients with Ischemic Heart Disease. Medical Science Monitor, 2020, 26, e922129.	1.1	1
1500	Estabilidad clÃnica en la insuficiencia cardiaca. Mito o realidad. Revista Clinica Espanola, 2020, 220, 356-358.	0.6	0
1501	The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia. Cureus, 2020, 12, e10032.	0.5	1
1502	The effect of beta-blockers in acute heart failure according to heart rate. Korean Journal of Internal Medicine, 2021, 36, 898-905.	1.7	4
1503	Cuidados paliativos. PAJAR - Pan-American Journal of Aging Research, 2020, 8, e33815.	0.1	0
1504	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. Drug Safety, 2022, 45, 65-74.	3.2	2
1505	Application of Extreme Learning Machine in the Survival Analysis of Chronic Heart Failure Patients With High Percentage of Censored Survival Time. Frontiers in Cardiovascular Medicine, 2021, 8, 726516.	2.4	9
1506	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of the American College of Cardiology, 2021, 78, e187-e285.	2.8	336
1507	A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure. Molecules, 2021, 26, 6600.	3.8	22
1508	Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. Joint Commission Journal on Quality and Patient Safety, 2022, 48, 25-32.	0.7	1
1509	Using the Evidence for Palliative Care to Improve Outcomes for Patients With Heart Failure. American Journal of Critical Care, 2021, 30, 479-482.	1.6	1
1510	Incidence, prognosis, and risk factors of sepsis-induced cardiomyopathy. World Journal of Clinical Cases, 2021, 9, 9452-9468.	0.8	12
1511	Effectiveness and safety of Xinyin tablet in treatment of chronic heart failure. Medicine (United) Tj ETQq0 0 0 rgB1	「Overlocl	R 10 Tf 50 26
1512	Care bundle to reduce readmission in patients with heart failure: a modified Delphi consensus panel in Argentina. BMJ Open, 2020, 10, e040028.	1.9	1
1513	Progress in drug treatment of older patients with chronic heart failure. Aging Pathobiology and Therapeutics, 2020, 2, 176-179.	0.5	0
1514	Sodium-glucose cotransporter-2 inhibitors in heart failure patients: an appraisal of recent cardiovascular outcome trials. Minerva Cardioangiologica, 2020, 68, 629-651.	1.2	2
1515	Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Annals of Pharmacotherapy, 2021, 55, 1069-1075.	1.9	8
1516	A REVIEW ON GLOBAL TRENDS IN HEART FAILURE AND EVOLUTION OF ANGIOTENSIN–NEPRILYSIN INHIBITOR. Asian Journal of Pharmaceutical and Clinical Research, 0, , 32-37.	0.3	O

#	Article	IF	Citations
1517	Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease. Journal of Veterinary Internal Medicine, 2021, 35, 22-32.	1.6	10
1519	Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study. Age and Ageing, 2021, 50, 1173-1181.	1.6	3
1520	Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study. European Heart Journal, 2021, , .	2.2	9
1521	Novel pharmacotherapies for heart failure. , 2020, , 359-380.		0
1522	Prognostic implications of mitral valve geometry in patients with secondary mitral regurgitation: the COAPT trial. European Heart Journal Cardiovascular Imaging, 2022, 23, 1540-1551.	1.2	5
1523	The Scientific Targets: the Myocardium, the Vasculature and the Body's Response to Heart Failure. International Cardiovascular Forum Journal, 0, 17, .	1.1	0
1524	Evaluation of pulse pressure and proportional pulse pressure as predictors of severity among patients having heart failure with reduced ejection fraction. Annals of African Medicine, 2020, 19, 188.	0.5	2
1525	Giant Cell and Hypersensitivity Myocarditis. , 2020, , 223-241.		1
1526	The Attitudes of Physicians and the General Public toward Prognostic Disclosure of Different Serious Illnesses: a Korean Nationwide Study. Journal of Korean Medical Science, 2020, 35, e401.	2.5	0
1528	Herzinsuffizienz und HypoxÃmie. Springer Reference Medizin, 2020, , 1987-1995.	0.0	0
1529	Heart Transplantation for Chagas Cardiomyopathy. International Journal of Cardiovascular Sciences, 2020, 33, 697-704.	0.1	0
1530	Stable Ischemic Heart Disease. , 2020, , 19-39.		1
1531	Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients. Yonsei Medical Journal, 2020, 61, 942.	2.2	0
1533	Left Atrial and Renal Functional Status as Drivers of Adverse Outcome in Heart Failure with Reduced Ejection Fraction: A Four-Chamber Deformation Study in a Small Cohort of Northern Sweden. Journal of the Indian Academy of Echocardiography & Cardiovascular Imaging, 2020, 4, 176.	0.1	0
1534	Chronic Heart Failure. , 2020, , 137-154.		0
1536	Mechanical Circulatory Support Therapies: Right Timing and Prognosis Considerations., 2020,, 141-150.		0
1537	Knowledge Structure of Nursing Studies on Heart Failure Patients in South Korea through Text Network Analysis. Korean Journal of Adult Nursing, 2020, 32, 409.	0.7	1
1538	Implantable Cardioverter-defibrillator Utilization and Its Outcomes in Korea: Data from Korean Acute Heart Failure Registry. Journal of Korean Medical Science, 2020, 35, e397.	2.5	2

#	Article	IF	CITATIONS
1539	A mayor riesgo, más beneficio: bloqueo del sistema renina-angiotensina tras intervención coronaria percutánea en pacientes con sÃndrome coronario agudo. Revista Espanola De Cardiologia, 2020, 73, 104-106.	1.2	0
1540	Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?. Cureus, 2020, 12, e7323.	0.5	0
1541	Early structural and functional left ventricular disorders in young patients with hypertension: a role of insulin resistance. Russian Journal of Cardiology, 2020, 25, 3774.	1.4	7
1542	Teaching Versus Learning. Critical Care Nurse, 2020, 40, 64-69.	1.0	0
1543	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e022859.	3.7	19
1544	Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis. Journal of Cardiac Failure, 2022, 28, 540-550.	1.7	10
1545	Revisiting the clinical evidence of heart rate target in patients with heart failure treated with beta-blockers., 2021, 25, 762-773.		0
1546	Impact of natriuretic peptide polymorphisms on diastolic and metabolic function in a populational cohort: insights from the STANISLAS cohort. ESC Heart Failure, 2021, , .	3.1	4
1547	Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 4469-4482.	2.4	5
1548	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2022, 7, 17.	6.1	77
1549	"Brown Bag Clinic― A Pharmacist-led Approach to Reduce Heart Failure Hospital Readmission. Innovations in Pharmacy, 2021, 12, 11.	0.6	0
1550	The effect of renin–angiotensin–aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design. Hipertension Y Riesgo Vascular, 2020, 37, 101-107.	0.6	0
1551	Physician Variability in Diastology Reporting in Patients With Preserved Ejection Fraction: A Single Center Experience. Cureus, 2020, 12, e9062.	0.5	0
1552	Letter: Associations among Obesity Degree, Glycemic Status, and Risk of Heart Failure in 9,720,220 Korean Adults (Diabetes Metab J 2020;44:592-601). Diabetes and Metabolism Journal, 2020, 44, 777-778.	4.7	0
1553	Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry. ESC Heart Failure, 2020, 7, 3821-3829.	3.1	3
1554	The Correlation Between Heart Failure and Gut Microbiome Metabolites. Infectious Microbes & Diseases, 2020, 2, 136-143.	1.3	2
1555	Anesthetic Management of Cardiac Surgery Patients with Uncommon Diseases., 2021,, 209-223.		0
1556	Pharmacoepidemiology in Cardiorenal Medicine. , 2021, , 315-331.		0

#	Article	IF	CITATIONS
1557	Consider Everything When PrescribingÂSacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 76, 1049-1050.	2.8	0
1558	Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 517-541.	0.2	0
1559	A syndromic approach to assess diagnosis and management of patients presenting with respiratory symptoms to healthcare facilities in Vietnam. ERJ Open Research, 2021, 7, 00572-2020.	2.6	4
1560	Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study. Colombia Medica, 2021, 52, e2034542.	0.2	2
1561	Differentiating Nonischemic Dilated Cardiomyopathy With Incidental Infarction From Ischemic Cardiomyopathy by Geometric Indices Derived From Cardiovascular Magnetic Resonance. Journal of Thoracic Imaging, 2021, 36, 248-253.	1.5	5
1562	After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan?. Journal of Geriatric Cardiology, 2019, 16, 151-155.	0.2	1
1563	Cardiovascular Effects of Tyrosine Kinase Inhibitors in Patients With Advanced Renal Cell Carcinoma at the VA San Diego Healthcare System. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S18-S24.	0.6	0
1564	Toward a Clinical Point of Care Tool for Managing Heart Failure. AMIA Summits on Translational Science Proceedings, 2019, 2019, 819-828.	0.4	O
1565	Altered function of the left ventricle and clinical significance of heart-type fatty acid-binding protein in cardiac dysfunction among patients with sepsis. Experimental and Therapeutic Medicine, 2020, 20, 58.	1.8	0
1566	Mitochondrial shaping proteins as novel treatment targets for cardiomyopathies. Conditioning Medicine, 2020, 3, 216-226.	1.3	2
1568	Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism: Clinical and Experimental, 2022, 127, 154936.	3.4	37
1569	Beneficial Extracardiac Effects of Cardiovascular Medications. Current Cardiology Reviews, 2022, 18, .	1.5	3
1570	HeartÂFailure Biomarker Education. Journal of the American College of Cardiology, 2021, 78, 2265-2266.	2.8	0
1571	Iron Deficiency in Heart Failure: Characteristics and Treatment. Current Geriatrics Reports, 2021, 10, 196-205.	1.1	5
1572	Prognostic Effects of Cardiac Rehabilitation in Patients With Heart Failure (from a Multicenter) Tj ETQq0 0 0 rgBT	/Qverlock	. 10 Tf 50 182
1573	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Heart Journal, 2021, 245, 10-10.	2.7	4
1574	Initiation of Anti-Hypertensive Drugs and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2022, 135, 737-744.	1.5	2
1575	Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. European Heart Journal Digital Health, 2022, 3, 38-48.	1.7	8

#	Article	IF	CITATIONS
1576	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC: Heart Failure, 2022, 10, 1-11.	4.1	11
1577	Heart Failure with Reduced Ejection Fractionâ€"Does Sex Matter?. Current Heart Failure Reports, 2021, 18, 345-352.	3.3	15
1578	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. Journal of Cardiac Failure, 2022, 28, 370-384.	1.7	16
1579	Effects of Cardiac Rehabilitation Training in Patients with Heart Failure Based on Traditional Chinese Exercise: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-14.	1.2	5
1580	Analysis of Cardiac Vibration Signals Acquired From a Novel Implant Placed on the Gastric Fundus. Frontiers in Physiology, 2021, 12, 748367.	2.8	1
1581	Serum Meteorinâ€ike is associated with weight loss in the elderly patients with chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 409-417.	7.3	13
1583	Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction. Clinical Drug Investigation, 2021, 41, 1027-1036.	2.2	3
1584	Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis. BMJ Evidence-Based Medicine, 2022, 27, 224-234.	3.5	3
1585	Combined prognostic value of malnutrition using GLIM criteria and renal insufficiency in elderly heart failure. ESC Heart Failure, 2022, 9, 704-711.	3.1	9
1586	Association Between Heart Failure With Preserved Left Ventricular Ejection Fraction and Impaired Left Atrial Phasic Function in Hypertrophic Cardiomyopathy: Evaluation by Cardiac <scp>MRI</scp> Feature Tracking. Journal of Magnetic Resonance Imaging, 2022, 56, 248-259.	3.4	10
1587	Drug-Related Problems Among Ambulatory Heart Failure Patients on Follow-Up at Debre Berhan Comprehensive Specialized Hospital, Ethiopia. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1165-1175.	2.0	3
1588	Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2022, 7, 130.	6.1	19
1589	Multimodality Cardiac Imaging in Patients with Systemic Lupus Erythematosus. Current Problems in Cardiology, 2023, 48, 101048.	2.4	3
1590	Hierarchical management of chronic heart failure: a perspective based on the latent structure of comorbidities. ESC Heart Failure, 2021, , .	3.1	5
1591	The Ratio of NT-proBNP to CysC1.53 Predicts Heart Failure in Patients With Chronic Kidney Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 731864.	2.4	4
1592	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical Drug Investigation, 2022, 42, 1-16.	2.2	4
1593	Sleep-disordered breathing is independently associated with elevated natriuretic peptide levels in patients with cardiovascular diseases. Heart and Vessels, 2021, , 1.	1.2	0
1594	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Frontiers in Cardiovascular Medicine, 2021, 8, 785109.	2.4	1

#	Article	IF	CITATIONS
1595	Heart failure as an adverse effect of infliximab for Crohn's disease: A case report and review of the literature. World Journal of Clinical Cases, 2021, 9, 10382-10391.	0.8	9
1596	Intensive Blood Pressure Lowering for Prevention of Heart Failure With Preserved and Reduced Ejection Fractions. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121009277.	3.9	1
1598	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Journal of Cardiovascular Computed Tomography, 2022, 16, 54-122.	1.3	57
1599	Association between lipoprotein (a) and heart failure with reduced ejection fraction development. Journal of Clinical Laboratory Analysis, 2022, 36, e24083.	2.1	6
1600	Management, survival, and predictors of mortality among hospitalized heart failure patients at Debre Markos comprehensive specialized hospital, Northwest Ethiopia: Prospective cohort study. SAGE Open Medicine, 2021, 9, 205031212110573.	1.8	3
1601	Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC)Âof the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 173-185.	1.0	31
1602	The Effects of Nurse-Led Motivational Interviewing on Exercise and Quality of Life among Koreans with Heart Failure: A Randomized Controlled Trial. Korean Journal of Adult Nursing, 2021, 33, 588.	0.7	1
1603	Hemmstoffe des Renin-Angiotensin-Systems. , 2021, , 131-161.		O
1604	Cardiovascular therapeutics: A new potential for anxiety treatment?. Medicinal Research Reviews, 2022, 42, 1202-1245.	10.5	10
1605	Screeningâ€guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in atâ€risk patients. European Journal of Heart Failure, 2022, 24, 620-630.	7.1	7
1606	Proteomic differences among patients with heart failure taking furosemide or torsemide. Clinical Cardiology, 2022, , .	1.8	3
1607	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	2.8	561
1608	Altered function of the left ventricle and clinical significance of heartâ€'type fatty acidâ€'binding protein in cardiac dysfunction among patients with sepsis. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	1.8	2
1609	The 28-day survive for critically ill cancer patients undergoing continuous renal replacement with postoperative acute kidney injure: a retrospective study of 86 cases. Translational Cancer Research, 2020, 9, 6221-6231.	1.0	0
1610	Current U.S. Guideline-Based Management Strategies for Special Clinical Situations Involving Hypertensive Crises. Cardiology in Review, 2022, 30, 44-49.	1.4	5
1611	Đ"Đ,абеÑ,Đ,Ñ‡ĐµÑĐ°Đ°Ñ•Đ°Đ°Ñ€ĐƊ,Đ¾ĐĐ,ĐаĐ,аÑ,Đ,Ñ• ĐƊ,Đ°Đ³Đ½Đ¾ÑÑ,Đ,Ñ‡ĐµÑаĐ,е бĐ,Đ	<sup>3</sup> ⁄4 <b>ᡚ 4</b> ⁄4 аÑ	Ń€ <b>Đ</b> ºĐμÑ€Ñ≪
1612	Continuous Remote Patient Monitoring: Evaluation of the Heart Failure Cascade Soft Launch. Applied Clinical Informatics, 2021, 12, 1161-1173.	1.7	3
1613	Improved hospitalization rates in a specialty center for heart failure with preserved ejection fraction and pulmonary hypertension. Pulmonary Circulation, 2022, 12, .	1.7	1

#	Article	IF	CITATIONS
1614	Validation of Heart Failure-Specific Risk Equations in 1.3 Million Israeli Adults and Usefulness of Combining Ambulatory and Hospitalization Data from a Large Integrated Health Care Organization. American Journal of Cardiology, 2022, 168, 105-109.	1.6	4
1615	Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials, 2022, 23, 36.	1.6	2
1616	Thyroid disorders and cardiovascular manifestations: an update. Endocrine, 2022, 75, 672-683.	2.3	33
1617	Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Medicine, 2022, 20, 21.	5.5	5
1618	Key Points for Pharmacists From the ACC Expert Consensus Decision Pathway for Patients Hospitalized With Heart Failure. Journal of Pharmacy Practice, 2022, , 089719002110647.	1.0	0
1619	Galectinâ€3 as an independent prognostic factor after heart transplantation. Clinical Transplantation, 2022, 36, e14592.	1.6	1
1620	A populationâ€based study of 92 clinically recognized risk factors for heart failure: coâ€occurrence, prognosis and preventive potential. European Journal of Heart Failure, 2022, 24, 466-480.	7.1	14
1621	A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 587-599.	3.0	4
1622	Traditional Chinese Medicine Targeting Heat Shock Proteins as Therapeutic Strategy for Heart Failure. Frontiers in Pharmacology, 2021, 12, 814243.	3.5	0
1623	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	1.7	8
1624	Decelerated Dark Flow Measured Using Steady-State Free Precession Magnetic Resonance Imaging for Specific Detection of Left Ventricular Myocardial Strain and Dyssynchrony in Dilated Cardiomyopathy. Cardiovascular Imaging Asia, 2022, 6, 4.	0.1	0
1625	Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis. Frontiers in Cardiovascular Medicine, 2021, 8, 785279.	2.4	5
1626	Editorial commentary: Cardiac MRI imaging in heart failure with preserved ejection fraction. Trends in Cardiovascular Medicine, 2023, 33, 148-149.	4.9	0
1627	Background and Design of the Biological and Physiological Mechanisms of Symptom Clusters in Heart Failure (BIOMES-HF) Study. Journal of Cardiac Failure, 2022, , .	1.7	0
1628	Transcatheter Implantation of Interatrial Shunt Devices to Lower Left Atrial Pressure in Heart Failure. International Journal of Heart Failure, 2022, 4, 12.	2.7	2
1629	Risk Prediction Scores in Cardiovascular Disease: Useful Tool or "Model of the Week�. Journal of Cardiac Failure, 2022, , .	1.7	1
1630	The Role of CD147 in Pathological Cardiac Hypertrophy Is Regulated by Glycosylation. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	4.0	11
1631	Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated HeartÂFailure. JACC: Heart Failure, 2022, 10, 41-49.	4.1	15

#	Article	IF	CITATIONS
1632	Development and Validation of a Long-Term Incident Heart Failure Risk Model. Circulation Research, 2022, 130, 200-209.	4.5	9
1633	"Heart in DRESS†Cardiac Manifestations, Treatment and Outcome of Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 704.	2.4	26
1634	Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study. Frontiers in Pharmacology, 2021, 12, 769896.	3.5	2
1635	Chronic Heart Failure: Clinical Implications of Iron Homeostasis Disturbances Revisited. Cureus, 2022, 14, e21224.	0.5	1
1636	Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 829151.	2.4	4
1637	Cardiac Imaging for the Assessment of Left Atrial Mechanics Across Heart Failure Stages. Frontiers in Cardiovascular Medicine, 2021, 8, 750139.	2.4	9
1638	Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. European Heart Journal, 2022, 43, 1941-1951.	2.2	68
1639	Objectively measured physical activity in patients with heart failure: a sub-analysis from the HF-Wii study. European Journal of Cardiovascular Nursing, 2022, , .	0.9	O
1640	Using machine learning to uncover heterogeneity of beta blocker response in heart failure. Cell Reports Medicine, 2022, 3, 100504.	6.5	0
1641	Splenic size as an indicator of hemodynamics and prognosis in patients with heart failure. Heart and Vessels, 2022, , 1.	1.2	3
1642	Acetylcholine Reduces IKr and Prolongs Action Potentials in Human Ventricular Cardiomyocytes. Biomedicines, 2022, 10, 244.	3.2	3
1643	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 132-142.	7.1	30
1644	Change in Lifetime Risk of HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 264-266.	2.8	0
1645	Drug Treatment of Heart Failure in Children: Gaps and Opportunities. Paediatric Drugs, 2022, 24, 121-136.	3.1	3
1646	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death. Journal of the American Heart Association, 2022, 11, e022833.	3.7	11
1647	Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers, 2022, 27, 264-269.	1.9	3
1648	Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Fulminant Myocarditis: A Review of Contemporary Literature. Medicina (Lithuania), 2022, 58, 215.	2.0	6
1649	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23

#	Article	IF	CITATIONS
1650	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2022, 10, 73-84.	4.1	115
1651	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	2.8	21
1652	Criteria for Iron Deficiency in PatientsÂWith HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 341-351.	2.8	73
1653	Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles. Journal of Controlled Release, 2022, 343, 207-216.	9.9	30
1654	Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure. International Journal of Cardiology Congenital Heart Disease, 2022, 7, 100336.	0.4	2
1655	Chapter 13: Heart Failure., 2022,,.		0
1656	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. European Heart Journal, 2022, 43, 1157-1172.	2.2	297
1657	Sacubitril/valsartan, sodiumâ€glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438.	2.5	5
1658	Abnormal Sleep Duration as Predictor for Cardiovascular Diseases: A Systematic Review of Prospective Studies. Sleep Disorders, 2022, 2022, 1-10.	1.4	5
1659	Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study. Frontiers in Physiology, 2021, 12, 757268.	2.8	7
1660	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. Journal of Internal Medicine, 2022, 291, 713-731.	6.0	23
1661	Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy. Radiation Oncology, 2022, 17, 33.	2.7	O
1662	Relationship between spleen size and exercise tolerance in advanced heart failure patients with a left ventricular assist device. BMC Research Notes, 2022, 15, 40.	1.4	1
1663	Biomarker Development in Cardiology: Reviewing the Past to Inform the Future. Cells, 2022, 11, 588.	4.1	2
1664	Agreement between visually estimated left ventricular ejection fraction on echocardiography and quantitative measurements using cardiac magnetic resonance., 2022, 26, 127-132.		0
1665	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. Heart Failure Reviews, 2022, 27, 1761-1777.	3.9	3
1666	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
1667	Identifying CRT responders: Moving from electrical to mechanical dyssynchrony. Journal of Nuclear Cardiology, 2022, 29, 2649-2651.	2.1	3

#	Article	IF	CITATIONS
1668	Comparative effects of left bundle branch area pacing, His bundle pacing, biventricular pacing in patients requiring cardiac resynchronization therapy: A network metaâ€analysis. Clinical Cardiology, 2022, 45, 214-223.	1.8	19
1669	Exercise Systolic Reserve and Exercise Pulmonary Hypertension Improve Diagnosis of Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2022, 9, 814601.	2.4	1
1670	A scale development study for evaluating the dietary behaviors of patients with heart failure. Heart and Lung: Journal of Acute and Critical Care, 2022, 53, 61-66.	1.6	1
1671	First-Phase Ejection Fraction Predicts Response to Cardiac Resynchronization Therapy and Adverse Outcomes. JACC: Cardiovascular Imaging, 2021, 14, 2275-2285.	5.3	7
1672	Race and Ethnicity in HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 2589-2598.	2.8	27
1673	Combinatorial, additive and dose-dependent drug–microbiome associations. Nature, 2021, 600, 500-505.	27.8	102
1676	Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment. Frontiers in Cardiovascular Medicine, 2021, 8, 760152.	2.4	7
1677	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	1.9	9
1678	Factors associated with the identification of drug therapy problems among older patients in Primary Health Care. Einstein (Sao Paulo, Brazil), 2022, 20, eAO6544.	0.7	0
1680	Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). Medicinski Arhiv = Medical Archives = Archives De Médecine, 2022, 76, 17.	0.9	2
1681	Predictors of Referral to Cardiac Rehabilitation in Patients following Hospitalisation with Heart Failure: A Multivariate Regression Analysis. Journal of Clinical Medicine, 2022, 11, 1232.	2.4	3
1682	Characterization of heart failure patients with reverse left ventricular remodelling postâ€angiotensin receptor blockers/neprilysin inhibitors therapy. ESC Heart Failure, 2022, 9, 1682-1688.	3.1	6
1683	Construction of a Non-Mutually Exclusive Decision Tree for Medication Recommendation of Chronic Heart Failure. Frontiers in Pharmacology, 2021, 12, 758573.	3.5	4
1684	Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience. Medicina (Lithuania), 2022, 58, 320.	2.0	2
1685	Clinical value of the HATCH score for predicting adverse outcomes in patients with heart failure. Heart and Vessels, 2022, 37, 1363-1372.	1.2	5
1686	Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications. Circulation Research, 2022, 130, 578-592.	4.5	13
1687	Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2022, 11, 1063.	2.4	2
1688	Elevated Myoglobin in Patients With Primary Aldosteronism: A Cross-Sectional Study. Frontiers in Endocrinology, 2022, 13, 799174.	3.5	0

#	Article	IF	CITATIONS
1689	Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention. Current Diabetes Reports, 2022, 22, 129-136.	4.2	5
1690	Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 783707.	2.4	8
1691	Management of Obstructive Sleep Apnea in Patients With Heart Failure. Frontiers in Medicine, 2022, 9, 803388.	2.6	2
1692	A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure. European Heart Journal - Case Reports, 2022, 6, ytac077.	0.6	1
1693	Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation. Clinical Cardiology, 2022, 45, 447-456.	1.8	5
1694	Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Journal of Clinical Hypertension, 2022, 24, 339-349.	2.0	7
1695	The effects of early exercise on cardiac rehabilitation-related outcome in acute heart failure patients: A systematic review and meta-analysis. International Journal of Nursing Studies, 2022, 130, 104237.	5.6	7
1696	Depressive Symptoms and Incident Heart Failure in the Jackson Heart Study: Differential Risk Among Black Men and Women. Journal of the American Heart Association, 2022, 11, e022514.	3.7	9
1697	Long Atrial Fibrillation Duration and Early Recurrence Are Reliable Predictors of Late Recurrence After Radiofrequency Catheter Ablation. Frontiers in Cardiovascular Medicine, 2022, 9, 864417.	2.4	14
1698	Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts. Scientific Reports, 2022, 12, 4760.	3.3	1
1699	First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure. Journal of Medical Science, 2022, 91, e606.	0.7	0
1700	A Systematic Review and Meta-Analysis of the Efficacy and Safety of Xinbao Pill in Chronic Heart Failure. Frontiers in Pharmacology, 2022, 13, 846867.	3.5	3
1701	Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS). Journal of Clinical Medicine, 2022, 11, 1762.	2.4	2
1702	Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review. Current Heart Failure Reports, 2022, 19, 146-156.	3.3	5
1703	Classifying heart failure based on ejection fraction: imperfect but enduring. European Journal of Heart Failure, 2022, 24, 1154-1157.	7.1	7
1704	Moving the Paradigm Forward for Prediction and Risk-Based Primary Prevention of Heart Failure in Special Populations. Current Atherosclerosis Reports, 2022, 24, 343-356.	4.8	1
1705	Prognostic Cardiac Magnetic Resonance Markers of Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy for Predicting Heart Failure Outcomes. Journal of the American Heart Association, 2022, 11, e023167.	3.7	12
1706	Opportunistic screening for asymptomatic left ventricular dysfunction in type 2 diabetes mellitus. Postgraduate Medical Journal, 2023, 99, 476-483.	1.8	3

#	Article	IF	CITATIONS
1707	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	1.7	23
1708	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153.	7.1	11
1709	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e10.	3.0	0
1710	Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk. ESC Heart Failure, 2022, 9, 1564-1573.	3.1	3
1711	Temporal trends in characteristics and outcome of heart failure patients with and without significant coronary artery disease. ESC Heart Failure, 2022, 9, 1812-1822.	3.1	8
1712	Precision measurement of cardiac structure and function in cardiovascular magnetic resonance using machine learning. Journal of Cardiovascular Magnetic Resonance, 2022, 24, 16.	3.3	30
1713	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	2.3	1
1714	Multifactorial Benefits of Chronic Vagus Nerve Stimulation on Autonomic Function and Cardiac Electrical Stability in Heart Failure Patients With Reduced Ejection Fraction. Frontiers in Physiology, 2022, 13, 855756.	2.8	9
1715	Fluid and Salt Balance and the Role of Nutrition in Heart Failure. Nutrients, 2022, 14, 1386.	4.1	5
1716	Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF). Cureus, 2022, 14, e22778.	0.5	4
1717	Food as medicine? Exploring the impact of providing healthy foods on adherence and clinical and economic outcomes. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100129.	1.0	2
1718	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure. Frontiers in Immunology, 2022, 13, 817514.	4.8	7
1719	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923.	3.3	10
1720	A Survival Prediction for Acute Heart Failure Patients via Web-Based Dynamic Nomogram with Internal Validation: A Prospective Cohort Study. Journal of Inflammation Research, 2022, Volume 15, 1953-1967.	3.5	5
1721	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With HeartÂFailure and Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137.	2.8	36
1722	Artificial Intelligence-Enabled Electrocardiography Predicts Left Ventricular Dysfunction and Future Cardiovascular Outcomes: A Retrospective Analysis. Journal of Personalized Medicine, 2022, 12, 455.	2.5	12
1723	Impact of Antihypertensive Drug Class on Outcomes in SPRINT. Hypertension, 2022, 79, 1112-1121.	2.7	7
1724	Association between self-management behaviour and quality of life in people with heart failure: a retrospective study. BMC Cardiovascular Disorders, 2022, 22, 90.	1.7	5

#	Article	IF	CITATIONS
1726	Effects of early rehabilitation on functional outcomes in patients after coronary artery bypass graft surgery: a randomized controlled trial. Journal of International Medical Research, 2022, 50, 030006052210870.	1.0	5
1727	Serum-Induced Expression of Brain Natriuretic Peptide Contributes to Its Increase in Patients with HFpEF. International Journal of Molecular Sciences, 2022, 23, 2991.	4.1	1
1728	Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology, 2022, 19, 593-606.	13.7	160
1729	F2RL3 Methylation in the Peripheral Blood as a Potential Marker for the Detection of Coronary Heart Disease: A Case-Control Study. Frontiers in Genetics, 2022, 13, 833923.	2.3	5
1730	Differential mRNA Expression and Circular RNA-Based Competitive Endogenous RNA Networks in the Three Stages of Heart Failure in Transverse Aortic Constriction Mice. Frontiers in Physiology, 2022, 13, 777284.	2.8	8
1731	Effect of Cocaine, Amphetamine, and Cannabis Use Disorders on 30-day Readmissions of Patients with Heart Failure. Current Problems in Cardiology, 2023, 48, 101189.	2.4	2
1732	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. Journal of the American Heart Association, 2022, 11, e024505.	3.7	21
1733	1 Year HIIT and Omega-3 Fatty Acids to Improve Cardiometabolic Risk in Stage-A HeartÂFailure. JACC: Heart Failure, 2022, 10, 238-249.	4.1	6
1734	Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2022, 11, e022765.	3.7	16
1735	Prevalence and Prognostic Implications of Left Ventricular Systolic Dysfunction in Adults With Congenital Heart Disease. Journal of the American College of Cardiology, 2022, 79, 1356-1365.	2.8	17
1736	Heart Failure, Precision Medicine, and Incremental Equity. JAMA - Journal of the American Medical Association, 2022, , .	7.4	1
1737	Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators. Internal Medicine, 2022, 61, 969-977.	0.7	4
1738	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. Journal of the American Heart Association, 2022, 11, e021327.	3.7	5
1739	Clinical Phenotypes of Cardiovascular and Heart Failure Diseases Can Be Reversed? The Holistic Principle of Systems Biology in Multifaceted Heart Diseases. Neurology International, 2022, 12, 142-169.	0.5	0
1740	Emerging Antiarrhythmic Drugs for Atrial Fibrillation. International Journal of Molecular Sciences, 2022, 23, 4096.	4.1	21
1741	Spironolactone alleviates myocardial fibrosis via inhibition of Ets‹1 in mice with experimental autoimmune myocarditis. Experimental and Therapeutic Medicine, 2022, 23, 369.	1.8	3
1742	Representativeness of the GALACTICâ€HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2022, 11, e023766.	3.7	4
1743	Effectiveness of Telemedicine Visits in Reducing 30â€Day Readmissions Among Patients With Heart Failure During the COVIDâ€19 Pandemic. Journal of the American Heart Association, 2022, 11, e023935.	3.7	29

#	Article	IF	CITATIONS
1744	Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. ERJ Open Research, 2022, 8, 00002-2022.	2.6	8
1745	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	2.8	314
1746	Multisystem inflammatory syndrome in children: Inputs of BNP, NT-proBNP and Galectin-3. Clinica Chimica Acta, 2022, 529, 109-113.	1.1	3
1747	A Scoping Review of Galectin-3 as a Biomarker of Cardiovascular Diseases in Pediatric Populations. International Journal of Environmental Research and Public Health, 2022, 19, 4349.	2.6	3
1748	Heart failure readmission reductions during the COVID-19 pandemic. Nursing Management, 2022, 53, 26-33.	0.4	2
1749	Levosimendan and Continuous Outpatient Support With Inotropes in Patients With Advanced Heart Failure: A Single-Centre Descriptive Study. Journal of Cardiovascular Pharmacology, 2022, 79, 583-592.	1.9	6
1750	Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2022, 79, 549-557.	1.9	4
1751	Mendelian Randomization Study of Heart Failure and Stroke Subtypes. Frontiers in Cardiovascular Medicine, 2022, 9, 844733.	2.4	6
1752	Soluble ST2 Is a Sensitive and Specific Biomarker for Fulminant Myocarditis. Journal of the American Heart Association, 2022, 11, e024417.	3.7	16
1753	An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. Journal of Clinical Medicine, 2022, 11, 2020.	2.4	6
1754	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	2.8	774
1755	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	3.0	58
1756	Providers' accuracy in decision-making with assessing NYHA functional class of patients with heart failure after use of a classification guide. Heart and Lung: Journal of Acute and Critical Care, 2022, 54, 85-94.	1.6	3
1757	Characterizing Pain Leading to Emergency Medical Services Activation in Heart Failure. Journal of Cardiovascular Nursing, 2022, 37, 427-436.	1.1	1
1758	Medical management of acute heart failure. Faculty Reviews, 2021, 10, 82.	3.9	6
1759	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Advances in Therapy, 2022, 39, 845-861.	2.9	13
1760	Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, E12-E14.	3.0	5
1761	Cardiovascular risk factors of poor prognosis in COVID-19 $\hat{a}$ €" a review. Journal of Medical Science, 0, , e571.	0.7	4

#	Article	IF	CITATIONS
1762	Contemporary Etiologies, Outcomes, andÂNovel Risk Score for Isolated Tricuspid Regurgitation. JACC: Cardiovascular Imaging, 2022, 15, 731-744.	5.3	31
1763	Comparative study on the main active components of <i>Baoyuan</i> decoction in plasma and urine of normal and heart failure rats. Biomedical Chromatography, 2022, 36, e5294.	1.7	2
1764	The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules, 2022, 12, 46.	4.0	28
1765	Prognostic value of cartilage intermediate layer protein 1 in chronic heart failure. ESC Heart Failure, 2022, 9, 345-352.	3.1	3
1766	Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction. ESC Heart Failure, 2022, 9, 186-195.	3.1	3
1767	Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study. American Journal of Cardiovascular Drugs, 2021, , 1.	2.2	0
1768	Reply. Journal of the American College of Cardiology, 2021, 78, e323.	2.8	0
1770	Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design. International Journal of Heart Failure, 0, 4, .	2.7	2
1771	Heart Failure in Older Adults: Medical Management and Advanced Therapies. Geriatrics (Switzerland), 2022, 7, 36.	1.7	2
1772	Artificial Intelligence-Enabled Electrocardiogram Predicted Left Ventricle Diameter as an Independent Risk Factor of Long-Term Cardiovascular Outcome in Patients With Normal Ejection Fraction. Frontiers in Medicine, 2022, 9, 870523.	2.6	3
1773	Cost-Effectiveness of Sacubitril–Valsartan Compared to Angiotensin-Converting Enzyme Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction. Journal of Pharmacy Practice, 2023, 36, 915-924.	1.0	1
1775	Troponin is unrelated to outcomes in heart failure patients discharged from the emergency department. Journal of the American College of Emergency Physicians Open, 2022, 3, e12695.	0.7	2
1776	Management of atrial fibrillation: two decades of progress â€" a scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2022, 65, 287-326.	1.3	20
1777	Impact of medication therapy management interventions on drug therapy problems, medication adherence and treatment satisfaction among ambulatory heart failure patients at Tikur Anbessa Specialised Hospital, Addis Ababa, Ethiopia: a one-group pre–post quasi-experimental study. BMJ Open, 2022. 12. e054913.	1.9	0
1778	Beta-blockers and Ambulatory Inotropic Therapy Journal of Cardiac Failure, 2022, , .	1.7	0
1779	Value of FT3/FT4 Ratio in Prognosis of Patients With Heart Failure: A Propensity-Matched Study. Frontiers in Cardiovascular Medicine, 2022, 9, 859608.	2.4	11
1780	A Systematic Review of the Development and Implementation of Needs-Based Palliative Care Tools in Heart Failure and Chronic Respiratory Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 878428.	2.4	3
1781	Exploring the Causal Effects of Circulating ST2 and Galectin-3 on Heart Failure Risk: A Mendelian Randomization Study. Frontiers in Cardiovascular Medicine, 2022, 9, 868749.	2.4	1

#	Article	IF	CITATIONS
1782	Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. International Journal of Cardiology, 2022, 359, 76-83.	1.7	2
1783	Short-term effects of COVID-19 on the risk of traumatic fractures in China cities. Scientific Reports, 2022, 12, 6528.	3.3	7
1784	A multimodal deep learning model for cardiac resynchronisation therapy response prediction. Medical Image Analysis, 2022, 79, 102465.	11.6	8
1785	Effect of hypothyroidism on contractile performance of isolated end-stage failing human myocardium. PLoS ONE, 2022, 17, e0265731.	2.5	2
1786	Comparison of clinical symptoms and bioimpedance to pulmonary capillary wedge pressure in heart failure. American Heart Journal Plus, 2022, , 100133.	0.6	0
1787	Favorable Impact of a Multidisciplinary Team Approach on Heart Transplantation Outcomes in a Mid-Volume Center. Journal of Clinical Medicine, 2022, 11, 2296.	2.4	4
1788	Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game. European Journal of Heart Failure, 2022, 24, 885-886.	7.1	0
1789	Health System–Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. Journal of Cardiac Failure, 2022, , .	1.7	7
1794	The effect of early aggressive diuresis on hospital length of stay in acute congestive heart failure. Heart Views, 2021, 22, 108.	0.2	1
1795	Left Atrial Ejection Force as a Marker for the Diagnosis of Heart Failure with Preserved Ejection Fraction Journal of Cardiovascular Echography, 2021, 31, 125-130.	0.4	0
1796	Comparing the effects of teach-back method, multimedia and blended training on self-care and social support in patients with heart failure: A randomized clinical trial. Journal of Education and Health Promotion, 2021, 10, 248.	0.6	4
1797	Sex-Specific Differences in Ventricular Remodeling and Response After Cardiac Resynchronization Therapy. American Journal of Cardiology, 2022, , .	1.6	1
1799	Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin. Heart Failure Reviews, 2022, , .	3.9	5
1800	Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAIDÂTrial. JACC: Clinical Electrophysiology, 2022, , .	3.2	0
1801	Systolic Blood Pressure and 1-Year Clinical Outcomes in Patients Hospitalized for Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, 877293.	2.4	4
1802	The triple win $\hat{a} \in \mathbb{C}$ implementation science benefits patients, healthcare systems and industry alike. Journal of Comparative Effectiveness Research, 2022, 11, 639-642.	1.4	5
1803	Relationship Between Initial Urine Output and Mortality in Patients Hospitalized in Cardiovascular Intensive Care Units: More Is Not Better. Frontiers in Cardiovascular Medicine, 2022, 9, 853217.	2.4	0
1804	Strategic Recommendations to Bridge the Gaps in Awareness, Diagnosis and Prevention of Heart Failure in the Middle East Region and Africa. Journal of the Saudi Heart Association, 2022, 34, 53-65.	0.4	1

#	Article	IF	Citations
1805	2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders. Heart Rhythm, 2022, 19, e61-e120.	0.7	13
1806	Making the heart grow stronger: reversal of dilated cardiomyopathy in an elderly patient American Journal of Medicine, 2022, , .	1.5	0
1807	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e16.	3.0	6
1809	Prospective assessing metabolic abnormalities, lifestyle and dietary pattern in a Chinese population with heart failure: the MALD-HF study protocol. BMJ Open, 2022, 12, e049225.	1.9	0
1810	Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. Journal of Molecular Cell Biology, 2022, 14, .	3.3	16
1811	Diuretic combinations in critically ill patients with respiratory failure: A systematic review and meta-analysis. World Journal of Critical Care Medicine, 2022, 11, 178-191.	1.8	2
1812	Perceived symptoms as the primary indicators for 30-day heart failure readmission. PLoS ONE, 2022, 17, e0267820.	2.5	4
1813	Association of Pathogenic DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause Mortality. JAMA Cardiology, 2022, 7, 723.	6.1	15
1814	Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial. PLoS Medicine, 2022, 19, e1003997.	8.4	4
1815	Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovascular Disorders, 2022, 22, 217.	1.7	9
1816	Left Atrial Strain Has Superior Prognostic Value to Ventricular Function and Delayed-Enhancement in DilatedÂCardiomyopathy. JACC: Cardiovascular Imaging, 2022, 15, 1015-1026.	<b>5.</b> 3	35
1817	Non-invasive Imaging in Women With Heart Failure — Diagnosis and Insights Into Disease Mechanisms. Current Heart Failure Reports, 2022, 19, 114-125.	3.3	2
1818	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an <scp>individual patient data metaâ€analysis</scp> of <scp>COMPANION</scp> and <scp>CAREâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 1080-1090.	7.1	11
1819	Efficacy of Dialectical Comprehensive Treatment of Traditional Chinese Medicine in Patients with Chronic Stable Heart Failure: A Randomized Controlled Trial. Cardiology Research and Practice, 2022, 2022, 1-9.	1.1	1
1820	Left Ventricular Assist Devices: A Primer for the Non-Mechanical Circulatory Support Provider. Journal of Clinical Medicine, 2022, 11, 2575.	2.4	1
1821	Mitochondrial damage and activation of the cytosolic DNA sensor cGAS–STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice. Cell Death Discovery, 2022, 8, 258.	4.7	61
1822	Association of Mild Valvular Lesions With Long-term Cardiovascular Outcomes Among Black Adults. JAMA Network Open, 2022, 5, e2211946.	5.9	2
1823	A multi-scale and multi-domain heart sound feature-based machine learning model for ACC/AHA heart failure stage classification. Physiological Measurement, 2022, 43, 065002.	2.1	6

#	Article	IF	CITATIONS
1824	Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients. Journal of Cardiovascular Translational Research, 2022, 15, 1192-1202.	2.4	4
1825	Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. European Heart Journal Digital Health, 2022, 3, 284-295.	1.7	5
1826	Prognostic relevance of Bâ€type natriuretic peptide in patients with moderate mixed aortic valve disease. ESC Heart Failure, 2022, 9, 2474-2483.	3.1	10
1827	Classification of cardiovascular signals. , 2021, , .		0
1828	Behavioral Interventions for the Patient–Caregiver Unit in Patients with Chronic Heart Failure: A Systematic Review of Caregiver Outcomes. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 921-939.	2.7	5
1829	Novel biomarkers of inflammation in heart failure with preserved ejection fraction: analysis from a large prospective cohort study. BMC Cardiovascular Disorders, 2022, 22, 221.	1.7	3
1830	Prediabetes and insulin resistance in a population of patients with heart failure and reduced or preserved ejection fraction but without diabetes, overweight or hypertension. Cardiovascular Diabetology, 2022, 21, 75.	6.8	11
1831	Implementing Equity: Improving Blood Pressure and Glycemic Control Among Adults With Heart Failure. Circulation: Heart Failure, 2022, 15, e009650.	3.9	1
1832	Heart failure ejection fraction class conversions: impact of biomarkers, coâ€morbidities, and pharmacotherapy. ESC Heart Failure, 2022, 9, 2538-2547.	3.1	3
1833	Long-Term Beta-Blocker Therapy in Patients With Stable Coronary Artery Disease After Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	0
1834	Clinical predictors of hyponatremia in patients with heart failure according to severity of chronic kidney disease. Wiener Klinische Wochenschrift, 2022, , .	1.9	1
1835	Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018. Circulation: Heart Failure, 2022, 15, 101161CIRCHEARTFAILURE121009229.	3.9	5
1836	Mechanical circulatory support in cardiogenic shock: a critical appraisal. Expert Review of Cardiovascular Therapy, 2022, , 1-12.	1.5	2
1837	Effects of β‒blocker administration on cardiac function: a coronary computed tomography angiography study. Current Medical Imaging, 2022, 18, .	0.8	0
1838	High Resting Heart Rates Are Associated with Early Posthospitalization Mortality in Low Ejection Fraction Patients. Journal of Clinical Medicine, 2022, 11, 2901.	2.4	1
1840	Association of ambulatory blood pressure with coronary microvascular and cardiac dysfunction in asymptomatic type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	6.8	5
1841	Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. Journal of Personalized Medicine, 2022, 12, 898.	2.5	2
1842	Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria. Current Heart Failure Reports, 0, , .	3.3	1

#	Article	IF	Citations
1843	Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. International Journal of Molecular Sciences, 2022, 23, 5680.	4.1	20
1844	Development of Core Educational Content for Heart Failure Patients in Transition from Hospital to Home Care: A Delphi Study. International Journal of Environmental Research and Public Health, 2022, 19, 6550.	2.6	1
1845	Prognostic impact of the updated 2018 <scp>HFAâ€ESC</scp> definition of advanced heart failure: results from the <scp>HELPâ€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 1493-1503.	7.1	22
1846	Design of <scp>Midâ€Q</scp> Response: A prospective, randomized trial of adaptive cardiac resynchronization therapy in Asian patients. Journal of Arrhythmia, 0, , .	1.2	0
1847	Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	10
1848	Multi-Modality Imaging for Prevention of Coronary Artery Disease and Myocardial Infarction in the General Population: Ready for Prime Time?. Journal of Clinical Medicine, 2022, 11, 2965.	2.4	3
1849	Role of depressive symptoms in the prognosis of heart failure and its potential clinical predictors. ESC Heart Failure, 2022, 9, 2676-2685.	3.1	10
1850	Brain natriuretic peptide measurements using standard biochemical equipment: Comparisons with conventional immunoassays. PLoS ONE, 2022, 17, e0268895.	2.5	0
1851	When to Achieve Complete Revascularization in Infarct-Related Cardiogenic Shock. Journal of Clinical Medicine, 2022, 11, 3116.	2.4	6
1852	A Machine Learning Based Discharge Prediction of Cardiovascular Diseases Patients in Intensive Care Units. Healthcare (Switzerland), 2022, 10, 966.	2.0	5
1853	Prognostic value of RDW alone and in combination with NTâ€proBNP in patients with heart failure. Clinical Cardiology, 2022, 45, 802-813.	1.8	17
1854	Non-cardiovascular medication and readmission for heart failure: an observational cohort study. International Journal of Clinical Pharmacy, 0, , .	2.1	1
1855	Application of Mathematical Modeling to Quantify Ventricular Contribution Following Durable Left Ventricular Assist Device Support. Applications in Engineering Science, 2022, , 100107.	0.8	1
1856	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	8.6	109
1857	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. Journal of Clinical Medicine, 2022, 11, 3192.	2.4	10
1858	Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans. Journal of the American Heart Association, 2022, $11$ , .	3.7	22
1859	Structural heart disease management during cancer treatment., 2023,, 146-154.		0
1860	Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. JMIR Cardio, 2022, 6, e31302.	1.7	1

#	Article	IF	Citations
1861	Predictors for the Recovery of Left Ventricular Ejection Fraction in Myocardial Infarction., 2022, 1, 101.		1
1862	Continuous Remote Patient Monitoring in Patients With Heart Failure (Cascade Study): Protocol for a Mixed Methods Feasibility Study. JMIR Research Protocols, 2022, 11, e36741.	1.0	1
1863	Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers. International Journal of Molecular Sciences, 2022, 23, 6378.	4.1	5
1864	Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial. ESC Heart Failure, 2022, 9, 2862-2872.	3.1	19
1865	The Association Between Congestive Heart Failure and One-Year Mortality After Surgery in Singaporean Adults: A Secondary Retrospective Cohort Study Using Propensity-Score Matching, Propensity Adjustment, and Propensity-Based Weighting. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
1866	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. BMJ, The, O, , e068424.	6.0	18
1867	A clinical algorithm to determine target blood pressure in the elderly: evidence and limitations from a clinical perspective. Clinical Hypertension, 2022, 28, .	2.0	4
1868	Iron deficiency in patients of heart failure with reduced ejection fraction. Medical Journal Armed Forces India, 2022, , .	0.8	0
1869	Iron deficiency and pulmonary arterial hypertension. Nutrition in Clinical Practice, 0, , .	2.4	1
1870	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. Journal of the American College of Cardiology, 2022, , .	2.8	7
1871	Trends in prognosis after hospitalization for acute heart failure in Kurashiki Central hospital 2015â€"2018: single-center prospective study. Heart and Vessels, 2022, 37, 2014-2028.	1.2	3
1872	Baroreflex activation therapy with the <scp>Barostim</scp> â,,¢ device in patients with heart failure with reduced ejection fraction: a patient level metaâ€analysis of randomized controlled trials. European Journal of Heart Failure, 2022, 24, 1665-1673.	7.1	22
1873	Adherence to self-care recommendations and associated factors among adult heart failure patients in public hospitals, Addis Ababa, Ethiopia, 2021: cross-sectional study. BMC Cardiovascular Disorders, 2022, 22, .	1.7	6
1874	Research and Scholarly Methods: Implementation Science Studies. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0
1875	Nâ€ofâ€1 trials to facilitate evidenceâ€based deprescribing: Rationale and case study. British Journal of Clinical Pharmacology, 2022, 88, 4460-4473.	2.4	8
1876	Longâ€term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand. European Journal of Heart Failure, 2022, 24, 1519-1528.	7.1	24
1877	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation: Cardiovascular Quality and Outcomes, 0, , .	2.2	5
1878	Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Obstructive Sleep Apnoea in Patients with Cardiovascular Disease. European Cardiology Review, 0, 17, .	2.2	1

#	Article	IF	Citations
1879	Transcatheter Mitral Cerclage Ventriculoplasty. JACC: Cardiovascular Interventions, 2022, 15, 1249-1263.	2.9	5
1880	Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 2516-2525.	2.8	34
1881	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMPâ€HF. Journal of the American Heart Association, 2022, 11, .	3.7	3
1882	Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. Cardiology and Therapy, 2022, 11, 337-354.	2.6	12
1883	Incidence and Trends in the Use of Palliative Care among Patients with Reduced, Middle-Range, and Preserved Ejection Fraction Heart Failure. Journal of Palliative Medicine, 2022, 25, 1774-1781.	1.1	6
1884	Soluble ST2: a valuable prognostic marker in heart failure. Heart Failure Reviews, 2022, 27, 2155-2164.	3.9	8
1886	New strategies and therapies for the prevention of heart failure in highâ€risk patients. Clinical Cardiology, 2022, 45, .	1.8	4
1887	Clinical implications of the universal definition for the prevention and treatment of heart failure. Clinical Cardiology, 2022, 45, .	1.8	1
1888	Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect. Scientific Reports, 2022, 12, .	3.3	1
1889	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. Endocrinology and Metabolism, 2022, 37, 415-429.	3.0	3
1890	Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension. Progress in Cardiovascular Diseases, 2022, , .	3.1	0
1891	Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease. JACC Basic To Translational Science, 2022, 7, 956-969.	4.1	10
1892	Consensus on Recommended Functions of a Smart Home System to Improve Self-Management Behaviors in People With Heart Failure: A Modified Delphi Approach. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
1893	CNP, the Third Natriuretic Peptide: Its Biology and Significance to the Cardiovascular System. Biology, 2022, 11, 986.	2.8	4
1894	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
1895	Cardiovascular Research in FriedreichÂAtaxia. JACC Basic To Translational Science, 2022, 7, 1267-1283.	4.1	11
1896	Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPESTâ€CRT Upgrade trial. European Journal of Heart Failure, 2022, 24, 1652-1661.	7.1	9
1897	Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations. Journal of Cardiovascular Development and Disease, 2022, 9, 221.	1.6	1

#	Article	IF	Citations
1898	Impact of Modified H <sub>2</sub> FPEF Score on Chronic Limb-Threatening Ischemia in Patients With Lower Extremity Artery Disease Who Underwent Endovascular Therapy. Circulation Reports, 2022, , .	1.0	0
1899	Sacubitril/Valsartan in Advanced HeartÂFailure. JACC: Heart Failure, 2022, 10, 457-458.	4.1	1
1900	Effect of $\hat{l}^2\hat{a}$ blocker on patients with moderate functional mitral regurgitation undergoing surgical aortic valve replacement. ESC Heart Failure, 0, , .	3.1	1
1902	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. Circulation, 2022, 146, 80-90.	1.6	32
1903	Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation. Clinical Cardiology, 2022, 45, 839-849.	1.8	5
1904	Reduction of heart failure guidelineâ€directed medication during hospitalization: prevalence, risk factors, and outcomes. ESC Heart Failure, 2022, 9, 3298-3307.	3.1	4
1905	Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. <i>A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Geriatric Cardiology, the ESC Digital Health Committee and the ESC Working Group on eâ€Cardiology ⟨/i⟩. ESC Heart Failure, 2022, 9, 2808-2822.</i>	3.1	12
1906	Safety and Effectiveness of Intravenous Iron Therapy in Patients Supported by Durable Left Ventricular Assist Devices. Journal of Clinical Medicine, 2022, 11, 3900.	2.4	0
1907	KTI-RNN: Recognition of Heart Failure from Clinical Notes. Tsinghua Science and Technology, 2023, 28, 117-130.	6.1	0
1908	Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (⟨scp⟩CCMâ€HFpEF⟨/scp⟩). European Journal of Heart Failure, 2022, 24, 2275-2284.	7.1	19
1909	Association between Education Attainment and Guideline-Directed Medication Therapy in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Clinical Medicine, 2022, 11, 4235.	2.4	1
1910	Natriuretic Peptides, Extracellular Volume, and Subclinical Cardiovascular Changes in Chronic Kidney Disease Stages 1–3: A Pilot Study. Journal of Investigative Medicine, 2022, 70, 1520-1528.	1.6	0
1911	Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°Pâ€TIMI 50 trial. Clinical Cardiology, 2022, 45, 831-838.	1.8	4
1912	Prognostic Role of sST2 in Acute Heart Failure and COVID-19 Infection—A Narrative Review on Pathophysiology and Clinical Prospective. International Journal of Molecular Sciences, 2022, 23, 8230.	4.1	7
1913	Nurse-Provided Lung and Inferior Vena Cava Assessment in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2022, 80, 513-523.	2.8	8
1914	Effectiveness and Approach of Rehabilitation in Patients With Acute Heart Failure: A Review. Korean Circulation Journal, 2022, 52, 576.	1.9	5
1915	Natriuretic Peptide Screening for Primary Prevention or Early Detection of Heart Failure: A Pharmacist-Driven Team-Based Approach. , 2022, , .		0
1916	Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. Journal of Translational Internal Medicine, 2022, 10, 125-133.	2.5	8

#	Article	IF	CITATIONS
1917	High platelet reactivity is a predictor of left ventricular remodelling in patients with acute myocardial infarction. ESC Heart Failure, 2022, 9, 3565-3574.	3.1	2
1918	Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs. Balkan Medical Journal, 2022, 39, 282-289.	0.8	4
1919	Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1920	Anemia and Heart Failure: A Narrative Review. Cureus, 2022, , .	0.5	5
1921	Predictors and outcomes of quality of life in elderly patients with heart failure. American Heart Journal Plus, 2022, 19, 100188.	0.6	0
1922	Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Total Flavonoids in Dracocephalum moldavica on Chronic Heart Failure. International Journal of Molecular Sciences, 2022, 23, 8409.	4.1	4
1923	Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment. Journal of Cardiovascular Pharmacology, 2022, 80, 522-530.	1.9	5
1924	Current and future use of neuromodulation in heart failure. European Heart Journal Supplements, 2022, 24, E28-E34.	0.1	10
1925	Von Willebrand factor (vWF) in patients with heart failure with preserved ejection fraction (HFpEF): A retrospective observational study. Medicine (United States), 2022, 101, e29854.	1.0	5
1926	Neglected Comorbidity of Chronic Heart Failure: Iron Deficiency. Nutrients, 2022, 14, 3214.	4.1	7
1927	Validation of R-hf risk score for risk stratification in ischemic heart failure patients: A prospective cohort study. Annals of Medicine and Surgery, 2022, 80, 104333.	1.1	0
1928	Use and Outâ€ofâ€Pocket Cost of Sacubitrilâ€Valsartan in Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, .	3.7	4
1929	A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates. Pharmacoeconomics, 0, , .	3.3	0
1930	Prospective Observational Study of N-terminal Pro–Brain Natriuretic Peptide Levels in Obese and Nonobese Women during Pregnancy. American Journal of Perinatology, 2023, 40, 467-474.	1.4	1
1931	Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: A propensity-matched cohort study. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	4
1932	Palliative Care Needs and Clinical Features Related to Short-Term Mortality in Patients Enrolled in a Heart Failure Unit. Healthcare (Switzerland), 2022, 10, 1609.	2.0	2
1933	Management of heart failure with reduced ejection fraction. Heart, 0, , heartjnl-2020-318811.	2.9	4
1934	Prevalence and clinical associations of iron deficiency in patients with decompensated heart failure, depending on the diagnostic criteria used for iron deficiency. Terapevticheskii Arkhiv, 2022, 94, 844-849.	0.8	O

#	Article	IF	CITATIONS
1935	Evaluating Guideline Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction Post-coronary Artery Bypass Grafting. Journal of Pharmacy Practice, 0, , 089719002211181.	1.0	0
1936	Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy. ESC Heart Failure, 0, , .	3.1	5
1937	Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals. Journal of Clinical Medicine, 2022, 11, 4693.	2.4	3
1938	Predictors of weaning failure in case of VA ECMO implantation. Scientific Reports, 2022, 12, .	3.3	6
1939	Beta blocker versus ivabradine for cardiovascular outcomes among patients with atrial fibrillation. Postgraduate Medical Journal, 0, , postgradmedj-2022-141948.	1.8	0
1940	An artificial intelligence-based noninvasive solution to estimate pulmonary artery pressure. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1941	Soluble ST2 as a Potential Biomarker for Abdominal Aortic Aneurysmsâ€"A Single-Center Retrospective Cohort Study. International Journal of Molecular Sciences, 2022, 23, 9598.	4.1	2
1942	Nurses' personal perceptions of clinical work adaptation during COVID-19. Heart and Lung: Journal of Acute and Critical Care, 2022, 56, 175-180.	1.6	0
1943	Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study. BMJ Open, 2022, 12, e059905.	1.9	3
1944	Potassium management with finerenone: Practical aspects. Endocrinology, Diabetes and Metabolism, 2022, 5, .	2.4	8
1945	Device-based therapy for decompensated heart failure: An updated review of devices in development based on the DRI2P2S classification. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
1946	The role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy: HF-optimize. Heart and Lung: Journal of Acute and Critical Care, 2023, 57, 95-101.	1.6	5
1947	Influence of $\hat{l}^2$ <sub>1</sub> Adrenergic Receptor Genotype on Longitudinal Measures of Left Ventricular Ejection Fraction and Responsiveness to $\tilde{A}$ Ÿ-Blocker Therapy in Patients With Duchenne Muscular Dystrophy. Clinical Medicine Insights: Cardiology, 2022, 16, 117954682211168.	1.8	1
1948	Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure. ESC Heart Failure, 2022, 9, 4077-4087.	3.1	2
1949	The State of Heart Failure Care in Canada: Minimal Improvement in Readmissions Over Time Despite an Increased Number of Evidence-Based Therapies. CJC Open, 2022, 4, 667-675.	1.5	6
1950	Identification of intraoperative management strategies that have a differential effect on patients with reduced left ventricular ejection fraction: a retrospective cohort study. BMC Anesthesiology, 2022, 22, .	1.8	O
1951	Association of Systemic Sclerosis With Incident Clinically Evident Heart Failure. Arthritis Care and Research, 2023, 75, 1452-1461.	3.4	1
1952	Mortalidade por Insuficiência CardÃaca durante a Pandemia da COVID-19: Insights de uma Coorte de Hospitais Públicos no Brasil. Arquivos Brasileiros De Cardiologia, 2022, , .	0.8	0

#	Article	IF	CITATIONS
1953	Noninvasive Hemodynamic Monitoring in Advanced Heart Failure Patients: New Approach for Target Treatments. Biomedicines, 2022, 10, 2407.	3.2	4
1954	International Consensus Statement on Obstructive Sleep Apnea. International Forum of Allergy and Rhinology, 2023, 13, 1061-1482.	2.8	39
1955	Cardiomyopathy following COVID-19 vaccination in a patient with systemic lupus erythematosus. Modern Rheumatology Case Reports, $0$ , , .	0.7	1
1956	Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	4.0	4
1957	Left ventricular assessment with artificial intelligence increases the diagnostic accuracy of stress echocardiography. European Heart Journal Open, 2022, 2, .	2.3	4
1958	Effect of Integrative Chinese and Western Medicine Therapy on Long-Term Clinical Outcomes in Patients with Heart Failure: A Real-World Study Including 394 Patients. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-9.	1.2	0
1960	Chronic intermittent hypoxia accelerates cardiac dysfunction and cardiac remodeling during cardiac pressure overload in mice and can be alleviated by PHD3 overexpression. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
1961	Increased risk of metastasis in patients with incidental use of renin-angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on electronic medical records. Hypertension Research, O, , .	2.7	2
1962	Chronic Heart Failure. Orthopaedic Nursing, 2022, 41, 363-368.	0.4	1
1963	Neprilysin Inhibitors in HeartÂFailure. JACC Basic To Translational Science, 2023, 8, 88-105.	4.1	22
1964	Characteristics, Treatment Patterns, and Clinical Outcomes After Heart Failure Hospitalizations During the COVID-19 Pandemic, March to October 2020. Mayo Clinic Proceedings, 2023, 98, 31-47.	3.0	5
1965	Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial. European Journal of Heart Failure, 2022, 24, 1744-1747.	7.1	1
1966	Effects and Safety of Oral Iron for Heart Failure with Iron Deficiency: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. Cardiovascular Therapeutics, 2022, 2022, 1-16.	2.5	0
1967	Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction: The ARIC Study. Journal of the American Heart Association, 2022, 11, .	3.7	10
1968	Current Management of Heart Failure with Preserved Ejection Fraction. International Journal of Angiology, 2022, 31, 166-178.	0.6	0
1970	Detection of myocardial fibrosis: Where we stand. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	8
1971	Sacubitril/Valsartan in Patients With Heart Failure and Concomitant Endâ€Stage Kidney Disease. Journal of the American Heart Association, 2022, 11, .	3.7	14
1972	Long-term outcomes of papillary muscle relocation anteriorly for functional mitral regurgitation. Interactive Cardiovascular and Thoracic Surgery, 2022, 35, .	1.1	3

#	Article	IF	CITATIONS
1973	Effects of multifaceted optimization management for chronic heart failure: a multicentre, randomized controlled study. ESC Heart Failure, 0, , .	3.1	1
1974	Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes. International Journal of Cardiology, 2023, 370, 300-308.	1.7	3
1975	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. International Journal of Molecular Sciences, 2022, 23, 11336.	4.1	3
1976	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. Journal of Clinical Hypertension, 2022, 24, 1218-1225.	2.0	1
1977	Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIASTâ€CHF study. ESC Heart Failure, 2023, 10, 200-210.	3.1	7
1978	Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials. Heart Failure Reviews, 2023, 28, 905-923.	3.9	1
1979	The MAGGIC risk score in the prediction of death or hospitalization in patients with heart failure: Comparison with natriuretic peptides. Revista Portuguesa De Cardiologia, 2022, 41, 941-947.	0.5	1
1980	Management of Heart Failure. JAMA - Journal of the American Medical Association, 2022, 328, 1346.	7.4	11
1981	Medical therapy for patients with recent-onset heart failure with reduced ejection fraction during the COVID-19 pandemic: Insights from the Veteran's affairs healthcare system. American Heart Journal Plus, 2022, 22, 100210.	0.6	0
1982	Left ventricular strain patterns and their relationships with cardiac biomarkers in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
1983	Classification of Cardiovascular Diseases: Epidemiology, Diagnosis, and Treatment. , 2022, , 45-80.		1
1984	Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study. International Journal of Heart Failure, 2022, 4, 193.	2.7	8
1985	Diagnosis of Obstructive Sleep Apnea in Patients with Associated Comorbidity. Advances in Experimental Medicine and Biology, 2022, , 43-61.	1.6	3
1986	Treatment of Cheyne-Stokes Respiration in Heart Failure with Adaptive Servo-Ventilation: An Integrative Model. Advances in Experimental Medicine and Biology, 2022, , 79-103.	1.6	0
1987	Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. Journal of Clinical Medicine, 2022, 11, 5828.	2.4	2
1988	Association between remnant cholesterol and heart failure: A prospective cohort study. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
1989	Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure. Healthcare (Switzerland), 2022, 10, 2133.	2.0	1
1990	The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3

#	Article	IF	CITATIONS
1991	Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice. Journal of Cardiology, 2023, 81, 347-355.	1.9	3
1992	Transient gene therapy using cell cycle factors reverses renin–angiotensin–aldosterone system activation in heart failure rat model. Molecular and Cellular Biochemistry, 2023, 478, 1245-1250.	3.1	1
1994	Clinical performance and quality measures for heart failure management in China: the Chinaâ€Heart Failure registry study. ESC Heart Failure, 2023, 10, 342-352.	3.1	4
1995	Application Value of Systemic Inflammatory Indexes in the Clinical Evaluation of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF). Medicina (Lithuania), 2022, 58, 1473.	2.0	3
1996	Guideline Directed Medical Therapy at Discharge and Further Uptitration Leading to Reduction in Indication for Prophylactic ICD Implantation during Protected Waiting Period. Journal of Clinical Medicine, 2022, 11, 6122.	2.4	0
1997	Serum Uric Acid Is Associated with the Progression of Left Ventricular Diastolic Dysfunction in Apparently Healthy Subjects. Disease Markers, 2022, 2022, 1-12.	1.3	2
1998	Identification of hub genes and transcription factor regulatory network for heart failure using RNA-seq data and robust rank aggregation analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
2000	Editorial commentary: Role of autonomic neuromodulation for the treatment of heart failure with reduced ejection fraction: The jury is still out. Trends in Cardiovascular Medicine, 2024, 34, 108-109.	4.9	0
2001	New Biomarkers and Their Potential Role in Heart Failure Treatment Optimisation—An African Perspective. Journal of Cardiovascular Development and Disease, 2022, 9, 335.	1.6	6
2002	Nurses' Perception of, and Barriers to, Delivering Cardiopulmonary Rehabilitation for Heart Failure Patients: A National Survey in Saudi Arabia. International Journal of Environmental Research and Public Health, 2022, 19, 13586.	2.6	4
2003	Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study. ESC Heart Failure, 2023, 10, 322-333.	3.1	3
2004	Digoxin Induces Human Astrocyte Reaction In Vitro. Molecular Neurobiology, 2023, 60, 84-97.	4.0	1
2005	A systematic review on the association of sleep-disordered breathing with cardiovascular pathology in adults. Npj Primary Care Respiratory Medicine, 2022, 32, .	2.6	6
2006	Physiotherapists' Attitudes, and Barriers of Delivering Cardiopulmonary Rehabilitation for Patients with Heart Failure in Saudi Arabia: A Cross-Sectional Study. Journal of Multidisciplinary Healthcare, 0, Volume 15, 2353-2361.	2.7	5
2007	Prognostic impact of guideline-directed medical therapy in patients with heart failure on regular hemodialysis. International Journal of Cardiology, 2023, 370, 250-254.	1.7	0
2008	Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. European Journal of Heart Failure, 2023, 25, 108-113.	7.1	10
2009	Research progress on the relationship between mitochondrial function and heart failure: A bibliometric study from 2002 to 2021. Frontiers in Molecular Biosciences, 0, 9, .	3.5	4
2010	In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. Circulation: Heart Failure, 0, , .	3.9	3

#	Article	IF	CITATIONS
2012	Medication Complexity Among Older Adults with HF: How Can We Assess Better?. Drugs and Aging, 2022, 39, 851-861.	2.7	3
2013	Liver stiffness assessed by magnetic resonance elastography predicts clinical outcomes in patients with heart failure and without chronic liver disease. European Radiology, 2023, 33, 2062-2074.	4.5	4
2014	Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Frontiers in Pharmacology, 0, $13$ , .	3.5	8
2016	Cardiac MRI Risk Stratification for Dilated Cardiomyopathy with Left Ventricular Ejection Fraction of 35% or Higher. Radiology, 2023, 306, .	7.3	3
2017	Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2023, 174, 1-14.	1.9	4
2018	Prevalence and factors associated with adverse drug reactions among heart failure patients hospitalized at Mbarara Regional Referral Hospital, Uganda. BMC Cardiovascular Disorders, 2022, 22, .	1.7	4
2019	Contemporary Data on the Status and Medical Management of Acute Heart Failure. Current Cardiology Reports, 0, , .	2.9	2
2020	Oxidative stress markers-driven prognostic model to predict post-discharge mortality in heart failure with reduced ejection fraction. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2
2021	Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. Current Problems in Cardiology, 2023, 48, 101509.	2.4	5
2022	Development and Piloting of a Community-Partnered Heart Failure Training Course for Home Health Care Workers. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	2.2	3
2023	Anterior Myocardial Infarction Complicated by Apical Thrombus andÂPurulent Pericarditis. JACC: Case Reports, 2022, , 101675.	0.6	0
2024	Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review. Clinical Cardiology, 0, , .	1.8	2
2025	Rationale and Design of the Lead EvaluAtion for Defibrillation and Reliability (LEADR) Study: Safety and Efficacy of a Novel ICD Lead Design. Journal of Cardiovascular Electrophysiology, 0, , .	1.7	6
2026	Perioperative changes in left ventricular systolic function following surgical revascularization. PLoS ONE, 2022, 17, e0277454.	2.5	1
2027	A State of Natriuretic Peptide Deficiency. Endocrine Reviews, 2023, 44, 379-392.	20.1	5
2028	Treatment Differences in Medical TherapyÂfor HeartÂFailure With ReducedÂEjection Fraction Between Sociodemographic Groups. JACC: Heart Failure, 2023, 11, 161-172.	4.1	6
2029	Decisional Needs and Patient Treatment Preferences for Heart Failure Medications: A Scoping Review. CJC Open, 2023, 5, 136-147.	1.5	2
2030	Physicians' Perceptions of and Barriers to Cardiopulmonary Rehabilitation for Heart Failure Patients in Saudi Arabia: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 15208.	2.6	O

#	Article	IF	Citations
2031	The association of multidimensional sleep health with adiposity in heart failure with preserved ejection fraction. Heart and Lung: Journal of Acute and Critical Care, 2023, 58, 144-151.	1.6	1
2032	Artificial intelligence-enabled electrocardiogram screens low left ventricular ejection fraction with a degree of confidence. Digital Health, 2022, 8, 205520762211432.	1.8	1
2033	Patient-Facing Clinical Decision Support for High Blood Pressure Control: Patient Survey. JMIR Cardio, 0, 7, e39490.	1.7	1
2034	Renin-angiotensin system inhibitor exerts prognostic effects in HFpEF patients with low baseline chloride level. International Journal of Cardiology, 2023, 373, 83-89.	1.7	1
2035	Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. Scientific Reports, 2022, 12, .	3.3	4
2036	Left Ventricle Wall Motion Analysis with Real-Time MRI Feature Tracking in Heart Failure Patients: A Pilot Study. Diagnostics, 2022, 12, 2946.	2.6	0
2037	Cardiac Rehabilitation for Older Women with Heart Failure. Journal of Personalized Medicine, 2022, 12, 1980.	2.5	0
2038	Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGONâ€HF trial. ESC Heart Failure, 0, , .	3.1	2
2039	Educational Nursing Intervention in Reducing Hospital Readmission and the Mortality of Patients with Heart Failure: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2022, 9, 420.	1.6	1
2040	The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. Circulation: Heart Failure, 2023, 16, .	3.9	8
2041	Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
2042	Physical Activity Readiness in Patients with Heart Failure. International Journal of Environmental Research and Public Health, 2022, 19, 16332.	2.6	1
2043	Dynamic Evolution of Cardiac Function and Glucose and Lipid Metabolism in Ovariectomized Rats and the Intervention Effect of Erxian Decoction. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-14.	1.2	1
2044	Effect of renin–angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy. Open Heart, 2022, 9, e002135.	2.3	2
2045	Cardiovascular predictors of mortality and exacerbations in patients with COPD. Scientific Reports, 2022, 12, .	3.3	4
2046	Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Failure, 2023, 10, 1066-1076.	3.1	9
2047	Chinese Clinical Practice Guideline for the Management of "CKD-PeriDialysis―the Periods Prior to and in the Early-Stage of Initial Dialysis. Kidney International Reports, 2022, 7, S531-S558.	0.8	5
2048	8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: <i>Standards of Care in Diabetes—2023 </i> . Diabetes Care, 2023, 46, S128-S139.	8.6	83

#	Article	IF	CITATIONS
2049	Review of heart transplantation from hepatitis C-positive donors. World Journal of Transplantation, 0, 12, 394-404.	1.6	0
2050	Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure. Journal of the American Heart Association, 2022, 11, .	3.7	3
2051	Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Congenital Heart Disease. Circulation: Cardiovascular Imaging, 2022, 15, .	2.6	4
2052	Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial. Journal of Clinical Medicine, 2022, 11, 7168.	2.4	4
2053	Clinical Predictors of Adherence to Exercise Training Among Individuals With Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2023, 43, 205-213.	2.1	2
2054	The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus. ESC Heart Failure, 2023, 10, 943-954.	3.1	4
2055	Improvement in Heart Failure Self-Care and Patient Readmissions with Caregiver Education: A Randomized Controlled Trial. Western Journal of Nursing Research, 2023, 45, 402-415.	1.4	4
2056	Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure. Circulation: Heart Failure, 2023, 16, .	3.9	35
2057	Outcomes and predictors of one-year mortality in patients hospitalized with Acute Heart Failure. IJC Heart and Vasculature, 2022, 43, 101159.	1,1	1
2058	Pre-diagnostic predictors of mortality in patients with heart failure: The multi-ethnic study of atherosclerosis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
2059	Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review. Cost Effectiveness and Resource Allocation, 2022, 20, .	1.5	3
2060	Point-of-Care Diagnostic Testing in Urgent Cardiac Care. , 2022, , 155-171.		1
2061	The Heart in Diabetic Hypertensive Patients. Updates in Hypertension and Cardiovascular Protection, 2023, , 195-215.	0.1	0
2062	A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities. Circulation, 2023, 147, 254-266.	1.6	30
2063	How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome. European Journal of Medical Research, 2023, 28, .	2.2	8
2064	Heart Failure-Smart Life: a randomized controlled trial of a mobile app for self-management in patients with heart failure. BMC Cardiovascular Disorders, 2023, 23, .	1.7	2
2065	Effects of Hypocaloric Low-Fat, Ketogenic and Ketogenic & Supplement diets on Aldosterone and Renin. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	6
2066	Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1

#	Article	IF	CITATIONS
2067	Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Children, 2023, 10, 149.	1.5	3
2068	Design and pilot implementation for the BETTER CARE-HF trial: A pragmatic cluster-randomized controlled trial comparing two targeted approaches to ambulatory clinical decision support for cardiologists. American Heart Journal, 2023, 258, 38-48.	2.7	3
2069	Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE) Tj ETQq0 0 0 r	gBT/Over	·lock 10 Tf 50
2070	Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?. Cancers, 2023, 15, 207.	3.7	6
2071	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. Medicine (United States), 2022, 101, e32489.	1.0	1
2072	Estimating right atrial pressure using upright computed tomography in patients with heart failure. European Radiology, 0, , .	4.5	0
2073	Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort. BMC Cardiovascular Disorders, 2022, 22, .	1.7	3
2074	Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney diseaseBalance of efficacy and risk. Frontiers in Pharmacology, 0, 14, .	3.5	1
2075	Risk factor structure of heart failure in patients with cancer after treatment with anticancer agents' assessment by big data from a Japanese electronic health record. Heart and Vessels, 0, , .	1.2	1
2076	Preferred Place of End-of-Life Care Based on Clinical Scenario: A Cross-Sectional Study of a General Japanese Population. Healthcare (Switzerland), 2023, 11, 406.	2.0	1
2077	Adaptation of interdisciplinary clinical practice guidelines to palliative care for patients with heart failure in iran: application of adapte method. Iranian Journal of Nursing and Midwifery Research, 2023, 28, 92.	0.6	1
2078	A pharmacist-led medication review service with a deprescribing focus guided by implementation science. Frontiers in Pharmacology, 0, 14, .	3.5	1
2079	Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
2080	Biomarker sST2 in Adults with Transposition of the Great Arteries Palliated by Mustard Procedure: A Five-Year Follow-up. Pediatric Cardiology, 2023, 44, 927-932.	1.3	O
2081	Comparative effect of different physical exercise training on exercise capacity and cardiac function in heart failure with preserved ejection fraction: A network meta-analysis. ExIC-FEp Study. European Journal of Cardiovascular Nursing, 0, , .	0.9	1
2082	Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	2
2083	Validation of the Meta-Analysis Global Group in Chronic Heart Failure risk score for the prediction of 1-year mortality in a Chinese cohort. Chinese Medical Journal, 2022, 135, 2829-2835.	2.3	1
2084	Association between cardiopulmonary function, health-related quality of life and cognitive impairment among the older nursing home residents in Shanghai, China. Primary Health Care Research and Development, 2023, 24, .	1.2	O

#	Article	IF	CITATIONS
2085	The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy. Future Science OA, 2023, 9, .	1.9	0
2086	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines, 2023, 11, 662.	3.2	3
2087	Exercises in activating lymphatic system on fluid overload symptoms, abnormal weight gains, and physical functions among patients with heart failure: A randomized controlled trial. Frontiers in Cardiovascular Medicine, $0,10,1$ .	2.4	1
2088	The serum soluble scavenger with 5 domains levels: A novel biomarker for individuals with heart failure. Frontiers in Physiology, 0, 14, .	2.8	0
2089	Impact of the degree of worsening renal function and B-type natriuretic peptide on the prognosis of patients with acute heart failure. Frontiers in Cardiovascular Medicine, $0,10,10$	2.4	0
2090	Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction. American Heart Journal, 2023, 259, 42-51.	2.7	1
2091	Characteristics of Right Ventricular to Pulmonary Arterial Coupling and Association With Functional Status Among Older Aged Adults from the Multi-Ethnic Study of Atherosclerosis. American Journal of Cardiology, 2023, 196, 41-51.	1.6	1
2093	Effects of $\hat{l}^2$ -blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	1
2094	Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon, 2023, 9, e13323.	3.2	31
2095	Things We Do for No Reasonâ,,¢: Routinely obtaining repeat transthoracic echocardiography for acute decompensation of known chronic heart failure. Journal of Hospital Medicine, 2023, 18, 934-937.	1.4	0
2096	The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2023, 2023, 1-15.	1.2	1
2097	Persistent Hypochloremia Is Associated with Adverse Prognosis in Patients Repeatedly Hospitalized for Heart Failure. Journal of Clinical Medicine, 2023, 12, 1257.	2.4	0
2098	Global historical retrospect and future prospects on biomarkers of heart failure: A bibliometric analysis and science mapping. Heliyon, 2023, 9, e13509.	3.2	3
2099	Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment. Clinical Chemistry, 2023, 69, 350-362.	3.2	3
2101	Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and metaâ€analysis. ESC Heart Failure, 2023, 10, 1643-1655.	3.1	2
2102	Subtyping based on immune cell fractions reveal heterogeneity of cardiac fibrosis in end-stage heart failure. Frontiers in Immunology, 0, 14, .	4.8	0
2103	Red Blood Cell Distribution Width: A Risk Factor for Prognosis in Patients with Ischemic Cardiomyopathy after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2023, 12, 1584.	2.4	0
2104	Post discharge management of heart failure patients: clinical findings at the first medical visit in a single-center study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1

#	Article	IF	CITATIONS
2105	Point of care transthoracic echocardiography for the prediction of post $\hat{a} \in \text{``spinal anesthesia'}$ hypotension in elderly patients with cardiac diseases and left ventricular dysfunction. Journal of Clinical Monitoring and Computing, 2023, 37, 1207-1218.	1.6	2
2106	Realâ€world safety of neurohormonal antagonist initiation among older adults following a heart failure hospitalization. ESC Heart Failure, 0, , .	3.1	1
2108	Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation. Scientific Reports, 2023, $13$ , .	3.3	3
2109	The association of plasma NT-proBNP level and progression of diabetic kidney disease. Renal Failure, 2023, 45, .	2.1	1
2110	Low Prognostic Nutritional Index Predicts Adverse Outcomes in Patients With Heart Failure: A Systematic Review and Meta-analysis. Angiology, 2024, 75, 305-313.	1.8	2
2111	A deep learning system for heart failure mortality prediction. PLoS ONE, 2023, 18, e0276835.	2.5	2
2112	Assessment of sST2 Behaviors to Evaluate Severity/Clinical Impact of Acute Pulmonary Embolism. International Journal of Molecular Sciences, 2023, 24, 4591.	4.1	2
2113	Cardiorenal syndrome in the pediatric population: A systematic review. Annals of Pediatric Cardiology, 2022, 15, 493.	0.5	0
2114	Diet-Induced Microbiome's Impact on Heart Failure: A Double-Edged Sword. Nutrients, 2023, 15, 1223.	4.1	5
2115	Identification and verification of feature biomarkers associated in heart failure by bioinformatics analysis. Scientific Reports, $2023,13,\ldots$	3.3	3
2116	Efficacy of disease management program used among patients with chronic heart failure: protocol for a systematic review and network meta-analysis. Systematic Reviews, 2023, 12, .	5.3	0
2117	Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. New England Journal of Medicine, 2023, 388, 2037-2048.	27.0	74
2118	Virtual Care Team Guided Management of Patients With Heart Failure DuringÂHospitalization. Journal of the American College of Cardiology, 2023, 81, 1680-1693.	2.8	17
2119	Implantable Cardioverter-Defibrillator forÂPrimary Prevention in Asia. JACC Asia, 2023, , .	1.5	0
2120	Prevalence and Correlates of Elevated NT-proBNP in Pregnant Women in the General U.S. Population. , 2023, 2, 100265.		7
2122	Differential Gene Expression Among Patients With Heart Failure Experiencing Pain. Nursing Research, 2023, 72, 175-184.	1.7	0
2123	Peripartum cardiomyopathy: risk factors and predictors of outcome. Current Opinion in Cardiology, 2023, 38, 223-232.	1.8	2
2124	WGCNA combined with machine learning algorithms for analyzing key genes and immune cell infiltration in heart failure due to ischemic cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	3

#	Article	IF	CITATIONS
2125	Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis. Cureus, 2023, , .	0.5	0
2126	Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. Pharmaceutics, 2023, 15, 1002.	4.5	1
2127	Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository. Drugs - Real World Outcomes, 0, , .	1.6	1
2128	The association between comorbidities and self-care of heart failure: a cross-sectional study. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
2129	Systematic review of sodiumâ€glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failureâ€related events. ESC Heart Failure, 2023, 10, 1499-1530.	3.1	8
2130	Clinical Usefulness of Right Ventricle–Pulmonary Artery Coupling in Cardiovascular Disease. Journal of Clinical Medicine, 2023, 12, 2526.	2.4	7
2131	Evaluating the affinity and kinetics of small molecule glycomimetics for human and mouse galectin-3 using surface plasmon resonance. SLAS Discovery, 2023, 28, 233-239.	2.7	1
2132	The history and mystery of sacubitril/valsartan: From clinical trial to the real world. Frontiers in Cardiovascular Medicine, $0,10,10$	2.4	1
2133	Predictive value of global longitudinal strain by left ventricular ejection fraction. ESC Heart Failure, 2023, 10, 1937-1947.	3.1	2
2134	Heart Failure with Reduced Ejection Fraction. , 2023, , 67-88.		0
2135	Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease. American Journal of Medicine, 2023, 136, 677-686.	1.5	2
2136	Post-TB health and wellbeing. International Journal of Tuberculosis and Lung Disease, 2023, 27, 248-283.	1.2	24
2137	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. Korean Circulation Journal, 2023, 53, 195.	1.9	3
2138	A review of current key guidelines for managing highâ€risk patients with diabetes and heart failure and future prospects. Diabetes, Obesity and Metabolism, 2023, 25, 33-47.	4.4	0
2139	Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension. Hypertension Research, 2023, 46, 1727-1737.	2.7	7
2140	Regional Handling and Prognostic Performance of Circulating Insulin-Like Growth Factor Binding Protein-7 inÂHeartÂFailure. JACC: Heart Failure, 2023, 11, 662-674.	4.1	1
2141	Cardiac and Pulmonary Rehabilitation: Two Underutilized Approaches with Some Unexpected Benefits. Journal of Clinical Medicine, 2023, 12, 2847.	2.4	1
2142	Changes in gut microbiota linked to a prevention of cardiac remodeling induced by hypertension in spontaneously hypertensive rats fed a pawpaw fruit diet. Heliyon, 2023, 9, e15576.	3.2	4

#	ARTICLE	IF	CITATIONS
2143	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. International Journal of Heart Failure, 2023, 5, 51.	2.7	5
2144	Circulating ST2: from biomarker to pathogenic mediator. Revista Espanola De Cardiologia (English Ed) Tj $$ ETQq $$ 1 $$ 1 $$	0,784314 0.6	rgBT /Overl
2145	Clinical and Echocardiographic Diversity Associated With Physical Fitness in the Project Baseline Health Study: Implications for Heart Failure Staging. Journal of Cardiac Failure, 2023, , .	1.7	2
2146	Impact of Diabetes and Hypertension on Left Ventricular Structure and Function: The Jackson Heart Study. Journal of the American Heart Association, 2023, 12, .	3.7	2
2147	Efficacy of dapagliflozin in the treatment of HFrEF with obstructive sleep apnea syndrome (DAHOS) Tj ETQq0 0 0 2023, 24, .	rgBT /Over 1.6	rlock 10 Tf 5 2
2148	Ivabradine in the treatment of nonâ€paroxysmal junctional tachycardia with interference atrioventricular dissociation: A case report. Annals of Noninvasive Electrocardiology, 0, , .	1.1	0
2149	Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circulation: Heart Failure, 2023, 16, .	3.9	6
2150	Serum lipidomics reveals phosphatidylethanolamine and phosphatidylcholine disorders in patients with myocardial infarction and post-myocardial infarction-heart failure. Lipids in Health and Disease, 2023, 22, .	3.0	1
2151	Presence and impact of anemia in patients supported with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2023, 42, 1261-1274.	0.6	2
2152	Characteristics of cardiopulmonary exercise testing in patients with combined post- and pre-capillary pulmonary hypertension due to left heart disease. PLoS ONE, 2023, 18, e0286057.	2.5	0
2153	Importance of proper ventilator support and pulmonary rehabilitation in obese patients with heart failure: Two case reports. World Journal of Clinical Cases, 0, 11, 3029-3037.	0.8	0
2154	Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.  European Journal of Heart Failure, 2023, 25, 936-955.	7.1	20
2155	Multimodal Prehabilitation in Heart Transplant Recipients Improves Short-Term Post-Transplant Outcomes without Increasing Costs. Journal of Clinical Medicine, 2023, 12, 3724.	2.4	2
2156	Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States. Circulation: Cardiovascular Quality and Outcomes, 2023, 16, .	2.2	2
2157	Deep learning-based prognostic model using non-enhanced cardiac cine MRI for outcome prediction in patients with heart failure. European Radiology, 2023, 33, 8203-8213.	4.5	2
2158	Primary Prevention of Sudden CardiacÂDeath in Asia. JACC Asia, 2023, 3, 346-348.	1.5	1
2159	Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial. Clinical Research in Cardiology, 2024, 113, 425-432.	3.3	0
2160	NT-proBNP Reference Intervals in Healthy U.S. Children, Adolescents, and Adults. journal of applied laboratory medicine, The, 2023, 8, 700-712.	1.3	4

#	Article	IF	CITATIONS
2161	Integrative Interpretation of Cardiopulmonary Exercise Tests for Cardiovascular Outcome Prediction: A Machine Learning Approach. Diagnostics, 2023, 13, 2051.	2.6	0
2162	Opportunities and Achievement of Medication Initiation Among Inpatients With HeartÂFailure With Reduced EjectionÂFraction. JACC: Heart Failure, 2023, 11, 918-929.	4.1	2
2163	Cardiac MRI-based right-to-left ventricular blood pool T2 relaxation times ratio correlates with exercise capacity in patients with chronic heart failure. Journal of Cardiovascular Magnetic Resonance, 2023, 25, .	3.3	1
2164	Clinician challenges to evidenceâ€based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation. Journal of Evaluation in Clinical Practice, 2023, 29, 1363-1371.	1.8	0
2165	3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension. JACC: Heart Failure, 2023, , .	4.1	0
2166	A profile on the CardioMEMS HF system in the management of patients with early stages of heart failure: an update. Expert Review of Medical Devices, $0$ , $1$ - $11$ .	2.8	0
2167	A Comparative Review of Vagal Nerve Stimulation Versus Baroreceptor Activation Therapy in Cardiac Diseases. Cureus, 2023, , .	0.5	0
2168	sST2 and Heart Failure—Clinical Utility and Prognosis. Journal of Clinical Medicine, 2023, 12, 3136.	2.4	3
2169	The Relevance of Preventive Implantable Cardioverter-Defibrillators (ICDs) in Non-Ischemic Cardiomyopathy in the Presence of Effective Quadruple Therapy for Heart Failure: A Review of Contemporary Medical Literature. Cureus, 2023, , .	0.5	0
2170	Research Progress on the Application of Sacubitril/Valsartan to Heart Failure. Advances in Clinical Medicine, 2023, 13, 7203-7211.	0.0	0
2171	Low atrial natriuretic peptide to brain natriuretic peptide ratio is associated with left atrial remodeling. Journal of Cardiovascular Medicine, 2023, 24, 544-551.	1.5	2
2172	Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study. The Lancet Digital Health, 2023, 5, e370-e379.	12.3	8
2173	Reduced acetylation of TFAM promotes bioenergetic dysfunction in the failing heart. IScience, 2023, 26, 106942.	4.1	3
2174	Prognostic Value of Self-Reported Subjective Exercise Capacity in PatientsÂWith Acute Dyspnea. , 2023, 2, 100342.		1
2175	Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781.	0.1	0
2177	Clinical Characteristics and Outcomes of Clostridioides difficile Infection in Patients With Left Ventricular Assist Device. ASAIO Journal, 0, Publish Ahead of Print, .	1.6	0
2178	Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration. European Journal of Clinical Pharmacology, 2023, 79, 1173-1184.	1.9	3
2179	Nâ€terminal proâ€Bâ€type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study. Clinical Cardiology, 2023, 46, 989-996.	1.8	3

#	Article	IF	CITATIONS
2180	Defining pharmacist activities in ambulatory heart failure clinics: North American survey and modified Delphi study. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	1
2181	Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2023, 109, 4-9.	3.6	4
2182	Cardioprotective efficacy of Xin-shu-bao tablet in heart failure with reduced ejection fraction by modulating THBD/ARRB1/FGF1/STIM1 signaling. Biomedicine and Pharmacotherapy, 2023, 165, 115119.	5.6	2
2183	Hemodynamics of thrombus formation in intracranial aneurysms: An <i>in silico</i> observational study. APL Bioengineering, 2023, 7, .	6.2	1
2184	Disparities in Referral and Utilization of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death. Canadian Journal of Cardiology, 2023, 39, 1610-1616.	1.7	0
2185	Clinical outcomes of acute myocardial infarction arising from non-lipid-rich plaque determined by NIRS-IVUS. Scientific Reports, 2023, 13, .	3.3	O
2186	Trends in B-Type Natriuretic Peptide Testing. JACC: Heart Failure, 2023, 11, 1645-1647.	4.1	1
2187	Effect of axial flow blood pump's pulsation speed regulation on key hemodynamic parameters. Journal of Mechanics in Medicine and Biology, 0, , .	0.7	0
2188	Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations. Annals of Internal Medicine, 2023, 176, 1067-1080.	3.9	4
2189	Maturation of iPSC-derived cardiomyocytes in a heart-on-a-chip device enables modeling of dilated cardiomyopathy caused by R222Q-SCN5A mutation. Biomaterials, 2023, 301, 122255.	11.4	3
2190	Anabolic androgenic steroids and cardiomyopathy: an update. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1
2191	Multicentre medicoeconomic evaluation of cardiac magnetic resonance imaging for predicting coronary artery disease in left ventricular dysfunction: The CAMAREC study design. Archives of Cardiovascular Diseases, 2023, 116, 366-372.	1.6	0
2192	Outcome of mitral repair combined with Cox-maze procedure for atrial functional mitral regurgitation with heart failure with recovered ejection fraction. European Journal of Cardio-thoracic Surgery, 2023, 64, .	1.4	1
2193	Heart failure and atrial fibrillation: Is atrial fibrillation ablation in heart failure pointless or mandatory?. Journal of Cardiovascular Electrophysiology, 2024, 35, 530-537.	1.7	1
2194	Soluble suppression of tumorigenicity 2 associated with fulminant myocarditis in children: A retrospective observational study. Medicine (United States), 2023, 102, e34784.	1.0	0
2195	Editorial: Multimodality imaging of left ventricular assist devices: applications in advanced heart failure. Frontiers in Cardiovascular Medicine, 0, $10$ , .	2.4	0
2196	Kinesiophobia and associated variables in patients with heart failure. European Journal of Cardiovascular Nursing, $0$ , , .	0.9	0
2197	Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran. Health Economics Review, 2023, 13, .	2.0	0

#	ARTICLE	IF	CITATIONS
2198	Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure. Frontiers in Cardiovascular Medicine, 0, $10$ , .	2.4	0
2199	Preventing new-onset heart failure: Intervening at stage A. American Journal of Preventive Cardiology, 2023, 16, 100609.	3.0	0
2201	Part I: <scp>PSAP Live</scp> : Updates from 2022 <scp>Book</scp> 1 ( <scp><i>Cardiology</i></scp> ). JACCP Journal of the American College of Clinical Pharmacy, 2023, 6, 1163-1169.	1.0	0
2202	Postmortem biochemistry in deaths from ischemic heart disease. Journal of Clinical Forensic and Legal Medicine, 2023, 100, 102599.	1.0	0
2203	Gender specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
2204	Amphiphilic Particle-Stabilized Nanoliter Droplet Reactors with a Multimodal Portable Reader for Distributive Biomarker Quantification. ACS Nano, 2023, 17, 19952-19960.	14.6	1
2205	Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure. Heart and Vessels, 2024, 39, 216-225.	1.2	0
2206	Nebulized medications in the emergency department: A narrative review of nontraditional agents. American Journal of Health-System Pharmacy, 2024, 81, 88-105.	1.0	0
2207	Intravenous Iron for Heart Failure: Updated Systematic Review and Meta-Analysis. Angiology, 0, , .	1.8	0
2208	Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
2209	Metabolomics Assessment of Volume Overload-Induced Heart Failure and Oxidative Stress in the Kidney. Metabolites, 2023, 13, 1165.	2.9	0
2210	Associations between muscle quality and N-terminal pro-B-type natriuretic peptide (NT-proBNP): The multi-ethnic study of atherosclerosis. American Journal of the Medical Sciences, 2024, 367, 160-170.	1.1	0
2212	Diagnostic and Prognostic Role of Left Ventricular Strain Imaging in Adults with Coarctation of aorta. American Journal of Cardiology, 2024, 211, 98-105.	1.6	0
2213	Sex Differences in Pharmacotherapy and Long-Term Outcomes in Patients With Ischaemic Heart Disease and Comorbid Left Ventricular Dysfunction. Heart Lung and Circulation, 2023, , .	0.4	0
2214	Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC: Heart Failure, 2024, 12, 322-332.	4.1	2
2215	Underrepresentation of Women in Reduced Ejection Heart Failure Clinical Trials with Improved Mortality or Hospitalization., 2023,, 100743.		0
2216	The efficacy and safety of new potassium binders on renin–angiotensin–aldosterone system inhibitor optimization in heart failure patients: a systematic review and metaâ€analysis. ESC Heart Failure, 0, , .	3.1	0
2217	Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Third Version of the Atlanta Heart Failure Knowledge Test. Journal of Nursing Measurement, 2023, 31, 502-509.	0.3	0

#	Article	IF	CITATIONS
2218	Heart Failure with Preserved Ejection Fraction (HFpEF)., 2023,, 221-224.		0
2219	Impact and Implications of Neurocognitive Dysfunction in the Management of Ischemic Heart Failure. , 2023, 2, 101198.		0
2220	16.ÂCardiovascular Disease. , 2023, , .		0
2221	Heart Failure with Reduced Ejection Fraction (HFrEF)., 2023,, 197-219.		0
2222	8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: ⟨i⟩Standards of Care in Diabetes–2024⟨ i⟩. Diabetes Care, 2024, 47, S145-S157.	8.6	5
2223	Management of Cardiovascular Disease in the Elderly. , 2023, , 1-41.		0
2224	Left bundle branch pacing lead for sensing ventricular arrhythmias in implantable cardioverter-defibrillator: A pilot study (LBBP-ICD study). Heart Rhythm, 2023, , .	0.7	0
2225	Efficacy and prognostic impact of Pericarpium Trichosanthis injection combined with nicorandil for intractable angina pectoris in elderly patients: A retrospective study. World Journal of Cardiology, 0, 15, 633-641.	1.5	0
2226	Long Non-Coding RNAs (IncRNAs) in Heart Failure: A Comprehensive Review. Non-coding RNA, 2024, 10, 3.	2.6	1
2227	Macrophage-based therapeutic approaches for cardiovascular diseases. Basic Research in Cardiology, 2024, 119, 1-33.	5.9	0
2228	Chapter 1: The Burden of Heart Failure. American Journal of Medicine, 2024, 137, S3-S8.	1.5	0
2229	Evaluation of a New NT-proBNP Immunoassay on an Automated Core Laboratory System. journal of applied laboratory medicine, The, 2024, 9, 579-585.	1.3	O
2230	Revascularization for Patients With Heart Failure With Preserved Ejection Fraction and Coronary Artery Disease. American Journal of Cardiology, 2024, 213, 86-92.	1.6	0
2231	Prevalence and predictors of poor self-care behaviors in patients with chronic heart failure. Scientific Reports, 2024, 14, .	3.3	0
2232	Beyond sodium: nutritional status in heart failure. European Journal of Cardiovascular Nursing, 0, , .	0.9	0
2233	Serum uric acid and outcome in hospitalized elderly patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes. BMC Cardiovascular Disorders, 2023, 23, .	1.7	1
2234	Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure. American Journal of Medicine, 2024, 137, S1-S2.	1.5	0
2235	Chapter 4: Summary and a Patient Perspective on Living with Heart Failure. American Journal of Medicine, 2024, 137, S35-S42.	1.5	0

#	Article	IF	CITATIONS
2236	Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment. Journal of Cardiovascular Development and Disease, 2024, 11, 15.	1.6	0
2237	Triple Cascade Quantum-Strip for Heart Failure Point-of-Care Testing. ACS Sensors, 2024, 9, 29-41.	7.8	O
2238	Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and metaâ€analysis. European Journal of Heart Failure, O, , .	7.1	1
2239	Drug therapy problems among hospitalized patients with cardiovascular disease. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
2240	Lived Experience of Adult With Heart Failure at Tibebe Ghion Specialized Teaching Hospital Northwest Ethiopia, Qualitative Phenomenological Study. Risk Management and Healthcare Policy, 0, Volume 17, 127-144.	2.5	1
2241	Use of sacubitril/valsartan early after CABG. Open Heart, 2024, 11, e002492.	2.3	0
2242	Medizinische NotfÇe., 2024, , 521-537.		0
2244	Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study. Clinical Research in Cardiology, 0, , .	3.3	0
2245	Left ventricular ejection fraction: clinical, pathophysiological, and technical limitations. Frontiers in Cardiovascular Medicine, $0,11,.$	2.4	0
2246	Elective cardioversion at a district general hospital: a retrospective evaluation of outcomes. British Journal of Nursing, 2024, 33, 115-119.	0.7	0
2247	Management of Cardiovascular Disease in the Elderly. , 2024, , 343-383.		0
2248	Meta-analysis of initial natriuretic peptides in the setting of sepsis-induced myocardial dysfunction. Biomarkers in Medicine, 2024, 18, 145-155.	1.4	0
2249	Cardiac Biomarkers in the Progression to Heart Failure in Hypertension. Updates in Hypertension and Cardiovascular Protection, 2023, , 277-297.	0.1	0
2250	Acute heart failure – an EFIM guideline critical appraisal and adaptation for internists. European Journal of Internal Medicine, 2024, 123, 4-14.	2.2	0
2251	2024 ACC Expert Consensus Decision Pathway for Treatment of HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2024, 83, 1444-1488.	2.8	0
2252	Prognostic value of left ventricular trabeculae fractal analysis in patients with dilated cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2024, 26, 101005.	3.3	0
2253	Iron deficiency: prevalence, mortality risk, and dietary relationships in general and heart failure populations. Frontiers in Cardiovascular Medicine, 0, $11$ , .	2.4	0
2254	Interpretability of biâ€level variable selection methods. Biometrical Journal, 2024, 66, .	1.0	O

#	Article	IF	CITATIONS
2255	Nuclear AGO2 promotes myocardial remodeling by activating ANKRD1 transcription in failing hearts. Molecular Therapy, 2024, 32, 1578-1594.	8.2	0
2256	Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose–response meta-analysis. International Urology and Nephrology, 0, , .	1.4	0